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L-arginine is one of the most versatile amino acids due to the fact that it serves as
a precursor for many molecules which have important roles in bodily functions including
mammalian reproduction. The current studies sought to further examine the role that Larginine has in mammalian reproduction utilizing both in vivo and in vitro approaches. In
the first study, a novel bioluminescent murine pregnancy model was developed to
monitor VEGFR2 transcription activity non-invasively in the fetoplacental unit.
Secondly, the effect that dietary L-arginine supplementation has during mouse gestation
was examined. L-arginine supplementation increased weight gain during the latter third
of gestation, total litter size, number of implantation sites, and litter birth weight.
Additionally, L-arginine supplementation increased VEGFR2 transcription activity in the
fetoplacental unit which may create a more favorable environment for fetal survival.
Moreover, the increased number of implantation sites observed suggests an effect of Larginine at the level of the endometrium. To this end, the effect that L-arginine has on
apoptosis and cell proliferation in an established endometrial cell line was examined. The
addition of L-arginine at physiological (200 micromolar) and supra-physiological (800

micromolar) concentrations increased cell proliferation , and this effect was achieved
through biosynthesis of polyamines and nitric oxide. L-arginine also decreased the
proportion of cells that were experiencing mitochondrial mediated apoptosis, and it was
observed that this decrease in mitochondrial mediated apoptosis was concurrent with
increased phosphorylation of BAD protein, which induces apoptosis when not
phosphorylated. The final study examined the ability of porcine uterine epithelial (PUE)
cells to synthesize L-arginine from L-citrulline. L-citrulline was able to support PUE cell
proliferation in the absence of L-arginine. Additionally, ASS-1 and ASL, L-arginine
synthesizing enzymes, were expressed in PUE cells and were regulated by the presence
of L-arginine and L-citrulline, respectively. This data would support the hypothesis that
PUE cells may be able to convert L-citrulline to L-arginine. Together, the current
findings along with the plethora of relevant literature provide further evidence for the role
of L-arginine in mammalian reproduction and allow for new questions to be investigated
regarding this particular amino acid’s role in mammalian reproduction.
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CHAPTER I
INTRODUCTION

L-arginine is considered to be a conditionally essential amino acid for healthy
mature mammals but an essential amino acid for young, developing mammals and for
sick or injured adult mammals (Flynn et al. 2002). In addition to being incorporated into
many proteins and playing a role in ammonia detoxification (Visek 1986), L-arginine is
also a precursor for many molecules including proline, glutamate, creatine and most
notably polyamines and nitric oxide (NO), making L-arginine one of the most versatile
amino acids (Wu & Morris 1998). While early research has demonstrated that L-arginine
is not required in the diet (Scull & Rose 1930, Rose et al. 1954), much renewed interest
in L-arginine having a role in reproductive tissues has recently emerged. This renewed
interest in studying the relationship between L-arginine and mammalian reproduction can
be traced to work conducted by Wu and colleagues (1996a) who demonstrated an unusual
abundance of L-arginine in porcine allantoic fluid, which would suggest a critical role for
this particular amino acid in fetoplacental nutrition. In addition to being present in
porcine allantoic fluid, L-arginine has also been reported to exists in the uterine flushes of
sheep (Gao et al. 2009c), cows (Hugentobler et al. 2007), rats (Leese et al. 2007), and
humans (Casslen 1987). Moreover, research has demonstrated that dietary
supplementation enhances the reproductive performance of rats (Zeng et al. 2008) and
pigs (Mateo et al. 2007).
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Many of the effects that L-arginine has in reproductive tissues is likely due to the
metabolism of L-arginine into NO and polyamines. Nitric oxide and polyamines are both
powerful cell signaling molecules and are produced by both uterine and placental tissues
(Myatt et al. 1993, Swaisgood et al. 1997, Wu et al. 1998, Rodriguez-Sallaberry et al.
2001, Kwon et al. 2004, Zeng et al. 2008, Zhao et al. 2008). Expression of nitric oxide
synthase (NOS) has been shown to be increased at the site of implantation in mice
(Purcell et al. 1999), suggesting that NO may play an important role during embryo
implantation. Additionally, polyamines also appear to have a role during embryo
implantation, as inhibition of polyamine synthesis reduced pregnancy rates in mice (Zhao
et al. 2008). Nitric oxide and polyamines are also implicated in the stimulation of the
migration and proliferation of trophoblasts (Kim et al. 2011a), indicating that L-arginine
is a constituent of the uterine histotroph which nourishes the peri-implantation embryo.
In addition to being a component of uterine histotroph, L-arginine might also play
a role in angiogenesis during pregnancy. Angiogenesis is the development of new blood
vessels from the pre-existing vasculature, and this process is a critical component of
placental and fetal development. The key stimulator of angiogenesis is vascular
endothelial growth factor (VEGF) and its receptor (VEGFR2). Just as NO and
polyamines have been implicated in supporting early embryo development and
implantation, evidence also supports the hypothesis that NO and polyamines have a role
in angiogenesis and thus may be involved in this process during gestation. Nitric oxide
has been demonstrated to induce VEGF mRNA and protein in keratinocytes (Frank et al.
1999) and vascular smooth muscle cells (Dulak et al. 2000, Jozkowicz et al. 2001), and
in vitro exposure of ovine fetoplacental artery endothelial cells and human placental
2

artery endothelial cells to an exogenous source of NO results in enhanced cell
proliferation (Zheng et al. 2006). Similarly, inhibition of polyamine synthesis abrogates
neovascularization, while the addition of polyamines restores the degree of vasculature in
tumor cells (Jasnis et al. 1994), and it has been proposed that they have a similar role in
placental angiogenesis (Wu et al. 2004, Wu et al. 2006). To this end, it appears that Larginine, by serving as a precursor for NO and polyamines, may have a role in
angiogenesis during gestation.
The literature clearly establishes a role for L-arginine during pregnancy in
mammals; however, the full function of this amino acid in mammalian reproductive
tissues remains to be determined. To this end, the objectives of this series of studies were
to (1) determine and establish the usefulness of a bioluminescent VEGFR2-luciferase
murine pregnancy model to monitor the transcription activity of VEGFR2 in the
fetoplacnetal unit non-invasively, (2) to determine if the reported beneficial effect that
dietary L-arginine supplementation has on mammalian reproduction is associated with
enhanced fetoplacental VEGFR2 transcription activity, using the aforementioned
bioluminescent pregnancy model, and (3) to examine the effect that L-arginine may have
on endometrial cell proliferation and apoptosis using the established human endometrial
epithelial cell line, RL95-2, as an in vitro model for epithelial cells of the human
endometrium.

3

CHAPTER II
REVIEW OF LITERATURE

2.1

L-arginine
Often considered to be one of the most versatile amino acids, L-arginine is

classified as a basic, cationic amino acid with three amine groups comprising a guanidino
group in the side chain (Figure 2.1). L-arginine was first isolated from lupin seedlings by
Schulze and Steiger (1886), and shortly thereafter, Hedin (1895) discovered that Larginine is a component of animal proteins (as reviewed by Wu and Morris (1998)).
Following the discovery of L-arginine, many efforts to determine its essentiality or
dispensability were undertaken with a definitive answer still being debated today.
Classically, amino acids are categorized as being either indispensable (essential) or
dispensable (non-essential), with Cox and Rose (1926) and Borman and colleagues
(1946) defining an indispensable amino acid as “one that cannot be synthesized by the
animal organism, out of materials ordinarily available to the cells, at a speed
commensurate with the demands for normal growth.” Scull and Rose (1930) attempted to
determine the dispensability of L-arginine in their classical nutrition studies conducted in
the rat. When fed a diet with a reduced L-arginine content, Scull and Rose (1930)
reported that rats did not experience weight loss; in fact, the rats retained the ability to
gain weight. Moreover, whole body analysis revealed that rats on a reduced L-arginine
diet accrued more L-arginine in their tissues than the amount they consumed in their diet
4

(Scull & Rose 1930). As such, the rat’s ability to gain weight and accumulate L-arginine
in body tissues while on a reduced L-arginine diet led nutritionists to classify L-arginine
as a dispensable or non-essential amino acid. This finding has been repeated in humans
by Rose and colleagues (1954) who reported that removal of L-arginine from the diet did
not result in a negative nitrogen balance in adult males.
Like many observations in science, the classification of L-arginine as a
dispensable amino acid does not hold true under all circumstances. Shortly after Scull and
Rose (1930) reported their findings in the rat, Arnold and colleagues (1936) conducted a
series of experiments which demonstrated that the simple addition of L-arginine at 1% of
the diet enhanced the growth of one day-old chicks, but this effect diminished after six
weeks of age. Additionally, Klose and colleagues (1938) observed that removal of Larginine from the diet caused weight loss of chicks while the addition of L-arginine
stimulated weight gain. Together, these two sets of experiments (Arnold et al. 1936,
Klose et al. 1938) established L-arginine as a dispensable amino acid for the growing
chick and set forth the concept that essentiality of L-arginine may differ among species
and even within species depending upon the physiological circumstances. The species
differences regarding the essentiality of L-arginine was further supported by Morris and
Rogers (1978) and Ha and colleagues (1978) who reported weight loss and
hyperammonia when L-arginine was removed from the diets of cats and immature dogs,
respectively, suggesting that L-arginine is an indispensable amino acid for not only cats
and dogs, but also for carnivorous species in general.
Possibly one of the most compelling arguments regarding the discrepancy
surrounding the essentiality of L-arginine was offered by Borman and colleagues (1946).
5

In 1946, Borman and colleagues reevaluated the role of L-arginine in the growing rat.
Feeding an L-arginine-free diet and the same diet supplemented with L-arginine to
growing rats, Borman and colleagues observed that while L-arginine restriction does not
result in weight loss, the addition of L-arginine to the diet increased growth which
suggested L-arginine has a role in tissue growth. More importantly, Borman and
colleagues (1946) conjectured that the essentiality of L-arginine should not solely be
based upon its role in growth but also its role in other bodily functions such as
reproduction. This argument has led to the modern classification of L-arginine as being
dispensable amino acid for mature mammals (excluding carnivores) but an indispensable
amino acid for young growing animals and carnivores (Boger & Bode-Boger 2001) .
Additionally, the proposition by Borman and colleagues was somewhat revolutionary at
the time as the accepted dogma was to classify amino acids based upon their need for
normal body growth . To this end, the argument set forth by Borman and colleagues
supports the modern efforts to determine the role of L-arginine in other bodily functions
such as reproduction.
Much of the renewed interest regarding the role of L-arginine in bodily functions
other than growth stems from the fact that in addition to being incorporated into many
proteins and having a role in ammonia detoxification (Visek 1986), L-arginine is also a
precursor for many important molecules in cellular physiology, including proline,
glutamate, creatine, and most notably, polyamines and nitric oxide (Wu & Morris 1998).
Nitric oxide is a powerful vasodilator, a potent intracellular signaling molecule, and aids
in regulation of the redox state of cells. Polyamines are polycationic molecules that affect
a myriad of cellular functions through their ability to bind nucleic acids and proteins
6

(Igarashi & Kashiwagi 2000). Creatine can serve as a energy reservoir in the resting state
by being converted to phosphocreatine (Voet et al. 2008) and is known to have antiinflammatory (Bassit et al. 2008), antioxidant (Fang et al. 2002), and glucose tolerance
regulatory (Gualano et al. 2008) properties. Moreover, L-arginine has a direct role in
ammonia detoxification by serving as an intermediate during the urea cycle. Thus,
metabolism of L-arginine is an important physiological process for mammalian species.
2.1.1

Absorption of L-arginine
Following ingestion, dietary protein is subjected to enzymatic digestion (Adibi et

al. 1967), which is the process by which proteins are degraded into either smaller
peptides or individual amino acids through the action of digestive enzymes.
Subsequently, the small peptides or free amino acids are absorbed by enterocytes lining
the lumen of the small intestine (Bröer 2008). Absorption of free amino acids and other
products of protein digestion is achieved by enterocytes lining the duodenum and
proximal jejunum (Borgström et al. 1957, Nixon & Mawer 1970, Silk et al. 1985, Bröer
2008). Through much research, five amino acid transport systems have been proposed to
exist: 1) the “neutral system” which transports all neutral amino acids; 2) the “basic
system” which transports cationic amino acids and cystine; 3) the “acidic system” which
transports glutamate and aspartate; 4) the “iminoglycine system” which transports
proline, hydroxyproline, and glycine; and 5) the β-amino acid system which transports βamino acids (Bröer 2008). As a dietary component, L-arginine, a cationic amino acid,
exists as either a constituent of proteins or as a free amino acid achieved through direct
supplementation. To this end, discussion of the basic amino acid transport system is
7

paramount in terms of absorption in the small intestine and absorption by other bodily
tissues.
The major system for the influx transport of cationic amino acids, including Larginine, in the small intestine is designated as b0,+ (Bröer 2008). The b0,+ system has
been demonstrated to not require the presence of sodium to function properly and,
therefore, has been designated as a Na+-independent transport system (Munck 1985,
Munck & Munck 1997). Moreover, the functioning unit of this transport system is a
heteromic protein designated as rBAT/ b0,+AT (Palacín et al. 2001). Bertran and
colleagues (1992) isolated the rBAT subunit and demonstrated that its expression
increased uptake of L-argnine and that rBAT is a type II membrane glycoprotein with a
cytoplasmic N terminus, a single transmembrane domain, and a N-glycosylated
extracellular C terminus. Subsequently, the b0,+AT subunit was isolated and demonstrated
to be involved in L-arginine transport, contain 12 transmembrane domains and form a
disulfide bond with rBAT (Feliubadalo et al. 1999, Pfeiffer et al. 1999a). When
expressed together, the rBAT/ b0,+AT complex translocates to the apical membrane
(Bröer 2008) resulting in the antiport movement of amino acids whereby there is a 1:1
stoichiometric movement of cationic amino acids into the cell and neutral amino acids
out of the cell (Figure 2.2; Chillaron et al. 1996).
Following absorption into the intracellular space, cationic amino acids, including
L-arginine, are transported across the basolateral membrane of enterocytes and into the
vascular beds of the small intestine where they enter the general circulation. The system
that achieves the transport of cationic amino acids across the basolateral membrane of
enterocytes was initially described by Cheeseman (1983) in the small intestine of the
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frog. Using a vascularly perfused section of frog small intestine, Cheeseman (1983)
demonstrated that the presence of neutral amino acids in the vascular bed accelerated the
efflux of L-lysine, a cationic amino acid, across the basolateral membrane. This finding
was later replicated in erythrocytes, and this transport system was termed y+L (Devés et
al. 1992). The functioning unit of the y+L system is the heteromic protein complex
4F2hc/y+LAT1 (Bröer 2008). In this system, disulfide bonds link 4F2hc and y+LAT1
together which facilitates the interaction with both neutral and cationic amino acids in an
antiport fashion whereby an efflux of cationic amino acids is enhanced by the influx of
neutral amino acids which necessitates the presence of sodium (Figure 2.2; Pfeiffer et al.
1999b, Bröer 2008).
In adult mammals, approximately 40% of digested L-arginine is degraded by
enterocytes (Windmueller & Spaeth 1976, Castillo et al. 1993b) through the activities of
both NOS and arginase enzymes (Wu et al. 1996b). The remaining 60% of digested Larginine is absorbed by the small intestine by the aforementioned mechanisms, as was
demonstrated in rats (Windmueller & Spaeth 1976) and humans (Castillo et al. 1993b).
Once absorbed, L-arginine enters the portal circulation and is delivered to the liver (Flynn
et al. 2002); however, the L-arginine transport system, y+, is virtually absent from
hepatocytes (Kim et al. 1991), and as such, approximately 85% of L-arginine delivered to
the liver via portal circulation is not taken up (Wu & Morris 1998), which separates
systemic L-arginine pools from what is found in the liver (Boger & Bode-Boger 2001).
Once in the general circulation, L-arginine is absorbed into bodily tissues through the y+
cationic amino acid transport system (Wu & Morris 1998). The protein that is responsible
for the transport activity of the y+ system was discovered serendipitously while studying
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a protein which encoded a cell-surface receptor for ecotropic host-range murine
retroviruses known as ecoR (Wang et al. 1991). Wang and colleagues (1991) predicted
that ecoR was comprised of approximately 622 amino acids and may contain 14
hydrophobic membrane-spanning sequences. Furthermore, when ecoR was expressed in
Xenopus laevis oocytes, uptake of L-lysine, L-arginine, and L-ornithine was observed
independent of the presence of sodium (Figure 2.3; Wang et al. 1991), which led to the
classification of the y+ system as being a sodium independent specific cationic amino
acid transport system (Kilberg et al. 1993). Today, the ecoR protein has been
subsequently renamed mCAT1 (MacLeod & Kakuda 1996), and two other mCAT
proteins mCAT2 (Reizer et al. 1993) and mCAT2A (Closs et al. 1993) have been
described (MacLeod & Kakuda 1996). In contrast to hepatocytes, most other cell types in
the body posses an active y+ system, and this system is viewed as the most important
mechanism for L-arginine uptake in cells (Wu & Morris 1998).
2.1.2

L-arginine metabolism
L-arginine can be absorbed by the small intestine and enter circulation,

synthesized endogenously, or liberated through protein turnover, with the latter
representing the majority of circulating L-arginine (Wu & Morris 1998). Despite the
origin, L-arginine can be found in the serum at concentrations ranging from 115 µM to
210 µM depending on the species and stage of development (Wu & Morris 1998).
Metabolism of circulating L-arginine occurs rather quickly, as the half life of L-arginine
is reported to be around one hour (Wu et al. 2007). Once transported inside the cell, Larginine can be metabolized into NO, polyamines, ornithine, citrulline, urea, proline,
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glutamate, or creatine, and this is largely initiated through the action of NOS, arginase,
and arginine:glycine amidinotransferase (Wu & Morris 1998).
Nitric oxide synthase metabolizes L-arginine to produce NO and citrulline. Three
isoenzymes of NOS have been described to date: neuronal NOS (nNOS), endothelial
NOS (eNOS), and inducible NOS (iNOS; Rosselli et al. 1998). All three isoenzymes
originate from three different genes and share approximately 51 to 57% amino acid
homology (Alderton et al. 2001). Endothelial NOS and nNOS were once thought to be
constitutively expressed in cells, whereas iNOS was thought to be expressed only in
response to cytokines and lipopolysaccharides (Alderton et al. 2001). However, now all
three isoenzymes have been recognized as being both constitutively expressed and as
being able to be transcriptionally activated through appropriate stimuli in various tissues
(Flynn et al. 2002). Briefly, the synthesis of NO requires NADPH + H+, L-arginine,
oxygen and tetrahydrobiopterin as a cofactor (Wu & Morris 1998, Alderton et al. 2001).
In this reaction, NADPH + H+, L-arginine, and oxygen are converted to NO, L-citrulline,
and NADP+ (Figure 2.4; Wu & Morris 1998, Alderton et al. 2001). Despite the
importance of NO and the plethora of research exploring L-arginine and NO, only around
2% of L-arginine metabolism is represented by this pathway.
Unlike NOS, the degradation of L-arginine by the enzyme arginase represents the
majority of L-arginine catabolism (Wu & Morris 1998). Arginase exists as two
isoenzymes encoded by separate genes: arginase I and arginase II. Arginase II is localized
in the mitochondria, while Arginase I is found in the cytosol and is highly expressed in
hepatocytes where it has a major role in ammonia detoxification through the action of the
urea cycle (Wu & Morris 1998, Wu et al. 2009). Both types of arginase isoenzymes are
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thought to be expressed in all cell types (Wu & Morris 1998). Through hydrolysis of Larginine, arginase produces urea and ornithine (Figure 2.4; Voet et al. 2008). Further
catabolism of ornithine can yield either polyamines, glutamate, or proline.
Decarboxylation of ornithine by ornithine decarboxylase will yield the first polyamine
putrescine which serves as the precursor for the other naturally occurring polyamines
spermidine and spermine through the action of spermidine synthase and spermine
synthase, respectively (Figure 2.4; Wu & Morris 1998). Alternatively, ornithine can
undergo transamination to produce L-Δ1-Pyrroline-5-carboxylate (P5C), a precursor for
either proline or glutamate, through the action of ornithine aminotransferase (OAT;
Figure 2.4; Wu & Morris 1998).
In addition to the metabolites produced from NOS and arginase, L-arginine is also
a precursor for creatine. Arginine:glycine amidinotransferase transfers the guanidino
group from L-arginine to glycine, producing guanidinoacetate and ornithine (Figure 2.4;
Wu & Morris 1998). While arginine:glycine amidinotransferase is expressed in the liver,
pancreas, and kidney (McGuire et al. 1986), the kidney is the major site of
guanidinoacetate production (Wu & Morris 1998, Edison et al. 2007). Guanidinoacetate
enters the circulation and is methylated by guanidinoacetate N-methlytransferase in the
liver, producing creatine (Figure 2.4; Wu & Morris 1998).
To balance the catabolism of L-arginine by the aforementioned mechanisms and
to maintain L-arginine homeostasis, endogenous synthesis of L-arginine occurs.
Endogenous synthesis of L-arginine is depicted in Figure 2.5 and is an effort
accomplished by the small intestine and kidney. In brief, the two vital steps in this
process are the conversion of either glutamine/glutatmate or proline to P5C, with P5C
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synthase and proline oxidase being of importance (Wu & Morris 1998, Wu et al. 2009).
Next, through the action of ornithine aminotransferase (OAT), P5C undergoes
transamination with glutamic acid to produce ornithine. Ornithine combines with
carbamoyl-phosphate to form citrulline via ornithine carbamoyltransferase.
Argininosuccinate is then synthesized through the action of argininosuccinate synthase
(ASS) which combines aspartate and citrulline. Finally, L-arginine is synthesized from
argininosuccinate by argininosuccinate lyase (ASL; Figure 2.5; Wu & Morris 1998).
Windmueller and Spaeth (Windmueller & Spaeth 1974) demonstrated that
glutamine and glutamate are absorbed by the small intestine and metabolized to form
citrulline. Later, Wu and colleagues (1994) observed that the enterocytes of the small
intestine produced citrulline from glutamine. In adult mammals, the majority of Larginine synthesis does not occur in the small intestine despite the production of citrulline
(Blachier et al. 1993). However, the small intestine does synthesize endogenous Larginine in neonatal mammals (Blachier et al. 1993). Blachier and colleagues (1993)
observed that porcine enterocytes were able to synthesize L-arginine from L-glutamine,
L-citrulline, and L-ornnthine at the time of birth and up to 8 days of age. However, in
post-weaning pigs, the ability of enterocytes to synthesize L-arginine from L-gluatmine
and L-orninthine was absent, and L-citruline produced very small amounts of L-arginine
(Blachier et al. 1993). Moreover, the activity of L-arginine synthesizing enzymes is
relatively low in the kidney during the neonatal period (Hurwitz & Kretchmer 1986). As
development progresses, arginase activity in the small intestine increases (Blachier et al.
1993) and the L-arginine synthesizing enzymes increase in the kidney (Morris et al.
1991). Beyond the neonatal period, the small intestine continues to synthesize L-citrulline
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(Wu 1997), and the kidney becomes the major site of endogenous L-arginine synthesis
(Featherston et al. 1973, Dhanakoti et al. 1990). The kidneys extract circulating citrulline
from the blood, which is then converted to L-arginine via the actions of ASS and ASL
(Figure 2.5; Wu & Morris 1998). This is further supported by the work of Tizianello and
colleagues (1980) who demonstrated that renal uptake of citrulline positively correlates
with L-arginine output.
A commonly cited misconception is that endogenous synthesis of L-arginine
occurs in the liver (Wu et al. 2009). While it is true that L-arginine is synthesized by
hepatocytes through the urea cycle and that the largest quantities of L-arginine are
synthesized here (Wu & Morris 1998), the activity of arginase in these cells is so great
that there is virtually no net synthesis of L-arginine (Wu et al. 2009). Moreover,
channeling of the urea cycle substrates occurs due to the spatial orientation of the
enzymes and substrates that allows for a highly efficient transfer to occur (Cheung et al.
1989). In this sense, the substrates of the urea cycle, including L-arginine, are quickly
transferred to the next enzyme and rarely “exit” the cycle.
In addition to the kidneys, NO producing cells produce endogenous L-arginine
through a process called the citrulline/NO cycle or arginine/citrulline cycle (Hecker et al.
1990, Wu & Morris 1998). Interestingly, L-citrulline is the immediate precursor for Larginine, meaning that L-arginine can be regenerated after being converted to NO and Lcitrulline through this intracellular mechanism. Briefly, L-citrulline is converted to Largininosuccinate by the ASS, which requires one ATP molecule and aspartate. Largininosuccinate is then converted to L-arginine via ASL, which is then utilized by NOS
to produce NO and L-citrulline, starting the cycle over again (Wu & Morris 1998). This
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cycle can also be coupled with substrates from the citric acid cycle, allowing L-arginine
to be synthesized in NO producing cells.
In brief, L-arginine metabolism primarily occurs through actions of NOS,
arginase and Arginine:glycine amidinotransferase. Interestingly, many of the products of
L-arginine metabolism, such as citrulline, orninthine, glutamate, and proline, can be used
to synthesize L-arginine and maintain L-arginine homeostasis. L-arginine is synthesized
in the liver; however, no net synthesis occurs. Furthermore, NO producing cells possess
the ability to recycle citrulline to produce L-arginine, but by far, the kidney represents the
major site of endogenous synthesis of L-arginine through the conversion of citrulline to
L-arginine.
2.1.3

Safety of L-arginine supplementation
Interest in using amino acid supplementation products has increased in popularity

during the past decade, with the amino acids L-taurine, L-glutamine, and L-arginine
being three of the most utilized and well studied of supplemental amino acids (Shao &
Hathcock 2008). L-arginine is a popular amino acid that is supplemented quite frequently
and is sold under many names, such as L-arginine Plus®, Nature’s Bounty L-arginine ®,
and Doctor’s Best L-arginine ® to name a few. Such L-arginine supplements claim that
L-arginine will provide an overall improvement in cardiovascular health, hasten and
enhance bone, tissue, and wound healing, and promote healthy sexual performance.
Indeed, there is much scientific research that demonstrates that either L-arginine or one
its metabolites aids in these processes (Barbul et al. 1990, Martasek et al. 1991, Riancho
et al. 1995, Chen et al. 1999, Siani et al. 2000, Witte et al. 2002, Palloshi et al. 2004,
Kdolsky et al. 2005) which has further increased its popularity as an amino acid
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supplement. More recent research has demonstrated the role of L-arginine in reproductive
tissues and neonatal tissues suggesting a potential use for L-arginine as a supplement in
livestock species (Flynn & Wu 1996, Wu et al. 1996a, Wu et al. 1997, Kwon et al. 2003,
Kwon et al. 2004, Mateo et al. 2007, Gao et al. 2009a, Gao et al. 2009c, Kim et al.
2011a, Kim et al. 2011b, Kong et al. 2011). As a human health product, L-arginine is
classified as a nutraceutical, and as such, L-arginine supplementation products are not
regulated by the Food and Drug Administration. Moreover, exact upper intake levels and
well defined dosing information has not been established (Shao & Hathcock 2008). Thus,
discussion of the safety of L-arginine supplementation as well as potential complications
that can arise from taking this supplement is of importance.
L-arginine is a basic, cationic amino acid that is considered to be one of the least
toxic and most versatile amino acids (Visek 1986, Flynn et al. 2002). Adequate quantities
of L-arginine are naturally synthesized in healthy adult mammals (excluding some
carnivores) through a concerted effort between the small intestine and kidney in which
the small intestine synthesizes citrulline which is transported to the kidney and converted
to L-arginine (Wu & Morris 1998). Large quantities of L-arginine are also synthesized in
the liver through the action of the urea cycle, however, this process represents very little
net synthesis of L-arginine, as the substrates in this cycle are quickly channeled into the
next enzymatic reaction, allowing minimal L-arginine to escape this process (Wu &
Morris 1998). In addition to endogenously synthesized L-argnine, dietary consumption
represents another source of L-argnine within the body, with approximately 60 % of
digested L-arginine in the diet entering the circulation (Windmueller & Spaeth 1976). Larginine is found in abundant quantities in high quality plant proteins (i.e., soy proteins),
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and daily intake of L-arginine for adult humans ranges from 3 to 6 g (Shao & Hathcock
2008). Because the body can synthesize adequate amounts of L-arginine, it has been
labeled as a non-essential or conditionally essential amino acid; however, L-arginine and
its metabolites have many important physiological roles (Visek 1986, Shao & Hathcock
2008), and supplementation has been shown to produce beneficial effects, as previously
described.
Being an amino acid that is synthesized by the body and naturally found in
common foods, one would assume that L-arginine is safe for consumption with little risk
for side effects. Indeed, much of the literature would support this assumption. Wu and
colleagues (2007) found that chronic administration of varying amounts of L-arginine to
rats, sheep and pigs produced no observable health complications, and due to the use of
these animals as models for studying human health conditions, one could assume that the
same findings would hold true for humans. Using the data obtained from animal studies
as an estimate, Wu and colleagues (2007) concluded that a 5 kg infant, 30 kg adolescent
child, and 70 kg adult human should tolerate dietary L-arginine supplementation dosages
of ~ 3, 10, and 15 g per day, respectively. In support of this recommendation, McCaffrey
and colleagues (1995) reported that intravenous (i.v.) administration of 500 mg/kg of
body weight of L-arginine to neonates was an effective treatment for persistent
pulmonary hypertension of the newborn that produced no adverse effects. Moreover,
Beaumier and colleagues (1995), reported that i.v. infusion of 370mg/kg of body weight
of L-arginine produced no harmful effects as reviewed by Wu and colleagues (2007).
Oral administration of L-arginine has also been reported to be well tolerated. Three 7
gram oral doses of L-arginine administered to hypercholesterolemic adults improved
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endothelium-dependent vascular dilation with no reported clinical events (Clarkson et al.
1996). A single oral dose of 10 g has also been reported to be well tolerated by adults
(Tangphao et al. 1999b). In addition, it has been reported that most adults can tolerate as
much as 15 g per day of L-arginine taken orally (Tangphao et al. 1999a).
L-arginine is rapidly metabolized by the body. Wu and colleagues (2007) found
that the half life of L-arginine in the circulation is about 1 hour in pigs, sheep, and rats.
Moreover, pharmacokinetic analyses revealed that serum L-arginine concentrations
return to baseline values following either oral or i.v. administration within 5 hours for
rats, sheep, and pigs (Wu et al. 2007) and within 8 hours for humans (Tangphao et al.
1999b). This is important in considering the safety of L-arginine supplementation, as it
indicates that continuous oral or i.v. administration is needed to produce a constant
elevated serum L-arginine level (Wu et al. 2007). Interestingly, the beneficial effects of
L-arginine supplementation have been reported when L-arginine was supplemented only
once (Chen et al. 1999, Kdolsky et al. 2005) or twice (Mateo et al. 2007) per day,
indicating that the beneficial effects of L-arginine supplementation can be achieved
without chronic elevation of serum L-arginine levels. A recent meta-analysis by Shao and
Hathcock (2008) found that there were no consistent patterns of adverse health effects
associated with L-arginine supplementation in published human trials. Thus, the
extensive body of scientific data suggests that L-argnine supplementation is a safe
practice.
The literature establishes the safety of L-arginine supplementation, but as with all
chemical substances, there is always a chance that L-argnine may produce undesired side
effects or complications. L-arginine can be catabolized by nitric oxide synthase (NOS) to
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form nitric oxide (NO). One might speculate that L-arginine supplementation could cause
nitrite and nitrate poisoning. Nitric oxide has a very short half life and is rapidly
converted into nitrite (NO2-) or nitrate (NO3-). Nitrite reacts with hemoglobin to form met
hemoglobin (Chow & Hong 2002). When 30 to 40 % of all hemoglobin the blood is
converted to methemoglobin, the ability to transport oxygen through the blood and
deliver it to tissues becomes impaired (Chow & Hong 2002). Consequently, the argument
could be postulated that excessive L-arginine supplementation could cause an unsafe
level of nitrite in the blood, which could lead to nitrite poisoning; however, there does not
appear to be a documented case of this occurring as a result of excessive L-arginine
supplementation.
While it is purely speculation that L-arginine supplementation may potentially
cause nitrite poisoning, there have been some rare cases in which administration of Larginine has caused adverse effects. Nitric oxide is known to be a powerful vasodilator,
causing relaxation of the smooth muscle cells that surround blood vessels. Endothelial
cells, comprising the blood vessel, produce NO which diffuses into the surrounding
smooth muscle cells (Ignarro 1989). Nitric oxide has been shown to activate guanylate
cyclase, thereby increasing cyclic guanosine-cyclic monophosphate (c-GMP) levels
(Arnold et al. 1977). This increased c-GMP activates calcium pumps (Lincoln &
Cornwell 1993) and potassium channels (Archer et al. 1994) within the smooth muscle
cells. Alternatively, NO can also activate potassium channels directly, without the need
for cGMP (Bolotina et al. 1994). Through either mechanism, the activation of potassium
and calcium channels reduces the intracellular concentration of calcium within smooth
muscle cells (Ignarro 1989). Ultimately, this reduces the ability of the smooth muscle to
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contract, and vasodilatation occurs. Moreover, one might speculate that L-arginine taken
in excess could cause hypotension through an unsafe increase in NO, as L-arginine
supplementation can increase serum NO levels, measured as NO metabolites (Zeng et al.
2008). Nakaki and colleagues (1990) reported a single injection of L-arginine (500 mg/kg
of body) induced hypotension in patients. However, one might argue that this same
dosage taken orally may not produce the same result because only 60% of dietary Larginine enters the circulation (Windmueller & Spaeth 1976).
In other cases that report negative effects of L-arginine supplementation, there has
been a pre-existing complicating factor or a miscalculation of the L-arginine dosage. One
of the interesting properties of L-arginine is that it can displace intracellular potassium
because of its cationic nature (Dickerman & Walker 1964). This can lead to an increase
in blood potassium concentration resulting in hyperkalemia, which can lead to cardiac
arrest if left untreated. In normal patients, L-arginine has been reported to increase blood
potassium concentration, but this increase does not reach a pathological concentration
(Massara et al. 1981). In contrast, Massara and colleagues (1981) found that i.v.
administration of L-arginine (0.5 g/kg of body weight) to diabetic patients produced
hyperkalemia with a blood potassium concentration that was a pathological level,
suggesting a role for insulin in regulating the hyperkalemic effect of L-arginine.
Individuals with renal failure are also at increased risk to developing hyperkalemia
following L-arginine infusion (Hertz & Richardson 1972), possibly because the normal
mechanisms needed to excrete potassium are absent or impaired in these individuals.
Moreover, patients with both liver and kidney disease are even more prone to exhibiting
negative effects due to L-arginine supplementation. Bushinsky and Gennari (1978)
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observed that patients with liver and kidney disease exhibited severe hyperkalemia after
L-arginine infusion, with one patient dying from cardiac arrhythmia. It is thought that a
combination of both kidney and liver disease represents an extreme risk when
supplementing L-arginine. In these patients the ability to metabolize L-arginine and to
excrete potassium is absent or poorly functioning, which puts them at an increased risk of
developing severe hyperkalemia (Bushinsky & Gennari 1978). Hyperkalemia is not the
only rare side effect that has been associated with L-arginine supplementation.
Hyperammonemia has also been reported in a case study, but once again this was
associated with an underlying condition and an accidental dosing error. Arnold (2007)
reported a case of a 3-year old girl who experienced hyperammonemia with L-arginine
infusion. The girl suffered from ornithine transcarbamoylase deficiency (OTCD), a rare
disease in which ornithine transcarbamoylase, an important enzyme in the urea cycle, is
ineffective, resulting in hyperammonemia. As treatment, she received i.v. infusion of Larginine, which may serve to stimulate the urea cycle, as increased substrate availability
can increase the rate of deficient enzymes in the urea cycle (Voet et al. 2008). In one
particular episode of hyperammonemia, the 3-year old girl was accidentally administered
a dose of L-arginine that was 15 times more than normal. Consequently, she developed
severe hyperammonia (Arnold 2007) as a result of her decreased ability to produce urea
efficiently from the excess ammonia from the L-arginine overdose. Another rare
overdose of L-argnine was reported by Gerard and Luisiri (1997), which resulted in the
death of a 21-month old girl. L-arginine is routinely given to stimulate growth hormone
release (Boger & Bode-Boger 2001); however, approximately 8 times the normal amount
was accidently administered to the 21-month old girl. As a result, she developed
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hyponatremia (low salt content), acidosis, pontine and extrapontine myelinolysis, and
cardiac arrest and did not survive (Gerard & Luisiri 1997). The symptoms reported are
not similar to the other reported symptoms associated with L-arginine, such as
hyperkalemia and hyperammonemia, suggesting other mechanisms of action.
In summary, L-arginine is an amino acid that is commonly consumed and
naturally produced by the body. L-arginine and its metabolites have a myriad of functions
in cellular physiology, making L-argnine a versatile and important amino acid. Recently,
there has been a large increase in dietary supplementation of L-arginine due to the
reported health benefits associated with this amino acid, making discussion of its safety
important. Most studies that evaluate the use L-arginine as a supplement report that it
produces health benefits without causing severe side effects. Nevertheless, there have
been some cases in which L-arginine has been reported to cause complications; however,
one must keep in mind that most of these cases were associated with a dosage error
and/or a pre-existing complicating factor, such as liver or kidney disease. For the most
part, it appears that L-arginine supplementation is a safe practice.
2.2

Placental biology
Eutherian mammals have a distinct mechanism that imparts them with a

reproductive advantage over other species: the placenta (Senger 2003). Non-eutherian
mammals lay eggs in which their offspring develop prior to birth. In sharp contrast,
eutherian mammals exhibit intrauterine growth and development of offspring, and this
phenomenon is made possible by a transient organ known as the placenta. Intrauterine
growth and the placenta insure that the developing offspring has the best opportunity
receive nutritional support and protection during a critical time (Senger 2003). As a
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transient metabolic organ, the placenta serves as the point of exchange between the dam
and developing fetus (Senger 2003, Rosenfeld 2007). Moreover, the placenta provides a
means for respiratory gasses, nutrients, and waste products to be exchanged between the
dam and fetus. In addition to a point of nutrient exchange, the placenta provides structural
support for the developing conceptus, serves as a transient endocrine gland, and provides
an immunological barrier (Rosenfeld 2007). In this way, the placenta exerts significant
control over the normal and successful development of the fetus, and its proper
development and function is paramount for normal pregnancy.
2.2.1

Placental development and composition
During embryonic development, the fertilized embryo enters a developmentally

important stage known as the blastocyst stage in which two principal cell types are
formed: the inner cell mass and trophoblast cells (trophectoderm). This stage of
development exhibits great variation in terms of timing between species. In humans and
pigs, this stage occurs around day 5 post-ovulation. In horses, the embryo enters the
blastocyst stage during days 6 to 8 following ovulation, while in cattle and sheep, this
stage occurs between days 7 and 12 and days 4 and 10, respectively (Senger 2003).
Following the blastocyst stage, the embryo emerges from the existing zona pelucida in
preparation for adhesion or attachment to a receptive endometrium. At this stage, the
inner cell mass represents those cells that will eventually become the developing fetus
and the trophectoderm are the population of cells that will give rise to the fetal
contribution of the placenta.
At this point in the pregnancy, there exists much diversity between species. In
most domestic animal species (i.e., cattle, horses, pigs, and sheep), development of
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extraembryonic membranes occurs prior to adhesion to the endometrium; however, in
humans, the development of extraembryonic membranes occurs after the hatching
blastocyst implants in the endometrium (Senger 2003). The extraembryonic membranes
develop from all three germ layers (ectoderm, mesoderm, and endoderm) and include the
yolk sac, amnion, chorion, and allantois (Rosenfeld 2007). Originating from the
endoderm and mesoderm, the yolk sac and allantois are considered to be the vascular
extraembryonic membranes while the chorion and amnion orginate from the ectoderm
and mesoderm and are avascular (Rosenfeld 2007). In most species, the yolk sac is a
transient structure and eventually regresses, and the amnion serves as a fluid-filled
protective environment for the developing fetus (Senger 2003). The allantois is also a
fluid-filled sac and is mostly regarded as a collection site for fetal liquid waste (Senger
2003); however, some research suggests that the allantois and the associated fluid serves
as a nutrient reservoir for the developing fetus (Buhi et al. 1983, Wu et al. 1996a).
Ultimately, the chorionic membrane and the allantoic membrane fuse to form the
chorioallantois, and it is this structure that will eventually adhere or implant in the
endometrium. On the chorioallantoic membrane are structures referred to as chorionic
villi, and it is these structures that form functional unit of the placenta and the point of
exchange between the maternal and fetal circulation (Senger 2003). The chorionic villi
are comprised of numerous blood vessels supported by connective tissue, are surrounded
by trophoblasts which forms the epithelial surface of the villi, and is the component
which interfaces with the maternal endometrium (Benirschke 1998). Ultimately, the
blood vessels of the chorionic villi will pool into either the umbilical artery or vein which
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comprise the umbilicus and serves as the exchange mechanism whereby the fetus
receives nutrients and expels waste.
2.2.2

Classification of placentas
The placenta has been described as being one of the most species diverse organs

(Rosenfeld 2007); therefore, discussion of placental classification is of importance. There
are three classification systems used to describe the placenta: 1) the amount of
endometrial tissue expelled at birth; 2) distribution of chorionic villi; and 3) number of
microscopic tissue layers that separate maternal and fetal circulation.
2.2.2.1

Classification based upon loss of endometrial tissue
In this classification system, the placenta is categorized as being either non-

deciduate or deciduate. A non-deciduate placenta implies there is little to no expulsion of
maternal endometrial tissue or blood loss during parturition. This type of placenta is
present in most livestock species and in species with a non-invasive placentation. In
contrast, a deciduate placenta describes one in which there is shedding of the maternal
endometrium and considerable blood loss at parturition; such placentation is exhibited by
carnivores and humans (Rosenfeld 2007).
2.2.2.2

Classification based upon distribution of chorion villi
A second method for classifying placentas is based upon the fact the distribution

of chorionic villi varies greatly between species. As aforementioned, the chorionic villi
form the functional unit of the placenta, and depending upon the distribution of the
chorionic villi, placentas can be classified as being either diffuse, zonary, discoid or
cotyledonary (Senger 2003). The diffuse placenta is found in the mare and sow and is
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characterized by closely spaced chorionic villi that are distributed in a diffuse pattern
across the entire chorioallontoic membrane. In this fashion, the fetal-maternal interface is
distributed throughout the chorioallantois and endometrium. In addition, the mare
exhibits a unique type of diffuse placentation in that the chorionic villi form microscopic
structures called microcotyledons (Senger 2003). A zonary placenta exhibits chorionic
villi that form band- or ring-like structure around the chorioallantoic membrane that
attaches to maternal endometrium. Zonary placentation is found in carnivores and
depending upon the species, either one or two bands may be present (Senger 2003,
Rosenfeld 2007). Humans and rodents display a discoid placenta which forms a large
disk-shaped collection of chorionic villi (Benirschke 1998), and this form of placentation
is one that actually “implants” into the maternal endometrium, as it erodes the
endometrial epithelium, stroma, and endothelium during the implantation process
(Fazleabas 2003). The final classification of placentas that is based upon the distribution
of chorionic villi is the cotyledonary placenta which is exhibited by ruminants. The
cotyledonary placenta is characterized by the presence of macroscopically visible
structures called cotyledons. A cotyledon is a vascularized trophoblastic structure that
interdigitates with a structure on maternal endometrium known as a caruncle (Telugu &
Green 2007). Together, the fetal cotyledon and the maternal caruncle form a structure
known as the placentome. In sheep there are approximately 90 to 100 placentomes, and
cattle exhibit 70 to 120 placentomes (Senger 2003). The cotyledonary placenta differs
from the diffuse placenta found in the sow and mare in that the points of exchange, the
cotyledons, are macroscopic and far less in number than the points of exchange found in
the diffuse placenta.
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2.2.2.3

Classification based upon the number of microscopic tissue layers
separating maternal and fetal circulation
The third placental classification system is based upon the observation that the

number of microscopic tissue layers that separate maternal and fetal circulation also
differs drastically between species. As such, this classification provides a comparative
point of view in terms of the placental invasiveness. There are a possible total of six
tissue layers that may separate the maternal and fetal circulation: 1) uterine endothelium,
2) uterine stroma (connective tissue); 3) uterine epithelium; 4) chorionic (fetal)
epithelium; 5) fetal connective tissue; and 6) fetal endothelium (Rosenfeld 2007).
According to this classification system, there are three types of placentation: 1)
epitheliochorial; 2) endotheliochorial; and 3) hemochorial, with the number of
microscopic tissue layers separating maternal and fetal circulation being six, four, and
three, respectively. The epitheliochorial placenta (Figure 2.6) is found in cattle, sheep,
horses, and pigs. In the epitheliochorial placenta, all six layers are present: 1) uterine
endothelium, 2) uterine stroma (connective tissue); 3) uterine epithelium; 4) chorionic
(fetal) epithelium; 5) fetal connective tissue; and 6) fetal endothelium making this type of
placentation the least invasive type (Telugu & Green 2007). However, in sheep and
cattle, a derivative of the epitheliochorial placenta exists called the syneptitheliochorial
placenta. In this type of placentation, specialized chorionic binucleated epithelial cells
transiently migrate and fuse with the maternal epitheilium; thus cattle and sheep have five
to six tissue layers separating the maternal and fetal circulation (Rosenfeld 2007, Telugu
& Green 2007). The endotheliochorial placenta (Figure 2.7) has been observed in
carnivores, insectivores, and bats (Telugu & Green 2007) and has four layers separating
the fetal and maternal circulations: 1) uterine endothelium; 2) chorionic (fetal)
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epithelium; 3) fetal connective tissue; and 4) fetal endothelium. In this placentation, the
uterine epithelium and stroma are eroded by the invading trophoblasts, allowing the
chorion to be in direct apposition to the uterine endothelium (Rosenfeld 2007, Telugu &
Green 2007). Finally, the hemochorial placenta (Figure 2.8) is found in rodents and
primates and consists of only three tissue layers between fetal and maternal circulation:
1) chorionic (fetal) epithelium; 2) fetal connective tissue; and 3) fetal endothelium. In this
type of placentation, the invading trophoblasts erode all layers of the maternal interface
(Benirschke 1998) and the chorionic epithelium is in direct apposition to maternal pools
of blood (Senger 2003). This intimate setting allows gasses and nutrients from maternal
circulation to be in direct contact with the chorionic epithelium which facilitates
exchange (Senger 2003). Thus, the hemochorial placenta is classified as being the most
invasive type of placentation.
2.2.3

Angiogenesis in the placenta
One physiological process which is vital for properly functional placental tissue is

angiogenesis. Angiogenesis can be defined as the development of new vasculature from
existing vascular structures, and it is a physiological process that is required for all
developing tissues, especially the placenta (Reynolds & Redmer 2001, Redmer et al.
2004). Angiogenesis is particularly important for properly functional placenta tissues
because one of the primary roles of the placenta is to facilitate efficient nutrient, gas, and
waste exchange between the dam and fetus (Reynolds & Redmer 2001). The importance
of angiogenesis is apparent as the development of placental circulation is one the earliest
to occur during placental development (Reynolds & Redmer 2001); moreover, deficient
development of placental vascularization is associated with an increased incidence of
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early embryonic mortality (Meegdes et al. 1988). While placental angiogenesis is
important and occurs throughout gestation, there is a marked increase in the degree of
placental vasculature that occurs during the latter third of gestation. Placental capillary
length density increases by approximately four-fold during the latter third of gestation in
mice (Coan et al. 2004). Similarly, the vascular density in the cotyledons of the ovine
placenta increases by approximately four-fold (Stegeman 1974), while the relative
number of blood vessels in the porcine placenta increases by three-fold during the latter
third of gestation (Vonnahme et al. 2001). It is though that this increase in placental
vascular development is needed to support the fetus which undergoes tremendous growth
during this time. In terms of a physiological process, angiogenesis is quite complex and
several factors, such as vascular endothelial growth factor (VEGF), NO, polyamines, and
fibroblast growth factor (FGF), influence this important aspect of placental development.
2.2.3.1

Vascular endothelial growth factor
Vascular endothelial growth factor is a protein hormone that is vital for proper

fetal and placental angiogenesis (Reynolds & Redmer 2001), and without this hormone,
the pregnancy will fail (Ferrara et al. 1996). Vascular endothelial growth factor is
responsible for stimulating vascular permeability and vascular endothelial cell protease
production and migration, both of which are vital for the development of new vascular
structures as well as the turnover of old vasculature (Reynolds & Redmer 2001). The
importance of VEGF and its receptor (VEGFR2) in fetal and placental development was
demonstrated by Fong and colleagues (1995), Shalaby and colleagues (1995), and Ferrara
and colleagues (1996), who demonstrated that a pregnancy will fail when embryos lack
the genes necessary to produce VEGF and its receptor vascular endothelial growth factor
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2 (VEGFR2). Moreover, Ferrara and colleagues (1996) speculated that if VEGF activity
during pregnancy decreases to a critical point, organogenesis may be permanently
impaired.
As a pro-angiogenic factor, VEGF has been described as the most potent
stimulator of angiogenesis while VEGFR2 is considered to be the primary receptor by
which VEGF elicits its pro-angiogenic effects, including the stimulation of endothelial
cell growth in developing tissues (Otrock et al. 2007, Angst et al. 2010). In the ovine
placenta, VEGF mRNA increases from day 50 to 90 of gestation and remains elevated for
the remainder of gestation in the fetal cotyledons while VEGF mRNA in the maternal
caruncle remains steady from day 50 to day 100, peaks at day 130, then decreases near
term at day 140 of gestation (Borowicz et al. 2007). Vascular endothelial growth factor
mRNA expression parallels the expansion of placental blood vessels in the porcine
placenta with expression remaining relatively steady from day 25 to day 70 and then
increasing for the remainder of gestation (Vonnahme et al. 2001).
Hypoxia is one of the most powerful inducers of VEGF gene expression, and
hypoxia-inducible factor-1 (HIF) is the best characterized transcription factor that is
known to stimulate VEGF gene expression under hypoxic conditions (Josko & Mazurek
2004). Hypoxia inducible factor is only able to illicit transcription when it is in its active
form which is a heterodimer composed of the two subunits HIF-1α and HIF-1β (Josko &
Mazurek 2004). Hypoxia favors the interaction of HIF-1α and HIF-1β by stabilizing HIF1α, which is normally ubiquitinated and degraded by proteases under normoxic
conditions (Wenger 2000). The VEGF promoter contains a hypoxia-response element
which is activated by HIF (Kimura et al. 2000). Upon binding to VEGFR2, VEGF elicits
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a signal cascade through the Raf-MEK-ERK (MAPK) signaling pathway which sets a
series of cellular events into motion. One of the first processes to occur is degradation of
the basement membrane surrounding the initial blood vessel. Following this, VEGF also
stimulates the proliferation and migration of endothelial cells towards the area of
basement membrane degradation. At this site, the endothelial cells continue to proliferate,
forming a new vascular structure. Ultimately, the basement membrane is restored and the
new blood vessel is formed as a branch from the initial vessel (Angst et al. 2010).
2.2.3.2

Nitric oxide
Nitric oxide is an angiogenic promoter that is produced by the enzyme nitric

oxide synthase (NOS) and requires L-arginine as a substrate and tetrahydrobiopterin as a
co-factor (Wu et al., 2004, 2006). Nitric oxide mediates a number of reproductive process
in both males and females (Rosselli et al. 1998). Nitric oxide synthase is produced in the
human (Myatt et al. 1993), sheep (Kwon et al. 2004), pig (Wu et al. 1998), rat (Zeng et
al. 2008), and mouse (Swaisgood et al. 1997) placenta. Immunolocalization techniques
have revealed that NOS is present in the human umbilical artery and vein endothelium as
well as the trophoblasts of the chorionic villi (Myatt et al. 1993). In the ovine placenta,
NOS activity and NO synthesis are greatest in the placentome compared to the
intercotyledonary spaces of the chorioallantoic membranes. Nitric oxide synthase activity
in the intercotyledonary chorioallantoic membranes increases with a peak at day 60 of
gestation followed by a decline through the remainder of gestation, while activity in the
placentome increases with a peak at day 60 and remains elevated for the duration of
pregnancy (Kwon et al. 2004). Nitric oxide synthesis in the ovine placenta peaks at day
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60 and is followed by a decline in both the intercotyledonary chorioallantoic membranes
and placentome (Kwon et al. 2004).
Nitric oxide directly affects placental angiogenesis by stimulating the production
of placental endothelial cells which is a critical process in angiogenesis. In vitro exposure
of ovine fetoplacental artery endothelial cells and human placental artery endothelial cells
to an exogenous source of NO results in enhanced cell proliferation through the
activation of the mitogen activated protein kinase pathway (Zheng et al. 2006).
Interestingly, this is the same pathway through which VEGF elicits its pro-angiogenic
effects, leaving one to speculate a potential relationship between these two molecules.
Indeed, NO has been demonstrated to induce VEGF mRNA and protein in keratinocytes
(Frank et al. 1999) and vascular smooth muscle cells (Dulak et al. 2000, Jozkowicz et al.
2001). As aforementioned, VEGF transcription is induced under hypoxic conditions
through the stabilization of HIF-1α protein, and NO has been shown to increase HIF-1α
protein accumulation (Sandau et al. 2000). In addition to stimulating placental
endothelial cell proliferation, NO can also serve as pro-angiogenic stimulus through
induction of VEGF expression.
2.2.3.3

Polyamines
Polyamines are cationic molecules that affect cellular function through binding of

nucleic acids and proteins (Igarashi & Kashiwagi 2000). Arginine, a versatile amino acid,
serves as a precursor for polyamines through its conversion to ornithine via arginase.
Decarboxylation of ornithine by ornithine decarboxylase yields the first polyamine
putrescine which serves as the precursor for the other naturally occurring polyamines
spermidine and spermine through the action of spermidine synthase and spermine
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synthase, respectively (Wu & Morris 1998). In various cell lines, polyamines are
implicated in proper cell cycle functioning as well as promoting an anti-apoptotic state
(Seiler & Raul 2005). Futhermore, polyamines are important molecules needed for cell
proliferation. Because the placenta and associated vascular structures experience a
tremendous amount of growth during pregnancy, polyamines are important molecules for
placental development. The effect of polyamines on angiogenesis is exhibited in tumor
cells when inhibition of polyamine synthesis abrogates neovascularization and the
addition of polyamines restores the degree of vasculature (Jasnis et al. 1994), and it has
been proposed that they have a similar role in placental angiogenesis (Wu et al. 2004, Wu
et al. 2006). In addition, Akt1activity (protein kinase B) is critical for VEGF-mediated
angiogensis (Ackah et al. 2005). Recently, it has been demonstrated that L-arginine, the
precursor for polyamines, increases phosphorylation, and therefore the activity, of Akt-1
in ovine trophectoderm cells (Kim et al. 2011a), and Akt-1 phosphorylation is also
enhanced in cells with elevated expression of ornithine decarboxylase (Hayes et al.
2005), the enzyme responsible for converting ornithine to first polyamine putrescine.
Consequently, polyamines affect angiogenesis by serving as an enhancer of VEGF
stimulated cell signaling through protein phosphorylation.
In the pig placenta, polyamine synthesis is present throughout gestation,
increasing with a peak being observed around day 40 which is followed by a decline for
the remainder of term. Likewise, the activity of ornithine decarboxylase, the rate limiting
enzyme in polyamine synthesis, increases until day 40 of gestation and then declines (Wu
et al. 2005). Polyamine concentrations are greater in the ovine placentome compared to
the intercotyledonary chorioallantoic membranes. In the placentome, polyamine
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concentrations increase and peak at day 40 of gestation and then decline while the
polyamine concentration in the intercotyledonary chorioallantoic membranes increases
and peaks at day 80 and declines during the remainder of gestation (Kwon et al. 2003).
2.2.3.4

Fibroblast growth factor
Fibroblast growth factor (FGF) is a peptide hormone that possesses similar

angiogenic activity as VEGF and has a role in placental angiogensis. Like VEGF, FGF
increases the proliferation of placental endothelial cells, and in ovine placental
endothelial cells, FGF achieves this effect through the same signaling pathways as
VEGF, namely the Raf-MEK-ERK or mitogen activate protein kinase (MAPK) cell
signaling pathway (Zheng et al. 1999). Fibroblast growth factor expression has been
detected in the human placenta along with its receptors (Anteby et al. 2005). Using the
ovine model, Zheng and colleagues (1997) demonstrated that FGF concentration is
greater in the cotyledonary region compared to the intercotyledonary chorioallantoic
membranes. Additionally, FGF increases during the latter third of gestation in ovine
cotyledon until day 130, after which there is a decline at day 140, and interestingly this
pattern of expression parallels endothelial cell mitogenic activity of the cotyledon during
this time as well (Zheng et al. 1997).
2.2.4

Transport and metabolism of L-arginine in the placenta
Amino acids, including L-arginine, partially satisfy the carbon and nitrogen

demands of the developing placenta and fetus (Regnault et al. 2005). In addition to
providing carbon and nitrogen substrates, amino acids also serve as constituents of
proteins and are precursors for non-protein substances such as signaling molecules and
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nucleotides (Grillo et al. 2008). Concentrations of most essential amino acids are greater
in the fetal circulation compared to maternal circulation (Regnault et al. 2005), indicating
that active transport of amino acids is an important process during gestation. In terms of
nutrient transfer across the placenta, an interesting phenomenon occurs as the pregnancy
progresses. In the human, fetal weight increases by approximately 20-fold between weeks
16 and 40 (Regnault et al. 2005). However, during a similar time period (weeks 25 and
36), the villous surface area of the placenta increases by only a factor of 9.5 (Teasdale &
Jean-Jacques 1985). This would suggest that nutrient transfer across the placenta
increases in efficiency as gestation progresses (Teasdale & Jean-Jacques 1985, Regnault
et al. 2005). This increased efficiency could easily be achieved as there is an
approximately 10-fold increase in villous volume occupied by vasculature (Myatt 2006),
which would enhance the transfer of nutrients.
Recalling the anatomy of the placenta, amino acids that are to undergo placental
transport would be present either in the extracellular space at the maternal-fetal interface
(i.e., epitheliochorial and endotheliochorial placentas) or in the pools of maternal blood
(i.e., hemochorial placentas). As such, placental transport of amino acids involves three
general steps: 1) uptake across the apical membrane of the chorionic villi into the
trophoblasts; 2) transport through the cytoplasm of the trophoblasts; and 3) efflux of
amino acids across the basal lateral membrane into fetal circulation (Regnault et al.
2005). The transport of L-arginine across the placenta involves three systems: b0,+, y+L,
and y+. Studies in the human placenta have localized these sytems on trophoblasts, with
systems y+ and y+L functioning on the apical membrane of the chorionic villi and all
three systems being present on the basal membrane of the chorionic villi (Furesz & Smith
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1997, Ayuk et al. 2000). Additionally, the activities of these transport systems appears to
be temporally regulated during gestation. In the human placenta, the apical transport of
L-arginine by system y+ increases with gestational age; however, y+L transport of Larginine has a inverse relationship with gestational age (Ayuk et al. 2002).
In addition to being delivered to the fetal circulation, L-arginine can also be
metabolized by trophoblasts. As previously described, polyamines and NO are two Larginine metabolites that are synthesized through the actions of arginase and ornithine
decarboxylase (polyamines) and NOS (NO). Nitric oxide synthesis in the ovine placenta
peaks at day 60 and is followed by a decline in both the intercotyledonary chorioallantoic
membranes and placentome while NOS activity in the placentome increases with a peak
at day 60 and remains elevated for the duration of pregnancy (Kwon et al. 2004).
Arginase is expressed throughout gestation in the human placenta but decreases as
pregnancy progresses (Ishikawa et al. 2007). This corresponds well to the porcine and
ovine placenta in which polaymines and the activity of ornithine decarboxylase, the ratelimiting enzyme for polyamine synthesis, decreases after day 40 of gestation (Kwon et al.
2003). Interestingly, the elevated polyamine production in the early ovine placenta
suggest a role for polyamines in cell proliferation of the trophoblasts as it has been
demonstrated that polyamine biosynthesis enhances cell proliferation and protein
synthesis in early ovine trophectoderm cells (Kim et al. 2011a, Kim et al. 2011b).
2.3

Uterine biology
As a reproductive organ, the uterus has been designated as the organ of pregnancy

as it provides the maternal environment for the developing offspring. The uterus provides
nourishment for the conceptus throughout gestation. During the pre-implantation and
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peri-implantation periods, the uterus provides essential nutrients and growth factors in a
secretion known as uterine histotroph. Additionally, the uterus continues this supportive
role for the offspring following embryo attachment by acting as the of point interface
with the placenta and by providing the environment in which the conceptus will grow and
develop. In addition to providing an environment that is suitable for fetal growth and
development, the uterus also influences ovarian cyclicity, provides a means for sperm
maturation and transport, and generates the muscle contractions needed to expel the fetus
and the associated membranes at the time of parturition (Bartol 1998, Senger 2003).
2.3.1

Uterine anatomy
The uterus is comprised of three distinct sections: 1) the uterine horns; 2) the body

or corupus; and 3) the cervix (Constantinescu 2007), with the uterine horns or corpus
(depending upon the species) representing the sections that provide the intrauterine
environment for the developing offspring and the cervix providing a physical barrier to
the outside environment (Mossman 1977). The uterine horns and corpus are comprised of
three layers: the perimetrium, the myometrium, and the endometrium. Serving as the
serosal layer of the uterus, the perimetrium forms a tunic around the uterus and is
comprised of a thin layer of squamous epithelial cells that is continuous with the visceral
peritoneum and is suspended by the broad ligament (Senger 2003, Constantinescu 2007).
Underneath the perimetrium lies the myometrium or the muscular wall of the uterus
(Grainger 1998). Directly in apposition to the perimetrium is the outer layer of the
myometrium which consists of longitudinal smooth muscle (Senger 2003). The
myometrium also has two inner layers comprised of oblique and circular smooth muscle
(Constantinescu 2007). Collectively, the three layers of smooth muscle form the
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myometrium and provide the physical forces needed to expel the fetus at parturition.
Histologically, the endometrium consists of glandular and luminal epithelium and stroma
(fibroblasts). Comprised of fibroblast cells, the stroma forms the connective tissue base
upon which the endometrial epithelium attaches. The endometrium epithelium of
viviparious mammals contains both simple cuboidal and simple columnar epithelial cells
which form the surface to which the developing embryo attaches as well as the coiled
tubular glands which secrete the histotroph that is vital for early embryonic survival
(Bartol 1998).
2.3.2

Classification of uteri
Much like the mammalian placenta, the uterus is an organ that exhibits much

diversity between species. As a result, uteri have been classified based upon gross
morphology, type of placentation supported, and endometrial histology.
2.3.2.1

Classification based upon gross morphology
Using gross morphology to classify uteri, there are three types: simplex, duplex,

and bicornuate, with the duplex and bicornuate uteri having well defined uterine horns
and the simplex uterus lacking horns and consisting of only the corpus (Mossman 1977).
The simplex uterus is found in primates, has a single unpaired corpus, and has been
described as being pear-like in shape (Mossman 1977, Grainger 1998). The duplex uterus
differs from the bicornuate uterus in that it lacks a corpus and has two cervices instead of
one, allowing the two uterine horns to form completely separate compartments (Bartol
1998, Senger 2003). Rabbits and marsupials exhibit a duplex uterus (Senger 2003). The
bicornuate uterus is characterized by having poorly, yet distinguishable, to well
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developed uterine horns that are generally larger in size than the uterine body. Within this
category, there is species variation in terms of development of the uterine horns with the
mare having poorly pronounced uterine horns, the cow having moderately developed
uterine horns, and the sow exhibiting well defined uterine horns (Senger 2003). The
uterine horns of the bicornuate uterus fuse together to form the uterine body cranial to the
cervix; thus, the two uterine horns do not form separate compartments. This lack of
separation between the two horns is of physiological importance to litter bearing species
such as the pig as it allows the migrating embryos to become distributed throughout the
two horns, and in the horse, the migration of the embryo throughout the two horns serves
as the stimulus for the maternal recognition of pregnancy.
2.3.2.2

Classification based upon supported placentation
In addition to gross morphology, uteri are also classified according to the type of

placentation that is supported during pregnancy. As discussed previously, the placenta
can be categorized as being either non-deciduate or deciduate, with non-deciduate
placenta exhibiting little to no expulsion of maternal endometrial tissue or blood loss
during parturition and a deciduate placenta having considerable blood loss and shedding
of the maternal endometrium at parturition (Rosenfeld 2007). Thus, the deciduate uterus
is one that supports a deciduate placenta and is found in species with an invasive
placentation, such as humans and rodents. An important aspect of the deciduate uterus is
the physiological process of decidualization. Decidualization is a post-ovulatory event in
which the endometrium remodels itself in preparation for the implanting embryo
(Gellersen et al. 2007). This process includes the transformation of proliferative
epithelium into secretory epithelium, remodeling of the extracellular matrix, influx of
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bone-marrow derived cells and uterine natural killer cells, vascular remodeling, and the
proliferation, hypertrophy, and differentiation of stromal cells (Bartol 1998, Gellersen et
al. 2007). In the deciduate uterus, this process is critical as it allows the invading
trophoblast to erode all layers of the maternal interface (Benirschke 1998) and be in
direct apposition to maternal pools of blood (Senger 2003). Additionally, the deciduate
uterus is characterized by a substantial loss of endometrial tissue at the time of parturition
(Bartol 1998).
2.3.2.3

Classification based upon endometrial histology
Regardless of the type of uterus, all viviparous mammals exhibit a general

endometrial histological pattern comprised of epithelium and stroma. The distribution of
stromal cells is then categorized further into three patterns. In closest proximity to the
lumen of the uterus, the stratum compactum represents stromal cells that are densely
arranged near the lumen between the necks of the uterine glands. A collection of more
loosely distributed stromal cells between the uterine glands forms the stratum
spongiosum, and finally, the stratum basale is a dense group of stromal cells adjacent to
the myometrium (Bartol 1998). In non-menstruating, deciduate uteri, the endometrium
can be separated into two compartments: the superficial lamina functionalis and the deep
lamina basalis (Bartol 1998). For menstruating primates, quadripartite zonation is used to
describe the endometrium. Zone I and II are termed functionalis, with zone I being the
luminal epithelium and vascularized stroma and zone II being the upper portions of the
endometrial glands. The two functionalis zones are shed during menstruation, and
regeneration of this tissue occurs during the proliferative phase of the menstrual cycle.
Zones III and IV are termed basalis, with zone III being the coiled segments of the
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endometrial glands and zone IV being the basal regions of the glands and the stroma
adjacent to the myometrium. During the proliferative phase of the menstrual cycle, the
basalis zones (III and IV) serve as the germinal tissue compartment for the regeneration
of the functionalis zones (I and II; Bartol 1998).
2.3.3

The menstrual cycle
The menstrual cycle describes the series of events that leads to the development,

recruitment, selection, and ovulation of a competent oocyte. In addition to the
development of a competent oocyte, the menstrual cycle also entails a series of events in
the endometrium which are paramount for the establishment of pregnancy (Berga 1998,
Senger 2003). The menstrual cycle occurs in all higher primate species which includes
Old World monkeys, great apes, gibbons, and humans (Nelson 1998). A full menstrual
cycle begins with the onset of menstruation (menses; day 1), includes all of the events
that occur between that time which lead up to next menstruation, and is approximately 28
days in duration in humans. The menstrual cycle is divided into two major phases. When
referring to ovarian events these phases are the follicular phase (days 1 through 14) and
the luteal phase (days 14 to 28), with ovulation occurring on approximately day 14 or
mid-way through the menstrual cycle. Similarly, when referring to events occurring in the
endometrium, the menstrual cycle is divided into the proliferative phase (days 1 through
14) and the secretory phase (days 14 to 28).
2.3.3.1

Ovarian events of the menstrual cycle
The development of an oocyte occurs within a structure on the ovary termed a

follicle which is comprised of two cell types: an inner layer of granulosa cells which
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surrounds the developing oocyte and an outer layer of theca cells which surrounds the
granulosa cells. Follicular development necessitates the pulsatile release of gonadotropin
releasing hormone (GnRH) from the hypothalamus (Carmel et al. 1976) which in turn
stimulates the release of follicle stimulating hormone (FSH) and luteinizing hormone
(LH) from the anterior pituitary gland (Yen et al. 1972). At the level of the follicle, FSH
and LH stimulate follicular development and the production of estrogen (Richards et al.
1976, Erickson & Hsueh 1978, Bergh et al. 1993). During follicular development,
estrogen exerts negative feedback on the production and release of LH and FSH from the
anterior pituitary (Kanematsu & Sawyer 1963, Blake et al. 1972, Senger 2003), which
aids the selection of a dominate follicle that will ovulate while the others regress. As the
dominant follicle develops, circulating estradiol increases and reaches a threshold level
which stimulates a rapid release of LH (Yen & Tsai 1972). This rapid release of LH sets
forth a series of molecular events at the follicle which ultimately leads to the breakdown
and remodeling of ovarian tissue (theca cells, granulosa cells, stroma, and surface
epithelium). Once this occurs, the oocyte is released into the oviductal lumen and
ovulation has occurred (Richards et al. 1998).
At this point, the menstrual cycle enters the luteal phase during which the
follicular cells undergo a process known as luteinization. At this time, the granulosa and
theca cells differentiate into luteal cells and form a structure on the ovary known as the
corpus luteum. This differentiation includes the cessation of the cell cycle and the
expression of certain genes that result in a luteal cell phenotype (Richards et al. 1998).
One of the key features of luteal tissue is the biosynthesis of progesterone which
influences many processes and exerts negative feedback on the hypothalamus which
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suppresses LH and FSH (Wildt et al. 1981). If a developing embryo is present, human
chorionic gonadotropin, secreted by the trophoblasts, will prolong the survival of the
corpus luteum (Duncan 2000). However, in the absence of an embryo, the corpus luteum
will regress. Unlike most mammalian species, luteolysis in the human is independent of
uterus, yet the full mechanism is still not totally understood (Dickinson et al. 2008). The
process of luteolysis involves an increase in apoptosis in luteal tissue (Fraser et al. 1999),
expression of connective tissue growth factor (Duncan et al. 2005), and increased matrix
metalloproteinase activity (Duncan et al. 1998). Consequently, luteolysis is the structural
and functional demise of the corpus luteum which is noted by the cessation of
progesterone production that occurs during this process and immediately preceeds
menstruation (Duncan 2000, Dickinson et al. 2008). Thus, luteolysis concludes the
ovarian events associated with the menstrual cycle.
2.3.3.2

Uterine events of the menstrual cycle
As previously mentioned, the menstrual cycle beings with the process of

menstruation, which is the shedding of endometrial tissue during a cycle that does not
result in a pregnancy. The onset of menstruation occurs with the demise of the corpus
luteum which results in a decline of circulating progesterone. Withdrawal of progesterone
has been implicated as being the putative cause of the onset of menstruation. Following
progesterone withdrawal, there is induction of cyclooxygenase-2 (COX-2) expression in
the endometrium (Critchley et al. 1999). Cyclooxygenase-2 is the inducible form of
prostaglandin synthetase indicating that progesterone withdrawal results in the production
of prostaglandins in the endometrium (Critchley et al. 2001), as elevated levels of PGF2α
have been observed in the endometrium during the menstrual phase (Singh et al. 1975).
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Prostaglandin F2α causes vasoconstriction of uterine arteries (Grbović et al. 1996) and
enhances myometrial contractions (Coleman & Parkington 1988). In addition to
synthesizing PGF2α, COX-2 is also involved in the synthesis of PGE2, a powerful
vasodilator (Critchley et al. 2001). Progesterone withdrawal also induces endometrial
stromal cells to produce matrix metalloproteinases (Irwin et al. 1996, Lockwood et al.
1998), which are enzymes which break down the extracellular matrix. To this end, the
withdrawal of progesterone sets for forth a series of events that are characterized by
myometrial contractions, changes in vascular permeability, and tissue remodeling.
Ultimately, the combination of these events results in tissue ischemia which causes
necrosis of the two functionalis layers (Zones I and II) of the endometrium. This, along
with myometrial contractions, results in the sloughing and expulsion of the functionalis
layers of the endometrium, which represents the beginning of the menstrual cycle
(Nelson 1998).
Following menstruation, the functionalis layers of the endometrium must be
regenerated during the proliferative phase to prepare the endometrium for the possibility
of an implanting embryo. Rising circulating levels of estrogen from the developing
follicle aids in the stabilization of the recently degraded extracellular matrix and enables
clot formation in the uterine arties (Nelson 1998). In addition to aiding in clot formation
and stabilizing the extracellular matrix, estrogen is also the driving factor in generating
the epithelial cells that were lost during menstruation. Cell proliferation is a regulated
process, and an interplay between many factors can affect this normal physiological
process. In general, cells must progress through a series of checkpoints known as the cell
cycle in order for proliferation to occur.
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The cell cycle represents a one-way series of events that governs the proliferation
of cells. In general, cell division is characterized by DNA replication followed by the
formation of two separate cells through the segregation of the replicated chromosomes
(Vermeulen et al. 2003). These two processes comprise the cell cycle, which is divided
into four sequential phases: G1, S, G2, and M (Kiaris 2006). In brief, G1 and G2 are
considered preparatory stages during which molecular events prime the cell to enter the S
phase or M phase, respectively (Kiaris 2006). DNA replication takes place during the S
phase, and mitosis and cytokinesis occur during the M phase (Kiaris 2006). Regulation of
the cell cycle is achieved through the action of cyclin-dependent kinases (CDKs;
Vermeulen et al 2003). Cyclin-dependent kinases are serine/threonine kinases that
achieve their effects through the phosphorylation of target proteins only in the presence
of regulatory proteins called cyclins (Weinberg 2007), which exhibit a dynamic
expression pattern throughout the cell cycle (Vermeulen et al. 2003). In the endometrial
epithelium, estrogen, produced by the developing follicle, initiates cell proliferation by
transcriptionally and translationally activating cyclin D1 (Shiozawa et al. 2004). Cyclin
D1 interacts with CDK 4 and 6, and this interaction starts a series of preparatory events
needed for the cell to exit G1 and enter the S phase (Weinberg 2007). Thus, estrogen
stimulates endometrial cell proliferation by stimulating the transition from G1 to the S
phase. Continuing under the influence of estrogen, the endometrium continues to
proliferate for a period of 10 to 12 days following menstruation, peaking at a thickness of
approximately 5 to 6 cm (Grainger 1998, Nelson 1998). Also during this time, the uterine
spiral arteries undergo proliferation and the uterine glands elongate and become more
tortuous (Nelson 1998, Gray et al. 2001). The development of the uterine glands is of
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importance as they will secrete uterine histotroph which will nourish the periimplantation embryo. The significance of endometrial proliferation is apparent during the
implantation period, as it has been demonstrated that increased endometrial thickness is
associated with an improved pregnancy rates (Gonen & Casper 1990, Sher et al. 1991).
Around day 14 post-menstruation, ovulation of the dominant follicle occurs, and
the endometrium begins transitioning into the secretory phase of the menstrual cycle. As
this occurs, the follicular cells transition into luteal cells which begin to secrete copious
amounts of progesterone. As estrogen levels decrease and progesterone increase, the
proliferative nature of the endometrial epithelium slows, which is due to progesterone’s
influence on the luminal epithelium. In the presence of falling estrogen and rising
progesterone, the luminal epithelium begin to show reduced expression of estrogen
receptors (Okulicz et al. 1993); thus, the proliferative effect that estrogen has on these
cells is mitigated in the presence of progesterone. Not only does progesterone lessen the
proliferative effect of estrogen, but it also has an effect on the endometrial glands by
causing them to become more tortuous and begin to display a secretory phenotype
(Nelson 1998).
One of the most profound changes that occurs in the endometrium during the
secretory phase is decidualization. Decidualizaiton is the process by which maternal
endometrium undergoes cellular phenotypic changes which make it receptive to an
implanting embryo, and progesterone is driving force for this phenomenon (Gellersen et
al. 2007). While progesterone’s pro-secretory influence on the glandular epithelium is an
important aspect of decidualization, the most profound and striking change occurs within
the stromal cells of the endometrium. During the proliferative phase, stromal cells are
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characterized by the typical fibroblast appearance in which they are enlongated; however,
during decidualization and under the influence of progesterone, the stromal cells enlarge
and display a more round-like, epithelioid, polygonal morphology and transform into
decidual cells (Irwin & Guidice 1998, Gellersen et al. 2007). Concomitant with changes
in morphology, the stromal cells also begin to exhibit a secretory phenotype and secrete
products such as prolactin, insulin-like growth factor binding protein-1, and epidermal
growth factor (Gellersen et al. 2007). Ultimately, decidualization transform the
endometrium so that it can be receptive to an implanting embryo. While this process
allows for the invading trophoblast to erode the maternal endometrium, it also establishes
an extracellular matrix and secretes factors which limit the extent to which the
trophoblasts invade. Interestingly, decidualization only occurs during implantation in
most species, but in humans, this physiological process occurs cyclically during the
menstrual cycle regardless of the presence of an embryo (Gellersen et al. 2007). If an
embryo is present, human chorionic gonadotropin will prolong the existence of the
corpus luteum, and the decidua will remain as the endometrium of pregnancy. However,
without the survival of the corpus luteum, circulating progesterone will decline and
menstruation occurs, ending one menstrual cycle and beginning another.
2.3.4

The estrous cycle
Like the menstrual cycle, the estrous cycle describes a series of orchestrated

events that result in the development, recruitment, selection, dominance, and ovulation of
a competent oocyte which will give rise to the conceptus if fertilization occurs.
Moreover, just as in the menstrual cycle, there are both ovarian and uterine events that
occur, despite the common practice of focusing primarily on ovarian events when
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discussing the estrous cycle. The term estrous cycle refers to the series of ovarian and
uterine events that occurs in mammalian females that do not exhibit a menstrual cycle.
This includes species such as, but not limited to, mice, rats, cattle, sheep, pigs, and
horses. Despite the similarities that exist between the menstrual and estrous cycles, there
are some differences. In contrast to the menstrual cycle, the estrous cycle begins and ends
with ovulation of an oocyte rather than ovulation occurring in the middle of the cycle as
seen in the menstrual cycle. For example, one complete estrous cycle begins with the
ovulation of an oocyte and includes the series of events that culminates with the ovulation
of another oocyte which begins a new cycle. The estrous cycle, like the menstrual cycle,
is comprised of a follicular phase and luteal phase; however, unlike the menstrual cycle,
the follicular phase comprises approximately 20% of the cycle while the luteal phase
represents approximately 80% (Senger 2003). In addition, the estrous cycle is further
divided into four stages: proestrus, estrus, metestrus, and diestrus, with proestrus and
estrus representing the follicular phase and metestrus and diestrus occurring during the
luteal phase (Senger 2003).
2.3.4.1

Ovarian events of the estrous cycle
The ovarian events of the estrous cycle are very similar to the ovarian events that

occur during the mentstrual cycle, and as such, discussion of these events will be
minimal. Like the menstrual cycle, oocyte development occurs within the follicle and is
stimulated by the pulsatile release of FSH and LH (Butcher et al. 1974, Cunningham et
al. 1975) from the anterior pituitary which is influenced by the release of GnRH
(Chakraborty et al. 1973) from the hypothalamus. At the level of the follicle, FSH and
LH stimulate follicular development and the production of estrogen (Richards et al. 1976,
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Erickson & Hsueh 1978), which exerts negative feedback on the production and release
of LH and FSH (Kanematsu & Sawyer 1963, Blake et al. 1972) allowing for the selection
of one or multiple dominate follicle(s) depending upon the species. Ultimately, estrogen
produced by the follicle will reach a threshold amount at which time it stimulates a rapid
release of LH from the anterior pituitary (Butcher et al. 1974), resulting in a series of
molecular events that result in ovulation of the oocyte into the oviductal lumen (Richards
et al. 1998).
Following ovulation, the luteal phase of estrous cycle begins during which
follicular cells undergo a process known as luteinization that transforms the postovulatory follicle into a structure termed the corpus luteum. This process involves a series
of molecular events involving the cessation of the cell cycle and expression of genes
which cause the granulosa and theca cells to differentiate into luteal cells (Richards et al.
1998). Interestingly, in rodents, this process only occurs if mating takes place. The
neuroendocrine response produced by mating stimulates prolactin release by the anterior
pituitary gland which serves as a luteotrophic stimuli that is necessary for corpus luteum
formation in rodents (Soares 2004). As in the menstrual cycle, one of the key
characteristics of a functional corpus luteum is the biosynthesis of progesterone which
has an influence on many processes, including negative feedback LH and FSH secretion
(Ireland & Roche 1982). The corpus luteum will persist on the ovary if a viable embryo is
present in uterine lumen. In ruminant species, the embryo produces interferon tau which
reduces estrogen receptors in the endometrium negating estrogen’s stimulation of
oxytocin receptor production. In this way, luteal produced oxytocin cannot bind to its
receptors in the endometrium, preventing the endometrium from secreting PGF2α which
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would cause luteolysis (Bazer et al. 2009). In pigs, the embryo secretes prolactin and
estrogen which, together, reroute uterine produced PGF2α into the uterine lumen rather
than into the circulation, thus preventing delivery of PGF2α to ovary and preventing
luteolysis (Bazer & Thatcher 1977). Luteolysis in rodents is prevented by the secretion of
prolactin from the conceptus and uterine decidua; however, this does not occur until
about day 12 of pregnancy, and until then anterior pituitary prolactin, which was
stimulated by the act of mating, maintains the corpus luteum (Soares 2004). In the mare,
the migration of the equine embryo throughout the uterine lumen during days 12 to 14 of
is responsible for maintaining a functioning corpus luteum (Leith & Ginther 1984,
McDowell et al. 1988). Regardless of the species, without the appropriate embryonic
stimulus, the uterine endometrium will secrete PGF2α causing regression of the corpus
luteum.
2.3.4.2

Uterine events of the estrous cycle
Commonly, the estrous cycle is only used to refer to events that occur in the

ovary, with the cyclic changes that take place in the uterine endometrium being
overlooked. While not as well manifested and discussed as seen with the menstrual cycle,
cyclic changes occur in the endometrium during the estrous cycle and aid in embryo
survival, embryo implantation/attachment, and regulation of luteolysis. One of the most
noted changes that occurs in the endometrium during the estrous cycle is the development
of functional uterine glands. During the estrous cycle, under the influence of estrogen, the
uterine glands develop from the mucosal layer of the endometrium and begin to coil and
penetrate into the submucosa. Then during the luteal phase, when progesterone is the
dominant reproductive hormone, the uterine glands exhibit their full secretory function
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(Senger 2003). Uterine glands are present in all mammalian uteri and secrete a variety of
substances, such as peptides, hormones, and nutrients that are collective referred to as
histotroph. The cyclic nature of endometrial secretory function is apparent as the
expression of uterine milk proteins is not detectable in ovine glandular epithelium until
day 13 to day 15 of the ovine estrous cycle, a time during which maternal recognition and
embryo attachment takes place (Stewart et al. 2000). Histotroph is vital to supporting and
promoting the survival of the early peri-implantation embryo and is especially important
in species, such as sheep, cattle, pigs, and horses, which exhibit an extended preattachment period (Gray et al. 2001).
Just as cyclic changes in terms of cell proliferation and death occur in the
menstrual cycle, a similar, yet less drastic, phenomenon occurs during the estrous cycle,
and these cyclic changes in cell endometrial and apoptosis are vital for the successful
fertilization and implantation of the conceptus (Johnson et al. 1997). In the cycling bitch,
the surface epithelium undergoes proliferation with maximal cell proliferation being
observed at proestrus and positively correlating with serum concentrations of estradiol
17-β (Van Cruchten et al. 2004). Similarly, the rat endometrium also displays cyclic
proliferation with it being minimal at estrus, increasing during the luteal phase, and
peaking during proestrus (Marcus 1974). Interestingly, proestrus in the rat occurs around
day 4 of the estrous cycle which is also the time during which an embryo, if present, will
begin to implant into the endometrium, suggesting a role for endometrial cell
proliferation in preparing the endometrium for an implanting embryo. In support of this
argument, apoptosis, which often exhibits an inverse relationship with cell proliferation
(Ambrosini et al. 1998), is undetectable in the endometrium epithelium at day 12 of the
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sow estrous cycle (Okano et al. 2007) which is the time during which maternal
recognition occurs and that immediately precedes embryo attachment on day 14 postovulation. Moreover, endometrial estrogen receptor expression, which is involved in
promoting cell proliferation, declines following estrus but then rises again at day 11 of
the ovine estrous cycle (Spencer & Bazer 1995), and DNA content of endometrial tissue,
an indicator of cell number, is greatest at day 12 of the ovine estrous cycle (Johnson et al.
1997), both being time periods that precede embryo attachment which occurs at day 15
post-ovulation in sheep. To this end, despite species differences, it appears that
endometrial epithelial apoptosis is minimized and cell proliferation is greatest during a
time period of the estrous cycle that immediately precedes the potential attachment of an
embryo; thus, the endometrium experiences cyclic changes in terms of cell proliferation
and apoptosis that may be involved in preparing the endometrium for the attachment of a
viable embryo. In support of this argument, it has been recently documented that
increased endometrial thickness is associated with increased pregnancy rates in cattle
(Souza et al. 2011).
The cyclic changes that occur in the endometrium during the estrous cycle are
also involved in the synthesis of prostaglandins which influence embryo
attachment/implantation (Kraeling et al. 1985) and govern luteolysis. Using a porcine
model, it has been demonstrated that prostaglandin-endoperoxide synthase 2 (PTGS2)
mRNA and protein expression peaks at day 15 of the estrous cycle (Ashworth et al.
2006). Prostaglandin-endoperoxide synthase is involved in the conversion of arachidonic
acid to prostaglandins. Thus, it appears that the cellular machinery needed for
prostaglandin synthesis is elevated at day 15 of the porcine estrous cycle. Additionally,
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prostaglandin binding sites in porcine endometrium are also increased at day 15 of the
estrous cycle (Kennedy et al. 1986). Interestingly, day 15 of the porcine estrous cycle
corresponds to the period during which an embryo, if present, attaches to the
endometrium. Of importance also is the fact that inhibiting endometrial prostaglandin
synthesis prevents embryo attachment in the pig (Kraeling et al. 1985); thus, the cyclic
changes in prostaglandin synthesis and prostaglandin binding sites that occur during the
estrous cycle could represent another mechanism involved in preparing the endometrium
for embryo attachment or implantation.
Prostaglandins, specifically PGF2α, are also involved in stimulating the
regression of the corpus luteum. As previously described, the expression of the
prostaglandin synthesizing enzyme, PTGS2, peaks at day 15 of the porcine estrous cycle
(Ashworth et al. 2006). In addition to being the day during which embryo attachment
occurs, day 15 post-ovulation in the sow is also time period during which luteoysis
occurs if embryonic estrogen does not signal the re-routing of PGF2α into the uterine
lumen. Endometrial oxytocin receptors, which promote PGF2α secretion, are elevated at
day 17 of the bovine estrous cycle (Fuchs et al. 1990) which also corresponds to the time
of luteolysis. Moreover, progesterone receptor expression peaks at day 5 of the porcine
estrous cycle and then decreases during the remainder of the cycle, indicating that the
loss of the progesterone receptor removes the inhibitory effect that progesterone exerts on
PGF2α secretion (Geisert et al. 1994), which exhibits an initial pulse during this time
(Bazer et al. 1984). To this end, the temporal changes that occur with regard to
prostaglandin synthesis act either to support the attachment of the potential embryo or
induce luteolysis in its absence.
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2.3.5

Transport and metabolism of L-arginine in the uterus
The endometrium has the ability to metabolize L-arginine in numerous species,

including sheep (Massmann et al. 1999, Kwon et al. 2003, Kwon et al. 2004), pigs (Wu
et al. 1998), mice (Yu et al. 2003), rats (Zeng et al. 2008), and humans (Telfer et al.
1997), due to the presence of NOS and/or arginase enzymes. Nitric oxide is produced in
the endometrium (Cameron & Campbell 1998) and is involved in embryo implantation
and development (Gouge et al. 1998, Purcell et al. 1999, Manser et al. 2004).
Additionally, the endometrium is a site of polyamine synthesis (Rodriguez-Sallaberry et
al. 2001, Zhao et al. 2008) which have been shown to be necessary for embryo
implantation, as inhibition of polyamine synthesis reduced pregnancy rates in mice (Zhao
et al. 2008). Nitric oxide synthase is expressed in endometrial tissue throughout the
menstrual cycle in women (Telfer et al. 1997). In addition, the ovine endometrium has
been used extensively as a model for studying endometrial metabolism of L-arginine.
Nirtic oxide synthase I (nNOS) mRNA and protein exhibits temporal changes during the
ovine estrous cycle, while NOS II (iNOS) weakly expressed and NOSIII (eNOS)
expression does not fluctuate (Gao et al. 2009b). The mRNA expression of ornithine
decarboxylase (ODC), a key enzyme needed for polyamine synthesis, also exhibits
temporal changes during the ovine estrous cycle; however, ODC protein expression does
not appear to fluctuate (Gao et al. 2009b). During ovine gestation, NOS enzymatic
activity peaks at days 40 and 60 and then declines during the remainder of gestation, with
NO synthesis following the same pattern (Kwon et al. 2004). Arginase activity, which is
involved in polyamine synthesis, peaks at days 40 and 60 of gestation in the ovine
endometrium followed by declining activity during the remainder of gestation, and ODC
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activity peaks at day 40 of gestation and then declines (Kwon et al. 2003). Moreover,
polyamine concentrations in the ovine endometrium peaks at days 40 and 60 of gestation
and then declines (Kwon et al. 2003). Interestingly, day 60 of ovine gestation represents a
time point during which uterine milk protein mRNA expression begins to increase
(Stewart et al. 2000), suggesting that the peak synthesis of NO and polyamines (Larginine metabolites) may be involved in endometrial signaling that promotes uterine
gland secretory function.
In addition to being metabolized in endometrial tissue, L-arginine is also
transported across endometrial tissue and secreted into the uterine lumen. The y+ amino
acid transport system is comprised of CAT1, CAT2, and CAT3, which are encoded by
the genes SLC7A1, SLC7A2, and SLC7A3. During the ovine estrous cycle, SLC7A2
mRNA expression does not change; however, SLC7A1 mRNA does exhibit temporal
changes with an increase being observed on day 16 of the cycle (Gao et al. 2009a). Larginine has been reported to be present in the uterine flushes of sheep (Gao et al. 2009c),
cows (Hugentobler et al. 2007), rats (Leese et al. 2007), and humans (Casslen 1987). In
women, uterine lumen concentrations of L-arginine fluctuates during the menstrual cycle,
with the greatest amounts being observed during the proliferative phase (Casslen 1987),
suggesting that L-arginine may have a role in the regeneration of the endometrial
epithelium that is shed during menstruation. During the ovine estrous cycle, uterine
lumen concentrations of L-arginine is also dynamic and exhibits an increase following
estrus with the peak being observed on day 15 of the cycle (Gao et al. 2009c). Similarly,
in cow, the concentration of L-arginine in the uterine lumen also increases following
estrus and is elevated at day 14 of the estrous cycle (Hugentobler et al. 2007).
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Interestingly, in both the cow and ewe, L-arginine is elevated at a time when a potential
embryo would be recognized by the maternal environment and attach to the endometrial
lining. Furthermore, the positive influence that L-argnine has on cell signaling,
proliferation, hypertrophy, hyperplasia, and migration of ovine trophectoderm cells (Kim
et al. 2011a, Kim et al. 2011b) suggests that L-arginine is a component of the uterine
histroph that is transported into the uterine lumen to support growth and development of
the peri-implantation embryo.
2.4

Bioluminescence imaging
Bioluminescence describes a process by which a biological entity possesses the

necessary cellular machinery to produce light through a chemical reaction. This process
is achieved through the action of enzymes that belong to the luciferase family. These
proteins are naturally present in bacteria, marine crustaceans, fish and insects, and they
oxidize an enzyme-specific substrate (a luciferin) in the presence of oxygen and usually
ATP (Contag & Bachmann 2002). The oxidation of the luciferin molecule is an exergonic
reaction, and as such, creates an oxidized molecule that is in an electronically excited
state and releases this energy in the form of a photon (Wilson & Hastings 1998).
With advances in genetic engineering, scientists have been able to harness this
biological process and utilize it to study biological processes in living animals,
mammalian cells, and bacteria that, under normal conditions, would not expresses the
necessary enzyme and/or substrate. In these experimental settings, the genes encoding the
luciferase enzymes (and in some cases the luciferin molecules) are incorporated into
either a whole organism, mammalian cell, or bacteria so that they are either constituently
expressed or induced under certain physiological circumstances. In many cases, non-light
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producing bacteria, such as Escherichia coli, are genetically altered so that they express a
lux operon, isolated from Photorhabdus luminescens, which encodes the bacterial
luciferases and the biosynthetic enzymes for the corresponding substrate (Karsi et al.
2006). As such, the bacteria constituently express the genes encoded by the lux genes and
can be utilized to non-invasively and quickly monitor pathogen progression in a living
animal, a process that normally requires extensive sampling and considerable labor
(Curbelo et al. 2010).
In addition to monitoring pathogen progression, bioluminescence has been
utilized to monitor the transcriptional activity of genes in living cells and animals. In
these models, a light producing enzyme, such as firefly luciferase, is used as a reporter
gene by incorporating it in the genome so that its expression is induced whenever the
gene of interest is transcriptionally active. When luciferin, the substrate for luciferase, is
administered, oxidation of luciferin occurs releasing energy in the form of light which is
proportional to amount of gene transcription activity. For example, Zhang and colleagues
(2004) utilized a transgene comprised of a murine VEGFR2 promoter region cloned
upstream from the luciferase gene to create founder FVB/N – Tg(VEGFR2-luc) – Xen
mice (VEGFR2-luc). When VEGFR2 is transcriptionally activated, luciferase is also
transcribed, allowing VEGFR2 gene expression activity to be monitored non-invasively
and quantitatively in real-time using imaging equipment that is highly sensitive to lowemitting light. This particular application has potential advantages because it allows gene
transcription activity to monitored non-invasively within the context of the living animal.
Additionally, because imaging can be performed more than once on the same animal,
there exists the potential to reduce the number of animals needed for time-course
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experiments as animals are not sacrificed at each time point for end-point analysis.
Moreover, serial imaging allows researchers to pinpoint a particular time point that then
can be assessed using traditional end-point molecular analysis.
Traditionally, bioluminescent imaging has been strictly used in the biomedical
research field; however, more recent approaches have been attempted to apply this
technology to species relevant to animal agriculture (Curbelo et al. 2010, Ryan et al.
2011, Feugang et al. 2012). In addition, new technologies such as quantum dot
nanoparticles coupled with luciferases offer the possibility of developing new
bioluminescent paradigms that do not require genome modification. Overall, the use of
bioluminescence imagining as a research tool affords researchers the capability to
monitor physiologically relevant events within the context of the living animal in a noninvasive manner.

Figure 2.1

Chemical structure of L-arginine depicting the guanidino group in red.
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Figure 2.2

Transport mechanisms involved in the intestinal absorption and efflux of Larginine.

L-arginine (L-arg) is transported across the apical membrane of enterocytes through the
b0,+ amino acid transporter system which involves the antiport movement of a neutral
amino acid (AA0). Efflux of L-arginine across the basolateral membrane of enterocytes is
accomplished by the y+L system which also involves the antiport movement of a neutral
amino acid and requires extracellular sodium (Na+). Modified from Broer (2008).

Figure 2.3

Amino acid transport y+ of L-arginine into body tissues.

L-arginine (L-arg) is transported across the apical membrane of cells through the y+
amino acid transporter system which is accomplished independent of sodium. Modified
from Broer (2008).
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.
Figure 2.4

Catabolism of L-arginine.

Enzymes that catalyze the indicated reactions are: 1) arginine decarboxylase; 2) nitric
oxide synthase; 3) arginine:glycine amidinotrasnferase; 4) arginase; 5) ornithine
decarboxylase; 6) guanidinoacetate N-methyltransferase; 7) ornithine aminotransferase;
8) spermidine synthase; 9) spermine synthase; 10) P5C reductase; 11) spontaneous, nonenzymic reaction; 12) P5C dehydrogenase. Abbreviations : DCAM, decarboxylated Sadenosylmethionine ; MTA, methylthioadenosine ; SAM, S-adenosylmethionine ; SAHC,
S-adenosylhomocysteine ; BH4, (6R )-5,6,7,8-tetrahydro-L-biopterin. Modified from Wu
and Morris (1998).
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Figure 2.5

Biosynthesis of L-arginine.

Enzymes that catalyse the indicated reactions are : 1) phosphate-dependent glutaminase;
2) aspartate aminotransferase; 3 and 4) P5C synthetase; 5) spontaneous, non-enzymic
reaction; 6) proline oxidase; 7) ornithine aminotransferase; 8) N-acetylglutamate
synthase; 9) carbamoyl-phosphate synthase I; 10) ornithine carbamoyltransferase; 11)
argininosuccinate synthase; 12) argininosuccinate lyase. Abbreviations: OAA,
oxaloacetate; CP, carbamoyl phosphate. Modified from Wu and Morris (1998).
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Figure 2.6

Epitheliochroial placentation.

Figure 2.7

Endotheliochorial placentation.
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Figure 2.8

Hemochorial placentation

.
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CHAPTER III
IN VIVO MONITORING OF FETOPLACENTAL VEGFR2 GENE ACTICITY IN A
MURINE PEGNANCY MODEL USING A VEGFR2-LUC REPORTER GENE AND
BIOLUMINESCENT IMAGING

3.1

Abstract
Vascular endothelial growth factor receptor-2 (VEGFR2) plays a pivotal role in

angiogenesis by eliciting vascular endothelial cell growth when bound to VEGF, a
powerful pro-angiogenic ligand. While VEGF and VEGFR2 are expressed throughout
gestation, the latter third of gestation in mice is characterized by a marked increase in
fetoplacental angiogenesis. Thus, the objective of this study was to determine the
feasibility of monitoring fetoplacental VEGFR2 gene activity non-invasively using a
VEGFR2-luc reporter transgenic mouse and bioluminescent imaging. Imaging
parameters were optimized using two wild-type (WT) females, bearing VEGFR2-luc
fetuses. Then, seven WT females, bred to VEGFR2-luc males, were imaged from
gestational day (GD) 12 to 18 to determine the usefulness of the VEGFR2-luc mouse as a
model for studying fetoplacental VEGFR2 activity during pregnancy. Semi-quantitative
RT-PCR of VEGFR2 was also performed on whole fetoplacental units during this time.
Additionally, resultant neonates were imaged at postnatal day (PND) 7, 14 and 21 to
monitor VEGFR2 activity during post-natal development.Fetoplacental VEGFR2 gene
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activity was detected as light emissions beginning on GD 12 of gestation and increased
throughout the imaging period (P < 0.05), and this paralleled the VEGFR2 mRNA data
obtained from RT-PCR analysis. A decline in fetoplacental light emissions was
associated with a poor pregnancy outcome in one pregnancy, indicating that this
approach has potential use for studies monitoring pregnancy well being. Additionally,
neonatal VEGFR2 activity was detected at PND 7, 14 and 21 but declined with time (P <
0.0001). In utero fetoplacental VEGFR2 gene activity was monitored longitudinally in a
quantitative manner using a luciferase reporter gene and bioluminescent imaging during
the latter third of gestation. This study demonstrates the feasibility of using the VEGFR2luc mouse to monitor late gestation fetoplacental angiogenic activity under normal and
experimental conditions. Additionally, neonatal VEGFR2 gene activity was monitored
for three weeks postpartum, allowing continuous monitoring of VEGFR2 activity during
the latter third of gestation and postnatal development within the same animals.
3.2

Introduction
Angiogenesis is the process by which new vasculature develops from preexisting

vascular structures, and vascular endothelial growth factor A (VEGFA) and its cellsurface receptor, vascular endothelial growth factor receptor 2 (VEGFR2), are two
proteins that are vital for this process. As a pro-angiogenic factor, VEGFA has been
described as the most potent stimulator of angiogenesis while VEGFR2 is considered to
be the primary receptor by which VEGFA elicits its pro-angiogenic effects, including the
stimulation of endothelial cell growth in developing tissues (Otrock et al. 2007, Angst et
al. 2010). While VEGF and VEGFR2 expression is a hallmark process of angiogenesis
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during normal wound healing and tumor development, transcription of VEGF and
VEGFR2 is also critical for pregnancy success (Dumont et al. 1995, Shalaby et al. 1995,
Carmeliet et al. 1996, Ferrara et al. 1996, Reynolds & Redmer 2001, Maniscalco et al.
2002, Gogat et al. 2004).
Recent advances in bioluminescent imaging technology have allowed real-time
monitoring of gene expression in vivo using transgenic animal models. In these models, a
light producing enzyme, such as firefly luciferase, is used as a reporter gene by
incorporating it in the animal genome so that its expression is induced whenever the gene
of interest is transcriptionally active. When luciferin, the substrate for luciferase, is
administered, oxidation occurs releasing energy in the form of light which is proportional
to the amount of gene activity. By allowing real-time measurements, these models allow
gene expression to be studied within the physiological parameters of the living animal
system (Ryan et al. 2005). Additionally, by reducing the need for numerous end-point
measurements, which usually involve sacrificing animals to obtain tissue samples, fewer
animals are needed to monitor physiological events over time in longitudinal studies
(Ryan et al. 2005) allowing the targeting of specific time points for further end-point
analysis. In 2004, Zhang and colleagues (2004) utilized a transgene comprised of a
murine VEGFR2 promoter region cloned upstream from the luciferase gene to create
founder FVB/N – Tg(VEGFR2-luc) – Xen mice (VEGFR2-luc), and recently, our
laboratory has employed the use of this transgenic mouse model to study the activity of
VEGFR2 in wound healing studies (Youngblood et al. 2004, Ryan et al. 2005). When
VEGFR2 is transcriptionally activated, luciferase is also transcribed, allowing VEGFR2
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expression activity to be monitored non-invasively and quantitatively in real-time using
imaging equipment that is highly sensitive to low-emitting light.
While several studies describe the use of this mouse model to monitor VEGFR2
expression during wound healing(Youngblood et al. 2004, Zhang et al. 2004, Ryan et al.
2005, Nguyen Huu et al. 2007, Ehrbar et al. 2008), there is no information in the
literature describing its use to monitor fetoplacental VEGFR2 activity longitudinally in
vivo. Therefore, in this paper, we describe a murine pregnancy model, utilizing the
VEGFR2-luc mouse, which allows real-time monitoring of fetoplacental VEGFR2 gene
activity using bioluminescent imaging.
3.3
3.3.1

Materials and Methods
Animals
Care and use of animals utilized in this study were conducted in accordance with

and under the approval of the Institutional Animal Care and Use Committee of
Mississippi State University. Homozygous VEGFR2-luc males were purchased from
Caliper Life Sciences, Inc. (Hopkinton, MA, USA), while wild type (WT) FVB/N
females were obtained from an in-house colony derived from two vendors (The Jackson
Laboratory Bar Harbor, ME, USA; Charles River Laboratories International, Inc.
Wilmington, MA, USA). Males were caged individually and females in groups of four to
five per cage until paired for breeding, after which bred females were housed
individually. All animals were housed in an environmentally controlled room set at 22oC
with a 12 h light/ 12 h dark cycle and allowed ad-libitum access to a phytoestrogen and
alfalfa free diet (Purina Test Diet, Richmond, IN, USA) and water. In order to assess
fetoplacental VEGFR2-luc expression, it was necessary to breed homozygous VEGFR267

luc males to WT FVB/N females so that only fetoplacental tissues would express
luciferase under the control of the cloned VEGFR2 promoter.
3.3.2

Optimization of imaging parameters
Due to the absence of information describing a VEGFR2-luc pregnancy model, a

preliminary study was performed with two pregnant WT females, bred to VEGFR2-luc
males, to determine the optimal imaging parameters. Females were checked daily
following pairing with males, and the day on which a vaginal plug was observed was
designated as gestational day (GD) 1. To avoid inferring with embryo implantation
(Carson et al. 2000), imaging was not performed until GD 6, at which time the two
females were imaged daily until GD 18 using the IVIS 100 Imaging System (Caliper Life
Sciences, Inc. Hopkinton, MA, USA). Briefly, mice were anesthetized with isoflurane
(1.5 to 3.0 %) and injected intraperitoneally (i.p.), as recommended, in the lower left
abdominal quadrant with luciferin (150 mg/kg; Caliper Life Sciences, Inc.) suspended in
Dulbecco’s phosphate buffered saline (15mg/ml). Additionally, the abdominal region of
the mice was shaven to reduce the effects of hair on light scattering and/or absorption.
Previously, dermal wound healing studies utilizing the VEGFR2-luc mouse, reported that
optimal luciferase activity for imaging purposes occurred 10 minutes after luciferase
administration (Zhang et al. 2004, Ryan et al. 2005); however, the time required for
luciferin to traverse the maternal vasculature and arrive at the fetoplacental tissues was
unknown. Therefore, mice were imaged for five minutes at 10, 15, 20, and 25 minutes
post luciferin injection to determine the optimal time needed for luciferin distribution.
Results from this preliminary study indicated that optimal signal intensity was
detected 20 minutes post luciferin injection but was not detected prior to GD 12 at which
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time, light emissions were consistently above background signal. Additionally, i.p.
injections in the lower left abdominal region resulted in bruising over the injection site
which may interfere with accurate signal acquisition from the fetoplacental tissues.
Therefore, a subcutaneous (s.c.) luciferin injection in the dorsal neck region was chosen
as an alternate site for luciferin delivery in subsequent mice given the similar luciferin
distribution kinetic characteristics between both methods (Bollinger 2006).
3.3.3

Bioluminescence imaging of pregnant and neonatal mice
After imaging optimization, we proceeded to determine the usefulness of the

VEGFR2-luc mouse as model for quantitative, longitudinal and real-time study of
fetoplacental VEGFR2 gene activity during pregnancy. Seven WT females bred to
VEGFR2-luc males were housed individually, and weights were recorded daily from GD
1 to 18 as an indicator of fetal growth. From GD 12 to 18 of pregnancy, bred females
were imaged utilizing the optimized parameters determined from the preliminary study.
Briefly, mice were anesthetized with isoflurane (1.5 to 3.0 %), and then the abdominal
region was shaven followed by administration of a luciferin (s.c.; 150 mg/kg BW) in the
dorsal neck region. Twenty minutes after luciferin administration, mice were imaged for
five minutes ventral side up using the IVIS 100 Imaging System while maintained under
isoflurane (1.5 to 3.0 %) anesthesia. Imaging terminated on GD 18 to prevent interfering
with parturition which averaged 19.5 days post breeding in our colony.
In addition to the pregnant mice, pups (n = 27) from six pregnancies were imaged
on post-natal day (PND) 7, 14, and 21 to evaluate VEGFR2 gene activity as a means of
assessing post natal angiogenesis. Imaging parameters for neonatal mice were adapted
from Zhang and colleagues (2004). Briefly, pups were anesthetized with isoflurane (1.5
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to 3.0%), administered luciferin (s.c.; 150 mg/kg BW) in the dorsal neck region, and
subsequently imaged ventrally for two minutes using the IVIS 100 Imaging System 10
minutes post injection.
3.3.4

Image analysis
All images were analyzed using Living Image® 2.50 software (Caliper Life

Sciences, Inc. Hopkinton, MA, USA). Measurements were made by drawing regions of
interests (ROI) on the bioluminescent images. For the pregnant females, a 4.25 cm x 5.5
cm primary ROI was drawn, covering the abdominal region of the animal being measured
(Figure 3.1). In addition, a smaller ROI (1.5 cm x 1.9 cm) was drawn and placed on the
ventral neck region to obtain a background measurement for each animal to correct for
any autoluminescence that may originate from sources such as chemiluminescent
metabolic processes (Troy et al. 2004). The light emissions from the background ROI
were subtracted from the light emissions from the primary ROI, and these measurements
were expressed as calibrated units of photons per second (p/s). The data for the pregnant
females are presented as total light emissions (p/s) and as light emissions corrected for
fetoplacental mass (p/s/g), which was obtained by dividing the total light emissions for
each day by the amount of weight gain relative to the initial body weight recorded on GD
1. Because the entire body of the pups expressed light, driven by the cloned VEGFR2
promoter, a background ROI could not be drawn. Measurements were corrected for the
average pup weight of each litter and expressed as calibrated units of photons per second
per gram (p/s/g).
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3.3.5

RT-PCR analysis of VEGFR2 mRNA expression
Four additional WT females were bred to VEGFR2-luc males. At each time point,

GD 12, 14, 16, and 18, one female was imaged using the optimized imaging procedures
to detect luciferase activity. Following imaging, females were sacrificed via cervical
dislocation, and individual fetoplacental units (FPU’s) were collected, imaged, and then
frozen at -80oC until further analysis. Total RNA was extracted from three whole FPU’s
at each time point using Trizol reagent (Invitrogen Co., Carlsberg, CA, USA). RNA was
quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington,
DE, USA) and reverse-transcribed into cDNA (RETROScript, Ambion, Austin, TX).
Table 1 details the primer pairs’ characteristics. The PCR conditions were as follows: 5
min at 95oC; 28 cycles of 30 sec at 95oC, 90 sec at 58oC, and 30 sec at 72oC; followed by
a final extension of 10 min at 68oC. PCR products were resolved on 1.0% agarose gel
stained with GelStar Nucleic Acid Stain (Lonza Walkersville Inc., Walkersville, MD,
USA), and band intensity was determined using Image J 1.44c software (NIH Image).
VEGFR2 gene expression data are indicated as relative expression to β-actin.
3.3.6

Statistical analysis
One bred female was excluded from the analysis due to a failed pregnancy. Data

were compared among days of gestation for the pregnant females (n = 6) and among days
post-partum for pups (n = 27) using ANOVA. RT-PCR data were also analyzed using
ANOVA. Least square means were calculated and separated using Fisher’s least
significant difference when the P-value from the ANOVA was less than 0.05. Least
square means were considered to be significantly different at a value of P ≤ 0.05. Only
bioluminescent imaging data from GD 12, 14, 16, and 18 were used in the final statistical
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analysis as there were no daily significant changes from GD 12 to GD 17. Data are
presented as least square means ± standard error of the mean.
3.4
3.4.1

Results and Discussion
In vivo monitoring of fetoplacental VEGFR2 activity
Bioluminescent imaging of WT females, bearing VEGFR2-luc fetuses, proved to

be effective for monitoring fetoplacental VEGFR2 activity during the latter third of
gestation in a quantitative manner. Minimal signal was detected on GD 12 in one of the
six mice, while the other five mice produced a strong signal. Beginning on GD 13 and
continuing throughout the imaging period, all six mice produced a strong signal,
representing fetoplacental VEGFR2 transcriptional activity. The described approach is
one that utilizes a WT female bred to a VEGFR2-luc male. In contrast, utilizing a
VEGFR2-luc female bred to a VEGFR2-luc male would not allow fetoplacental light
emissions to be discriminated from light emissions originating from maternal tissues,
such as the uterus, which expresses VEGFR2 during gestation (Douglas et al. 2009) or
ovarian angiogenesis from vascularized corpus lutea (Ferrara et al. 1998). The advantage
of utilizing a WT female is that background signal originating from maternal tissues is
eliminated. This allows fetoplacental light emissions to be monitored, with large signal to
background ratios, since the only tissues bearing the VEGFR2-luc transgene are those of
fetal origin.
Previous studies utilizing the VEGFR2-luc mouse administered luciferin with an
i.p. injection given in the animal’s lower left abdominal quadrant (Youngblood et al.
2004, Zhang et al. 2004, Ryan et al. 2005); however, in our preliminary work, we
observed that this method of injection caused bruising at the injection site. This injection
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method was abandoned because the pooling of blood at the bruising site may interfere
with the transmission of light through the tissue (Deutsch 1997). Additionally, since the
uterus was rapidly expanding during this time, penetrating the uterus with an i.p. injection
became a concern. Given these considerations, it was determined that an s.c injection in
the dorsal neck region may be more appropriate for pregnant mouse model studies.
Subcutaneous injection proved to be a reliable and repeatable method for luciferin
administration, consistent with previous studies which determined that s.c. luciferin
administration avoids potential misadministration associated with i.p. luciferin
administration while providing similar light emission yields and luciferin distribution
kinetics (Bollinger 2006).
Preliminary observations also revealed that 20 minutes post luciferin injection
yielded optimal signal intensity for imaging purposes. Wound healing studies reported
optimal luciferase activity 10 minutes after luciferin administration when using the
VEGFR2-luc mouse (Zhang et al. 2004, Ryan et al. 2005); however, in our preliminary
work, waiting ten minutes post-luciferin administration did not provide adequate time for
luciferin to disperse through the fetoplacental tissues. It is likely that additional time is
needed for luciferin to traverse the maternal vasculature and be delivered to the
fetoplacental tissues as compared to the time needed to deliver luciferin to dorsal, dermal
skin wounds.
Utilizing the optimized imaging parameters from the preliminary study,
quantitative differences in total light emissions were found during the imaging period
(Figure 3.2a; P < 0.0001). Total light emissions on GD 12 and 14 did not differ (P > 0.05)
but were less (P < 0.05) than the amount of light emissions detected on GD 16 and 18.
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Additionally, total light emissions on GD 18 were significantly greater (P < 0.05) than
light emissions on GD 12, 14, and 16. Accounting for fetoplacental mass, quantitative
differences in light emissions were also found (Figure 3.2b; P = 0.0004). There were no
differences (P > 0.05) in light emissions between GD 12 and 14 or between GD 14 and
16. However, light emissions on GD 16 were greater (P < 0.05) than light emissions on
GD 12, and light emissions on GD 18 were greater (P < 0.05) than light emissions on GD
12, 14, and 16, indicating that fetoplacental VEGFR2 gene activity was greatest on GD
18. In addition to the quantitative data, qualitative data (Figure 3.2c) also depicts an
increase in light emissions occurring during this time period. Moreover, in vivo imaging
of the pregnant dam (Figure 3.3a), followed by ex vivo imaging of the gravid uterus
(Figure 3.3b) and individual FPU (Figure 3.3c) further revealed that the light emissions
were originating from fetoplacental tissues.
Detection of light emissions during the latter third of gestation indicated that
VEGFR2 was transcriptionally active in fetoplacental tissues during this timeframe. It has
been previously reported that light emissions were associated with VEGFR2 expression
and angiogenesis when the VEGFR2-luc mouse was used to study dermal wound healing
(Zhang et al. 2004, Ryan et al. 2005), and indeed, semi-quantitative RT-PCR analysis, in
the current study, confirmed that VEGFR2 mRNA was present in fetoplacental tissues
and increased relative to β-actin (P < 0.05; Figure 3.3d). This is consistent with the
bioluminescent data and other reports detailing an increase in VEGF mRNA during this
time (Ng et al. 2001). Moreover, end-point measurements have revealed that VEGFR2 is
expressed as early as GD 7 during murine pregnancy and is continually expressed
throughout gestation in fetal and placental tissues (Breier et al. 1992, Millauer et al.
74

1993, Dumont et al. 1995). The current data indicate the ability to monitor fetoplacental
VEGFR2 activity in real time and over time in vivo during the latter third of gestation
using a luciferase reporter gene and bioluminescent imaging technology. Quantitative
differences in VEGFR2 activity were detected which further suggests the usefulness of
this approach for obtaining meaningful data regarding changes in fetoplacental VEGFR2
activity under experimental conditions.
Previous reports have revealed that the latter third of gestation in mice is
characterized by a marked increase in the amount of fetoplacental vasculature and fetal
growth (Coan et al. 2004, Rennie et al. 2007, Mu et al. 2008). In the current study
comparing GD 12 to GD 18, there was a 23-fold increase (P < 0.0001) and 9-fold
increase (P < 0.0001) in total light emissions and light emissions corrected for
fetoplacental mass, respectively, indicating a large increase in fetoplacental VEGFR2
activity with the advancement of gestation. Expression of VEGFR2 is induced by
increased activity of VEGF (Kremer et al. 1997), a powerful pro-angiogenic factor,
suggesting that the increase in fetoplacental light emissions observed in the current study
represents the angiogenic activity associated with the tremendous growth of the
fetoplacental vasculature network and fetus (Coan et al. 2004, Rennie et al. 2007, Mu et
al. 2008) during this period. By monitoring the transcriptional activity of VEGFR2 using
the luciferase reporter gene and bioluminescent imaging, the current approach affords the
capability to study late gestation fetoplacental angiogenesis from a molecular standpoint
in a non-invasive, quantitative, and longitudinal manner in vivo. Moreover, the results are
in agreement with previous work demonstrating the marked increase in angiogenic
activity occurring during the latter third of gestation in mice (Coan et al. 2004, Rennie et
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al. 2007), suggesting the usefulness of this approach for monitoring fetoplacental
angiogenic activity during this period.
We also report a serendipitous, yet interesting, finding in which a dramatic
decline in light emissions was associated with a poor outcome in a seventh pregnancy
(Figure 3.4a). During the imaging period for one mouse, light emissions remained
minimal and similar to background measurements on GD 12 and 13, indicating a weak
signal. Light emissions increased above background measurements on GD 14 and 15.
However on GD 16, there was a four-fold decrease in light emissions, followed by a
continuing decline on GD 17 and 18 of gestation. Interestingly, the decline in light
emissions was associated with a poor pregnancy outcome in which there were no
surviving offspring. Previous studies have revealed that VEGFR2 and VEGF are vital for
fetal development and survival (Shalaby et al. 1995, Carmeliet et al. 1996, Ferrara et al.
1996). Moreover, Ferrara and colleagues speculated that if VEGF activity during
pregnancy decreases to a critical point, organogenesis may be permanently impaired
(Ferrara et al. 1996). This may suggest that the observed decline in VEGFR2 gene
activity in the current study was associated with a compromised pregnancy that resulted
in fetal demise, or the decline in light emissions could be simply the result of fetal death
rather than fetal death stemming from an angiogenic defect. Either way, this unexpected
observation further highlights the importance of VEGFR2 during pregnancy and
demonstrates that the current approach could be utilized to evaluate pregnancy loss
resulting from inactivation of angiogenic pathways.
The approach detailed in the current study offers a novel method for studying late
gestational angiogenesis in mice. However, anesthetizing pregnant mice poses some
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concern for the developing fetuses. While isofluorane exposure has been reported to have
a deleterious effect on early mouse embryo development (Chetowski & Nass 1988),
recent reports have demonstrated that fetal exposure to isofluorane during
ultrasonography on GD 8.5 or GD 10.5 has no significant adverse biological effects
(Brown et al. 2004), which is consistent with the lack of negative effects observed in the
current study. Given that the model described herein requires the use of isofluorane
during late gestation, perhaps the deleterious effects that isofluorane has on early mouse
embryo development were avoided. However, it cannot be fully determined whether
isofluorane anesthesia contributed to the pregnancy demise in the seventh mouse.
3.4.2

In vivo monitoring of neonatal VEGFR2 activity
Angiogenesis is a developmental process that becomes relatively quiescent in

adulthood except during certain conditions such as tumor development (Ferrara et al.
2003), wound healing (Nissen et al. 1998) and corpus luteum development (Ferrara et al.
1998). However, angiogenesis, and thus VEGF and VEGFR2 activity, are extremely
important during the neonatal period with activity declining with age (Gerber et al. 1999,
Ng et al. 2001). Neonatal mice (n=27) from six pregnancies were imaged at PND 7, 14
and 21 to monitor VEGFR2 gene activity during postnatal development. Bioluminescent
signal was detected at PND 7, 14 and 21 and differed over the imaging period (P<0.0001;
Figure 3.4b). From PND 7 to 14, there was a 11.7-fold decrease in light emissions
(P<0.0001), followed by a tendency for a 7-fold decrease in light emissions from PND 14
to 21 (P=0.08). Overall, there was an 83-fold reduction in light emissions from PND 7 to
21 (P<0.0001), indicating a decrease in VEGFR2 gene expression and, thus, angiogenesis
as the neonates progressed in development. While the decline of VEGFR2 activity during
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the neonatal period is not a novel observation (Ng et al. 2001, Zhang et al. 2004), the
approach described in this study offers continuous monitoring of VEGFR2 activity
during the latter third of gestation and subsequent neonatal development within the same
animals.
3.5

Conclusion
In the current study, the usefulness of the VEGFR2-luc mouse as a research

model to measure fetoplacental VEGFR2 gene activity in vivo was assessed and
determined to be effective using bioluminescent imaging. Light emissions, representative
of fetoplacental VEGFR2 gene activity, were detected on GD 12 to 18 , monitored
quantitatively and longitudinally during this period, and were consistent with traditional
end-point molecular analysis. This novel approach offers the ability to obtain meaningful
data depicting changes in fetoplacental VEGFR2 activity in utero. Neonatal VEGFR2
activity was also monitored in the resultant offspring during the first three weeks of life.
Accordingly, this approach may have great potential for studying developmental
perturbations encountered in utero and how they may influence late fetal and early
postnatal angiogenesis.
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Table 3.1

Primer sequences and characteristics

Gene
VEGFR2

GenBank Acc. #, (NCBI)
NM_010612.2

Β-actin

NM_007393.3

S, Sense; AS, Anti-sense

Primer sequences (5’-3’)
S: CTTGCAGGGGACAGCGGGAC
AS: AATCGACCCTCGGCAGGGGA
S: TACAATGAGCTGCGTGTGGCCC
AS: AGGATGGCGTGAGGGAGAGCAT

Melt T (oC)
59.7
59.3
59.7
59.5

Amplicon size (bp)
314
257
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Figure 3.1

Analysis of bioluminescent images acquired from WT females bearing
VEGFR2-luc fetuses.

Images were analyzed using Living Image® 2.50 software. A 4.25 cm x 5.5 cm primary
ROI was drawn over the abdominal region, followed by a 1.5 x 1.9 cm background ROI
over the ventral neck region to correct for autoluminescence. The color scheme
represents the pseudo color scale applied to the image, with the red colors indicating the
greatest light emissions and the purple colors representing the least amount of light
emissions.
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Figure 3.2

In vivo bioluminescent imaging of fetoplacental VEGFR2 activity.

Quantitative differences in light emissions (p/s) were found during the seven day imaging
period (P < 0.05). (a) Comparing gestational day (GD) 12 to 18, total light emissions
(p/s) increased by approximately 23-fold (P=0.0006). The insert illustrates the increase in
maternal body weight (P = 0.0008) occurring during this period, indicating fetoplacental
growth. (b) Light emissions corrected for fetoplacental mass (p/s/g) also increased by
approximately 9-fold (P < 0.0001) during this time. (c) Additionally, the images
demonstrate qualitative monitoring of fetoplacental VEGFR2 gene activity in a complete
set of images chosen from a representative animal.
a,b,c means without a common letter differ (P ≤ 0.05).
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Figure 3.3

In vivo and ex vivo bioluminescent imaging and RT-PCR analysis of
VEGFR2 in fetoplacental tissues.

Figures represent bioluminescent imaging of fetoplacental VEGFR2 activity (a) in vivo in
a pregnant mouse, (b) ex vivo in a gravid uterus (inset bright field image), and (c) ex vivo
in a whole FPU (inset bright field image) from a single pregnancy at gestational day
(GD) 16. Additionally, (d) RT-PCR analysis revealed that VEGFR2 mRNA was present
and increased in the whole FPU during GD 12 to 18.
a,b,c means without a common letter differ (P ≤ 0.05).
* means tended to differ (P < 0.10).
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Figure 3.4

Bioluminescent imaging of VEGFR2 activity in failed pregnancy and
VEGFR2-luc neonates.

(a) Minimal signal was detected on gestational day (GD) 12 and 13. Light emission
increased on GD 14 and 15; however, light emission drastically declined on GD 16, 17,
and 18. This decrease in light emissions was associated with a poor pregnancy outcome,
in which there were no surviving offspring. (b) Light emissions were detected in the
neonates, and from PND 7 to 21, there was an 83-fold reduction in light emissions
(P<0.0001), indicating a decrease in VEGFR2 gene expression as the neonates
progressed in development. The inserted graph depicts the increase in average pup weight
(P < 0.0001) occurring during this period as an indicator of growth. The images are a
representative group of animals imaged during this period.
a,b,c means without a common letter differ (P ≤ 0.05)
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CHAPTER IV
DIETARY L-ARGININE SUPPLEMENTATION DURING MOUSE GESTATION
ENHANCES REPRODUCTIVE PERFORMANCE AND VEGFR2 TRANSCRIPTION
ACTIVITY IN THE FETOPLACENTAL UNIT

4.1

Abstract
Regarded as one of the most versatile amino acids, arginine serves as a precursor

for many molecules and has been reported to improve the reproductive performance of
rats and pigs. To this end, we sought to determine if dietary L-arginine alters
fetoplacental vascular endothelial growth factor receptor-2 (VEGFR2) transcription
activity. Eighteen wild-type FVB/N female mice were bred to homozygous FVB/NTg(VEGFR2-luc)-Xen male mice. Bred female mice received one of two experimental
diets: one supplemented with 2.00% (wt:wt) L-arginine (+Arg) or one supplemented
4.10% (wt:wt) alanine (+Ala) to serve as an isonitrogenous control for +Arg. In addition,
six mice were fed a non-supplemented control (Con) diet to normalize bioluminescent
imaging data. All data were analyzed using ANOVA followed by Fisher’s LSD. Total
feed intake did not differ significantly between groups; however, mice in the +Arg group
consumed more arginine (P < 0.05). Arginine supplementation increased weight gain
during the latter third of gestation (day 12 to day 18), total litter size, number of pups
born alive, number of placental attachment sites, litter birth weight, and litter weight of
pups born alive but decreased individual birth weights (P < 0.05). During days 12 to 18,
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arginine supplementation increased (P < 0.05) the mean total VEGFR2 transcription
activity and VEGFR2 transcription activity corrected for fetoplacental mass. Moreover,
mice in the +Arg group displayed an earlier rise in VEGFR2 transcription activity. In
conclusion, our results demonstrate that the beneficial effect of dietary L-arginine
supplementation on mammalian reproduction is associated with enahanced VEGFR2
transcription activity in fetoplacental tissues.
4.2

Introduction
While arginine is considered to be only a conditionally essential amino acid for

mature mammals, it is essential for young, developing mammals (Flynn et al. 2002). In
addition to being incorporated into many proteins and playing a role in ammonia
detoxification (Visek 1986), arginine is also a precursor for many molecules including
polyamines, proline, glutamate, creatine and most notably NO, making arginine one of
the most versatile amino acids (Wu & Morris 1998). Moreover, an unusual abundance of
arginine has been reported to exist in porcine allantoic fluid, suggesting a critical role for
this amino acid in fetoplacental nutrition (Wu et al. 1996a). Recently, it has been
demonstrated that arginine supplementation during gestation enhances the reproductive
performance of both rats (Zeng et al. 2008) and pigs (Mateo et al. 2007), while
expression of nitric oxide synthase (NOS), the enzyme responsible for converting
arginine to NO, has been shown to be increased at the site of implantation in mice
(Purcell et al. 1999), suggesting that NO may play an important role during embryo
implantation. While it is unclear how arginine enhances reproductive performance, it has
been suggested that arginine may influence angiogenesis, a critically important process
during pregnancy(Mateo et al. 2007).
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Angiogenesis is the process by which new vasculature develops from preexisting
vascular structures. Two proteins are extremely vital for angiogenesis to occur, namely
vascular endothelial growth factor (VEGF) and its cell-surface receptor, vascular
endothelial growth factor receptor 2(VEGFR2). As a pro-angiogenic factor, VEGF has
been described as the most potent stimulator of angiogenesis while VEGFR2 is
considered to be the primary receptor by which VEGF elicits its pro-angiogenic effects,
including the stimulation of endothelial cell growth in developing tissues (Otrock et al.
2007). Expression of VEGF and VEGFR2 in fetoplacental tissues occurs early in
gestation (Dumont et al. 1995), and the latter third of gestation in mice is characterized
by a tremendous amount of fetoplacental vascular growth and fetal growth (Coan et al.
2004, Rennie et al. 2007, Mu et al. 2008), indicating the importance of VEGF, VEGFR2,
and angiogenesis in the fetoplacetal unit.
Previously, we have described a mouse pregnancy model that allows fetoplacental
VEGFR2 transcription activity to be monitored during the latter third of gestation in realtime and in vivo using bioluminescent imaging and the VEGFR2-luc mouse (Greene et
al. 2011), which contains a transgene, comprised of a mouse VEGFR2 promoter region
cloned upstream from the luciferase gene (Zhang et al. 2004). In this model, when the
exogenous substrate, luciferin, is administered, oxidation occurs, producing light which is
then measured using imaging equipment that is highly sensitive to low-emitting light.
Using this approach, the activation of the VEGFR2 promoter sequence, referred to as
VEGFR2 transcription activity, is monitored through luciferase production, which allows
VEGFR2 to be studied longitudinally within the same mouse non-invasively.
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To this end, the goal of this study was to determine if the reported beneficial effect that
dietary L-arginine supplementation has on mammalian reproduction is associated with
enhanced fetoplacental VEGFR2 transcription activity, using a novel bioluminescent
mouse pregnancy model.
4.3
4.3.1

Materias and Methods
Mice and diets
Care and use of mice utilized in this study were conducted in accordance with and

under the approval of the Institutional Animal Care and Use Committee of Mississippi
State University. Homozygous VEGFR2-luc male mice were purchased from Caliper
Life Sciences, Inc. (Hopkinton, MA, USA), while WT FVB/N female mice were
obtained from an in-house colony derived from two vendors (The Jackson Laboratory
Bar Harbor, ME, USA; Charles River Laboratories International, Inc. Wilmington, MA,
USA). Male mice were caged individually and female mice in groups of four to five per
cage until paired for breeding, after which bred female mice were housed individually.
All mice were housed in an environmentally controlled room set at 22oC with a 12 h light
/ 12 h dark cycle and allowed ad-libitum access to feed (Purina Test Diet, Richmond, IN,
USA) and water. The bioluminescent pregnancy model utilized in this study was based
upon previous work described by Greene and colleagues (2011).
In order to monitor only fetoplacental VEGFR2 transcription activity, eighteen
WT female mice were bred to the homozygous VEGFR2-luc male mice, restricting the
VEGFR2-luciferase transgene to the fetoplacental tissues. Conversely, breeding a
VEGFR2-luc female mouse would not allow fetoplacental luciferase expression to be
distinguished from maternal expression originating from tissues, such as the uterus
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(Douglas et al. 2009) and vascularized corpus lutea (Ferrara et al. 1998) which express
VEGF in abundance during gestation. After pairing WT female mice and VEGFR2-luc
male mice overnight, confirmation of breeding was determined by the presence of a
vaginal plug, and this day was designated as GD 1.
After observing a vaginal plug (GD 1), bred female mice were then housed
individually and randomly assigned to one of three custom purified diets (n = 6 per diet;
Purina Lab Test Diets; Table 1). Bred female mice received one of two experimental
diets: one supplemented with 2.00% (wt:wt) L-arginine (+Arg) or one supplemented
4.10% (wt:wt) alanine (+Ala) to serve as an isonitrogenous control for +Arg. In addition,
six mice were fed a non-supplemented control (Con) diet to normalize bioluminescent
imaging data. All three diets were formulated to be phytoestrogen-free and alfalfa-free,
as phytoestrogens can potentially influence VEGF expression (Virk-Baker et al. 2010)
and alfalfa can produce autoflourescence (Inoue et al. 2008) that can interefere with
bioluminescence imaging. Body weights were recorded daily from GD 1 to GD 18, and
total feed intake during gestation was also recorded. Mice were imaged from GD 12 to
GD 18 to detect luciferase activity as an indicator of VEGFR2 transcription activity.
Additionally, the number of pups and litter weight were recorded at birth. After birth, all
dams received the standard Con diet. Three weeks post-partum, dams were euthanized
via cervical dislocation, and the uterus was excised. The intact uterus was fixed in
formalin for determining the number of placental attachment sites. Additionally, three
weeks post-partum, all pups were euthanized via cervical dislocation, and the heart,
spleen, liver, and brain were excised and weighed.
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4.3.2

Bioluminescence Imaging
Pregnant female mice were imaged from GD 12 to GD 18 based upon previous

results demonstrating that light emissions were not detectable prior to this time of
gestation (Greene et al. 2011). Briefly, mice were anesthetized with isoflurane (1.5 to 3.0
%) and injected subcutaneously in the dorsal neck region with luciferin (150 mg/kg;
Caliper Life Sciences, Inc.) suspended in Dulbecco’s phosphate buffered saline (15000
mg/L). Additionally, the abdominal region of the mice was shaven to reduce the effects
of hair on light scattering and/or absorption. Twenty minutes after luciferin
administration, mice were imaged for five minutes ventral side up using the IVIS 100
Imaging System (Caliper Life Sciences, Inc.) while maintained under isoflurane (1.50 to
3.00 %) anesthesia based upon previous work which demonstrated this timeline to be
optimal for this particular model (Greene et al. 2011).
4.3.3

Image Analysis
All images were analyzed using Living Image® 2.50 software (Caliper Life

Sciences, Inc. Hopkinton, MA, USA). Measurements were made by drawing regions of
interests (ROI) on the bioluminescent images. A 4.25 cm x 5.5 cm primary ROI was
drawn (Figure 4.1), covering the abdominal region of the mouse being measured while a
smaller background ROI (1.50 cm x 1.90 cm) was positioned on the ventral neck region
to correct for autoluminescence (Troy et al. 2004). The light emissions from background
ROI were subtracted from the light emsissions from the primary ROI. The
bioluminescent data are presented as total light emissions (p/s) relative to the Con group
and as light emissions corrected for fetoplacental mass (p . s -1 . g -1) relative to Con
group, which was obtained by dividing the total light emissions for each day by the
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amount of weight gain relative to the initial body weight recorded on GD 1. In addition,
daily bioluminescent data separated by treatment group are expressed as light emissions
corrected for fetoplacental mass (p.μs -1.g -1).
4.3.4

Statistical Analysis
Data were analyzed using ANOVA with repeated measures when appropriate. For

repeated measures, least square means were calculated and separated using Tukey’s
honestly significant difference when the P-value from the ANOVA was less than 0.05.
Least square means were considered to be significantly different at a value of P ≤ 0.05
and tended to differ at a value of P ≤ 0.10. Data are presented as least square means ±
standard error of the mean. One mouse from the +Ala group was removed from the
statistical analysis due to data points being identified as extreme outliers through a boxplot interquartile range analysis.
4.4
4.4.1

Results
Reproductive performance and neonatal tissue weights
Total feed intake did not differ among mice (Table 1; P > 0.10), indicating that

total feed consumption did not contribute to any observed differences. However, mice
receiving the +Arg diet consumed more arginine (1530 ± 45.3 mg) compared to +Ala
group (332 ± 49.6 mg; Table 1; P < 0.0001). Weight gain during GD 12 to GD 18 was
17% greater (P < 0.01) for mice in the +Arg group compared to mice in the +Ala group
(Table 1). Additionally, total litter size was 102% greater (P < 0.01) for mice in the +Arg
group, and the number of pups born alive to arginine supplemented mice was 95%
greater (P < 0.01) than that observed in the +Ala group (Table 1). Compared to the +Ala
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group, arginine supplementation during gestation increased (P < 0.05) the number of
placental attachment sites by 66% (Table 1). Likewise, the litter birth weight was 83%
greater (P < 0.01) for mice in the +Arg group compared to mice consuming the +Ala diet,
while the litter weight of pups born alive was 78 % greater (P < 0.01) when mice received
arginine supplementation (Table 1). Conversely, individual birth weight of pups born
alive was 11% less (P < 0.05) in pups born to arginine supplemented dams compared to
pups from dams consuming the +Ala diet (Table 1). When evaluating neonatal organ
weights as a percentage of body weight three weeks post-partum, no differences were
found between dietary treatments for heart and spleen tissue weights. However, there
were differences for liver and brain tissue weights. Interestingly, the liver weight of pups
exposed to the +Arg diet during gestation was 5% less (P < 0.05) compared to pups
exposed to the +Ala diet (Supplemental Table 2). In contrast, the brain weight of pups
exposed to the +Arg diet during gestation was 18% greater (P < 0.0001) compared to
pups exposed to the +Ala diet (Supplemental Table 2).
4.4.2

Bioluminescence assessment of fetoplacental VEGFR2 transcriptional
activity
There were no diet by day interactions (P > 0.10) for fetoplacental VEGFR2

transcription activity; yet, arginine supplementation increased (P < 0.01) the mean total
VEGFR2 transcription activity in fetoplacental tissues by 56% during GD 12 to GD 18.
Using bioluminescence imaging to assess total fetoplacental VEGFR2 transcription
activity, a qualitative difference was also visualized between mice in the +Ala and +Arg
groups (Figure 4.2a). In these images (Figure 4.2a), a pseudo-color scheme is applied to
the images with the red areas representing the greatest amount of VEGFR2 transcription
91

activity, and the purple-blue areas representing the least amount of VEGFR2 transcription
activity. To this end, qualitative and visual differences are able to be noted between mice
consuming different diets.
To account for changes in fetoplacental mass, bioluminescent data was corrected
by dividing the daily light emission values by the amount of weight gain experienced by
the dam relative to GD 1 (Figure 4.2 b,c, and d). When the data was corrected for
fetoplacental mass, the mean fetoplacental VEGFR2 transcription activity was 46%
greater (P < 0.05) in mice in the +Arg group compared to +Ala group (Figure 4.2 b).
Moreover, when the data was separated by treatment group, the profiles for daily
fetoplacental VEGFR2 transcription activity were different (Figure 4.2 c and d). In mice
consuming the +Ala diet, fetoplacental VEGFR2 transcription activity remained
unchanged (P > 0.05) from GD 13 to GD 15, and there were no daily increases during
GD 12 to GD 18. In sharp contrast, for mice consuming the +Arg diet, fetoplacental
VEGFR2 transcription did not change on from GD 12 to GD 13 but did increase abruptly
(P ≤ 0.05) on GD 14 and remained elevated throughout the remainder of gestation,
revealing an earlier rise in VEGFR2 transcription occurring in tissues of the arginine
supplemented fetoplacental unit.
4.5

Discussion
Maternal nutrition during gestation is known to affect fetal growth and

development through its influence on the intrauterine environment (Wu et al. 2004).
Here, we report an association between maternal dietary L-arginine supplementation,
enhanced reproductive performance, and fetoplacental VEGFR2 transcription activity
using a novel bioluminescent mouse pregnancy model. The model utilized in the current
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study offers the ability to monitor fetoplacental VEGFR2 transcription activity noninvasively and longitudinally within the same mouse. Previously, we have demonstrated
that the data obtained using this approach parallels VEGFR2 gene expression data
obtained from traditional molecular analysis (Ryan et al. 2005, Greene et al. 2011). Not
only does this approach reduce the total number of mice needed to monitor physiological
events over time, but it also has the potential to reduce individual variation associated
with end-point analysis by allowing more than one measurement to be obtained from the
same mouse. Moreover, the results from the current study demonstrate that this novel
bioluminescent model is capable of monitoring fetoplacental VEGFR2 transcription
activity under experimental conditions during the later third of mouse gestation, in a
longitudinal and non-invasive manner.
Arginine is a versatile amino acid, serving as a precursor for many molecules
including NO (Wu & Morris 1998). Nitric oxide mediates a number of reproductive
process in both males and females (Rosselli et al. 1998). In females, NO is produced in
the endometrium (Cameron & Campbell 1998), and is involved in embryo implantation
and development (Gouge et al. 1998, Purcell et al. 1999, Manser et al. 2004). The
importance of NO during implantation and embryo development along with the
abundance of arginine found in porcine allantoic fluid reported by Wu and colleagues
(1996a) suggest a crucial role for arginine in fetoplacental nutrition. Consistent with the
previous findings observed in rats and pigs (Mateo et al. 2007, Zeng et al. 2008), dietary
L-arginine supplementation enhanced the reproductive performance of mice by
increasing the litter size and the number of placental attachment sites in the current study.
With dietary L-arginine supplementation though, the individual weight of the pups born
93

alive was reduced, which is a known consequence of increased litter size in mice (Gates
1925); however, the individual birth weights of the pups from + Arg dams were still
within the normal range for the FVB/N mouse strain (1999). Together, these results
highlight the beneficial effect that dietary L-arginine supplementation has on mammalian
reproduction and are in agreement with previous work performed by Zeng and colleagues
(2008) who reported an increase in litter size and number of placental attachment sites in
rats supplemented with 1.3% (wt:wt) L-arginine. Interestingly, in the current study,
gestational dietary L-arginine supplementation appeared to affect both the liver and brain
weights of neonates; however, at this time a definitive explanation for this phenomenon
cannot be offered, suggesting the need for further investigations.
Because dietary L-arginine supplementation began on GD 1 which is well before
the time of embryo implantation in mice (GD 4 to GD 5), it is tempting to speculate that
the observed increased number of placental attachment sites suggests that arginine
supplementation may have a positive influence on embryo implantation. Recent reports
have demonstrated that arginine supplementation increases expression of inducible and
endothelial NOS at the implantation sites of rats (Zeng et al. 2008). Nitric oxide, an
arginine metabolite, is produced by the endometrium (Cameron & Campbell 1998), and
the peri-implantation period in mice is characterized by elevated NOS expression at the
site of implantation (Purcell et al. 1999), which may suggest an important role for
arginine in embryo implantation. Furthermore, inhibition of NO synthesis impairs
embryo development at the 2-cell stage and morulae stage (Gouge et al. 1998) and
decreases the blastocyst development rate in cultured embryos (Manser et al. 2004),
providing additional evidence of NO’s role in embryonic survival. It is also worth noting
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that embyros express amino acid transporters, and the activity of b0,+, a transport system
for arginine, increases by 30-fold during the transition to the blastocysts stage (Van
Winkle 2001). Taken together, the previous body of literature (Gouge et al. 1998, Purcell
et al. 1999, Manser et al. 2004, Zeng et al. 2008) and the current data warrant the need to
further investigate whether, indeed, arginine supplementation influences embryo survival
and implantation through an NO-mediated event, translating into enhanced mammalian
reproductive performance.
In pigs, dietary L-arginine supplementation has also been proposed to enhance
mammalian reproduction by altering angiogenesis during gestation (Mateo et al. 2007).
Angiogenesis is an important process during gestation, and without it, pregnancy demise
may ensue (Carmeliet et al. 1996, Ferrara et al. 1996). Expression of VEGF and its
receptor (VEGFR2), which is up-regulated in response to VEGF expression (Kremer et
al. 1997), is vital for proper angiogenesis to occur (Otrock et al. 2007), making VEGFR2
an ideal marker for angiogenic activity. In the current study, dietary arginine
supplementation positively influenced fetoplacental VEGFR2 transcription activity
(Figure 4.2). Arginine might influence VEGF expression and, therefore, VEGFR2
expression by serving as a precursor for NO, which has previously been demonstrated to
increase VEGF mRNA and protein in keratinocytes (Frank et al. 1999) and vascular
smooth muscle cells (Dulak et al. 2000, Jozkowicz et al. 2001). It is known that NO
induces expression of hypoxia-inducible-factor -1 (Sandau et al. 2000), a stimulator of
VEGF transcription (Kimura et al. 2000), providing further evidence that dietary Larginine supplementation may alter angiogenesis by serving as NO precursor in
fetoplacental tissues.
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In the current study, dietary L-arginine supplementation resulted in an earlier
increase in fetoplacental VEGFR2 transcription, indicating that, perhaps, L-arginine
supplementation may create a more favorable in utero environment through earlier and
enhanced vascular development of the fetoplacental unit. The Chinese Meishan pig is
known to produce 3 to 5 more pigs per litter than U.S. and European breeds of pigs
(Biensen et al. 1998, Wilson et al. 1998), and interestingly, this particular breed exhibits
an increase in placental VEGF and VEGFR2 gene expression earlier in gestation
compared to the Yorkshire breed of pig at a time when the Chinese Meishan placenta
becomes more vascularized relative to the Yorkshire placenta (Vonnahme & Ford 2004).
The VEGF and VEGFR2 profiles of the Chinese Meishan pig placenta (Vonnahme &
Ford 2004) are similar to the trend for VEGFR2 transcription activity in the fetoplacental
unit observed in the current study whereby arginine supplementation resulted in an earlier
rise in fetoplacental VEGFR2 transcription activity compared to the activity observed in
the mice in the +Ala group. Interestingly, this earlier increase in fetoplacental VEGFR2
transcription activity observed in the +Arg mice occurs at a time during mouse gestation
when the placenta undergoes rapid vascular development and the fetus experiences
tremendous growth (Coan et al. 2004, Rennie et al. 2007, Mu et al. 2008). This may
suggest that dietary L-arginine supplementation promotes more favorable conditions for
fetal survival in a uterine environment with more offspring and offers another explanation
for the beneficial effects that dietary L-arginine supplementation has on mammalian
reproduction.
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4.6

Conclusion
In summary, dietary L-arginine supplementation increased the total number of

viable pups born per litter, demonstrating the beneficial effect that L-arginine has on
mammalian reproduction. Furthermore, we have demonstrated a relationship between
arginine supplementation and fetoplacental VEGFR2 transcription activity utilizing a
novel bioluminescent mouse pregnancy model. Our results illustrate that the positive
effects attributed to dietary arginine supplementation, in terms of litter size, are
associated with more VEGFR2 transcription activity and an earlier increase in VEGFR2
transcription activity in fetoplacental tissues which may create a favorable environment
for fetal survival during the latter third of gestation.
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Table 4.1

Composition and nutrient content of the three purified diets fed to gestating
mice 1.
Dietary Treatments, as-fed basis
Con
+ Ala
+ Arg

Ingredient, %
Corn Starch
Whey Protein
Maltodextrin
Sucrose
Corn Oil

34.0
24.3
14.7
10.0
7.00

31.9
24.3
14.7
10.0
7.00

33.0
24.3
14.7
10.0
7.00

Powdered Cellulose

5.00

3.00

4.00

AIN 93G Mineral Mix

3.50

3.50

3.50

AIN 93 Vitamin Mix
1.00
1.00
1.00
L-Cystine
0.300
0.300
0.300
Choline Bitartrate
0.250
0.250
0.250
t-Butylhydroquinone
0.0014
0.0014
0.0014
L-Alanine
0.000
4.10
0.000
L-Arginine
0.000
0.000
2.00
Component
Carbohydrates, %
58.8
56.7
57.8
Protein, %
20.0
24.0
24.0
Fat, %
9.00
9.00
9.00
Energy, kcal/g
3.96
4.04
4.08
Arg, %
0.560
0.560
2.56
Ala, %
1.24
5.34
1.24
1
Con, control diet; +Ala, L-alanine supplemented diet; +Arg, L-arginine supplemented
diet.
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Table 4.2

Reproductive performance of mice fed either the +Ala or +Arg diet during gestation 1.
Dietary Treatement
+ Ala

+ Arg

Total feed intake, g

59.3 ± 2.16

59.9 ± 1.97

Total L-arginine intake, mg

332 ± 49.6

1530 ± 45.3 *

Weight gain (GD 12 to GD 18), g

5.95 ± 0.260

7.01 ± 0.230 *

Total pups born per litter, n

4.20 ± 0.730

8.50 ± 0.670 *

Total pups born alive per litter, n

4.20 ± 0.750

8.17 ± 0.690 *

Number of placental attachment sites, n

5.80 ± 1.10

9.67 ± 1.00 **

Litter birth weight of all pups born, g

5.40 ± 0.870

9.88 ± 0.790 *

Litter birth weight of all pups born alive, g

5.40 ± 0.920

9.62 ± 0.840 *

Feed Intake

Reproductive performance parameters
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Individual birth weight of pups born alive, g
1.32 ± 0.0500
1.18 ± 0.0400 **
1
Data are presented as least square means ± the individual standard error of the mean. ANOVA P-values are *P < 0.01; **P < 0.05.
+Ala, L-alanine supplemented diet (n = 5); +Arg, L-arginine supplemented diet (n = 6).

Table 4.3

Neonatal organ weights from pups exposed to the +Ala or +Arg diet during
gestation1
Dietary Treatment

Organ, % of body weight

+ Ala

+ Arg

Heart

0.540 ± 0.0200

0.570 ± 0.0100

Spleen

0.540 ± 0.0200

0.520 ± 0.0100

Liver

4.73 ± 0.100

4.48 ± 0.0600**

Brain
3.15 ± 0.0800
3.72 ± 0.0500*
1
Data are presented as least square means ± the individual standard error of the mean.
ANOVA P-values are *P < 0.01; **P < 0.05. +Ala, L-alanine supplemented diet (n = 5);
+Arg, L-arginine supplemented diet (n = 6).

Figure 4.1

Analysis of bioluminescent images acquired from WT females bearing
VEGFR2-luc fetuses.
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Figure 4.2

Qualitative (A) and quantitative assessment of (B) mean and (C and D)
daily fetoplacental VEGFR2 transcription activity from mice fed either the
+Ala1 (n = 5) or +Arg1 (n = 6) diet during gestation.

Means without a common letter differ P ≤ 0.05. +Ala, L-alanine supplemented diet;
+Arg, L-arginine supplemented diet. Data are presented as least square means ± the
individual standard error of the mean.
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CHAPTER V
L-ARGININE ENHANCES CELL PROLIFERATION AND REDUCES APOPTOSIS
IN HUMAN ENDOMETRIAL RL95-2 CELLS

5.1

Abstract
L-arginine is considered to be one of the most versatile amino acids due to the

fact that it serves as a precursor for many important molecules in cellular physiology.
When supplemented in the diet, L-arginine can increase the number of implantation sites
in mice and rats, suggesting an effect at the level of the endometrium. To this end, this
study determined the effect that L-arginine has on apoptosis and cell proliferation in
human endometrial RL95-2 cells. L-arginine at physiological (200 µM) and supraphysiological (800 µM) concentrations increased cell proliferation at days 2 and 4 posttreatment with a dose-dependent effect being observed on day 2. Additionally, inhibition
of nitric oxide (NO) synthase and arginase, which are responsible for the conversion of
L-arginine to NO and polyamines, respectively, reduced the proliferative effect of Larginine. L-arginine also decreased the proportion of cells with TUNEL positive nuclei
and increased the ratio of cells with healthy mitochondria compared to cells with a
disrupted mitochondrial membrane potential, indicating that L-arginine prevents
mitochondrial mediated apoptosis in endometrial RL95-2 cells. Furthermore, exposure to
L-arginine did not affect total BAD protein expression; however, L-arginine increased the
abundance of phosphorylated BAD protein. In summary, L-arginine added to the culture
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media at physiological (200 µM) and supraphysiological concentrations (800 µM)
enhanced endometrial RL95-2 cell proliferation through mechanisms mediated by NO
and polyamine biosynthesis. In addition, L-arginine reduced endometrial RL95-2
mitochondrial mediated apoptosis through increased phosphorylation of BAD protein.
5.2

Introduction
L-arginine is considered to be a conditionally essential amino acid for healthy

mature mammals but an essential amino acid for young developing mammals (Flynn et
al. 2002), suggesting a role for arginine in tissue growth. Most dietary sources of protein
contain L-arginine; however, L-arginine is found in abundant quantities in high quality
plant proteins (i.e., soy proteins), and daily intake of L-arginine for adult humans ranges
from 3 to 6 g (Shao & Hathcock 2008). In addition to being incorporated into proteins
and being involved in ammonia detoxification (Visek 1986), L-arginine also serves as a
precursor for many molecules that are important for cellular physiology, including
proline, glutamate, creatine, nitric oxide (NO) and polyamines, making L-arginine one of
the most versatile amino acids (Wu & Morris 1998). L-arginine is converted to NO
through the action of NO synthase (NOS), while polyamines are generated through the
conversion of L-arginine to ornithine via arginase (Wu & Morris 1998). Decarboxylation
of ornithine by ornithine decarboxylase yields the first polyamine putrescine which
serves as the precursor for the other naturally occurring polyamines spermidine and
spermine through the action of spermidine synthase and spermine synthase, respectively
(Wu & Morris 1998).
Both polyamines and NO have vital roles in cellular processes and cell signaling.
Nitric oxide and polyamines stimulate cell proliferation and have a positive effect on
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progression through the cell cycle (Ziche et al. 1994, Ray et al. 1999, Vasa et al. 2000,
Ray et al. 2001, Zheng et al. 2004, Hu et al. 2005, Kim et al. 2011b). Polyamines exert
their cellular effect through their ability to bind nucleic acids and proteins (Igarashi &
Kashiwagi 2000) and have been demonstrated to promote an anti-apoptotic state in
various cell lines (Seiler & Raul 2005). Moreover, NO can stimulate PI3K/Akt-1
signaling pathways (Kawasaki et al. 2003, Fukumura et al. 2006, Bazer et al. 2012)
which promote cell survival. The role of L-arginine and its metabolites in cell signaling
has been studied extensively in ovine (Kim et al. 2011a, Kim et al. 2011b) and porcine
(Kong et al. 2011) trophectoderm cells, with L-arginine enhancing cell proliferation
through mammalian target of rapamycin (mTOR) related signaling pathways.
Wu and colleagues (1996a) reported an unusual abundance of L-arginine in
porcine allantoic fluid, suggesting a role for this particular amino acid in fetoplacental
nutrition. Moreover, dietary L-arginine supplementation has been demonstrated to
enhance the reproductive performance of rats (Zeng et al. 2008), pigs (Mateo et al. 2007),
and mice (Greene et al. 2012), and recently, we have shown that dietary L-arginine
supplementation increased the number of implantation sites in mice (Greene et al. 2012),
which suggests an effect of L-arginine at the level of the endometrium. The endometrium
has the ability to catabolized L-arginine in numerous species, including sheep (Massmann
et al. 1999, Kwon et al. 2003, Kwon et al. 2004), pigs (Wu et al. 1998), mice (Yu et al.
2003), rats (Zeng et al. 2008), and humans (Telfer et al. 1997), due to the presence of
NOS and/or arginase enzymes. Moreover, L-arginine has been reported to exist in human
uterine lumen flushes with the greatest concentration observed during the proliferative
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phase (Casslen 1987), suggesting a possible involvement in endometrial epithelial cell
proliferation.
In the current study we used the human endometrial epithelial carcinoma cell line,
RL95-2, as a model for endometrial epithelial cells. The RL95-2 cell line expresses
markers found on normal human endometrial epithelial cells such as progesterone
receptors, estrogen receptors α and β (Wadehra et al. 2008), MUC1 (Horne et al. 2006),
and E-cadherin (Thie et al. 1995, Rahnama et al. 2009). Furthermore, the RL95-2 cell
line has been used extensively as an in vitro model for studying the human endometrial
epithelium (Rohde & Carson 1993, Tinel et al. 2000, Wadehra et al. 2008, Yang et al.
2012). To this end, the objective of this study was to examine the effect that L-arginine
may have on endometrial cell proliferation and apoptosis using the established human
endometrial epithelial cell line, RL95-2, as an in vitro model for epithelial cells of the
human endometrium.
5.3

Materials and Methods

5.3.1

Cell Culture
Human endometrial carcinoma cells (RL95-2; ATCC # CRL-1671) were acquired

from the American Type Culture Collection (Rockville, MD). Cells were cultured in a
humidified incubator containing 5% CO2 using a complete growth media comprised of
DMEM:F12 media (ATCC, Rockville, MD) supplemented with 10% fetal bovine serum
(FBS; Gibco, Grand Island, NY), 1 % penicillin/streptomycin (Gibco, Grand Island, NY),
and 0.005 mg/mL insulin (Sigma-Aldrich, St. Louis, MO) in order to obtain frozen
stocks.
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5.3.2

Proliferation Assay
RL95-2 cells were transferred to 96 well plates (80,000 cells per well) in growth

media for a period of 24 h after which they were serum and L-arginine starved for an
additional 24 hours in an L-arginine free media (RPMI-1640 SILAC, Sigma-Aldrich, St.
Louis, MO). In the first experiment, cells were then treated (n = 3 wells per treatment)
with either 0 µmol/L, 200 µmol/L (physiological), or 800 µmol/L L-arginine (SigmaAldrich, St. Louis, MO) in a serum-free environment. At two days post-treatment, cell
proliferation was assessed for one plate of cells, and the media was replenished in the
second plate of cells. Cell proliferation was then assessed in the second plate 4 days after
the initial treatment. In the second experiment, cells were treated with 0 µmol/L, 200
µmol/L, or 800 µmol/L L-arginine with or without N-omega-hydroxy-nor-arginine (NorNOHA; Calbiochem-EMD4 Biosciences, Billerica, MA), a polyamine synthesis inhibitor,
in a serum-free environment. The media was replenished on day 2 post-treatment, and
cell proliferation was assessed on day 4 post-treatment. Additionally, a third experiment
examined the role of NO biosynthesis in endometrial RL95-2 cell proliferation: cells
were treated with either 0 µmol/L, 200 µmol/L, or 800 µmol/L L-arginine with or without
7-Nitroindazole (7-NI), a NOS inhibitor, in a serum-free environment. 7-NI was
dissolved in ethanol, and all cells not exposed to 7-NI received an equal amount of
ethanol. Cell proliferation was assessed according to procedures previously described by
Kueng and colleagues (1989). Briefly, cells were washed in Dulbecco’s PBS (DPBS) and
fixed in 3% glutaraldehyde for 15 min. Fixed cells were washed three times by
submersion in de-ionized water and air dried, after which they were stained with crystal
violet (0.1% in 20% methanol) for 20 min, followed by three washes with de-ionized
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water. Crystal violet was eluted using 10% glacial acetic acid, and the optical density was
measured at 590 nm. All experiments were repeated independently three times.
5.3.3

Detection of DNA Fragmentation
RL95-2 cells were transferred to chamber slides (100,000 cells per chamber) in

growth media for a period of 24 h, after which they were serum and L-arginine starved
for an additional 24 hours in an L-arginine free media (RPMI-1640 SILAC). Cells were
then treated (n = 1 chamber per treatment) with either 0 µmol/L, 200 µmol/L, or 800
µmol/L L-arginine in a serum-free environment for 24 hours. Cells were washed with
DPBS and fixed in a solution of 4% paraformaldehyde in PBS for 60 min, washed with
DPBS, and incubated with a permeabilization solution (0.1% Triton X-100 in 0.1%
sodium citrate) for 2 min on ice followed by two washes with DPBS. DNA fragmentation
was detected by incubating cells with a FITC-labeled terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) solution (Roche Applied Science,
Indianapolis, IN) at 37oC in a humidified incubator. After 60 min, cells were washed
three times with DPBS, the nucleus was counter-stained with DAPI (Santa Cruz
Biotechnology, Santa Cruz, CA), and the slides where covered with a coverslip. TUNEL
(ex. 490/20; em. 528/30) and DAPI (ex. 350/50; em. 457/50) staining were assessed
using a Nikon Eclipse TE 2000-U fluorescence microscope. Three frames per chamber
were acquired, and the proportion of cells that were TUNEL positive was counted. The
entire experiment was repeated three independent times.
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5.3.4

Assessment of mitochondrial membrane potential (ΔΨm)
RL95-2 cells were seeded into 12-well plates (750,000 cells per well) and grown

for 24 hours in growth media at which time they were serum and L-arginine starved for
an additional 24 hours. Cells were then treated (n = 3 wells per treatment) with either 0
µmol/L, 200 µmol/L, or 800 µmol/L L-arginine in a serum-free environment for 24
hours, followed by incubation with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolecarbocyanide iodine (JC-1; Cayman Chemical, Ann Arbor, MI) for 30 minutes at 37oC.
Loss of ΔΨm was determined using fluorescence microscopy (Nikon Eclipse TE 2000-U)
and flow cytometry (Becton Dickinson FACSCalibur). Immediately, following
incubation with JC-1, fluorescence microscopy was performed using a 490 nm excitation
filter, with an orange emission indicating healthy ΔΨm which is due to a potentialdependent aggregation of JC-molecules in the mitochondria. In contrast, a loss of ΔΨm
results in the monomeric form of JC-1 in the cytosol which produces a green emission.
For quantification, JC-1 labeled cells were harvested using EDTA (0.02 % in PBS) and
analyzed by flow cytometry (3,000 cells per sample). Excitation was achieved with a 488
nm argon laser, and emission fluorescence was measured in the FL-1 (530/30 nm) and
FL-2 (585/42 nm) channels to determine the proportion of cells with JC-1 monomers or
JC-1 aggregates, respectively. From this analysis, the ratio of cells with JC-aggregates
compared to cells with JC-1 monomers was determined. Flow cytometry analysis was
repeated three independent times, and fluorescence microscopy was performed once to
obtain representative images.
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5.3.5

Reverse transcriptase real time PCR
RL95-2 cells were transferred to culture dishes (1.0 x 106 cells per dish) in growth

media for a period of 24 h after which they were serum and L-arginine starved for an
additional 24 hours in an L-arginine free media (RPMI-1640 SILAC). Cells were then
treated (n = 3 culture dishes per treatment) with either 0 µmol/L, 200 µmol/L, or 800
µmol/L L-arginine in a serum-free environment. After 24 hours, cells were washed in
cold DPBS, trypsinized, and stored as pellets at -80oC. Total RNA was isolated (High
Pure RNA Isolation kit; Roche Applied Science, Indianapolis, IN), quantified (Nanodrop
1000; Thermo Scientific, Wilminton, DE), and reverse transcribed into cDNA
(Transcriptor First Strand cDNA Synthesis; Roche Applied Science, Indianapolis, IN)
using 500 ng of total RNA.
For gene expression analysis, NCBI Primer BLAST was used to design primers
for BAX, BCL2, and 18s rRNA (Table 1). Real-time PCR (Stratagene MX3005P;
Agilent Technologies, Inc, Santa Clara, CA) was performed using 0.5 μL of cDNA, a
final concentration of 0.5 μM of each primer, and SYBR Green I Master Mix (Roche
Applied Science, Indianapolis, IN). The PCR conditions were the following: 5 min at
95oC; 40 cycles of 30 sec at 95oC; 30 sec at the optimal annealing temperature (Table 1);
30 sec at 72oC. Relative gene expression was calculated using the 2-ΔΔCT method (Livak
& Schmittgen 2001). The entire experiment was repeated three independent times.
5.3.6

In cell ELISA and Western-immunoblot detection of BCL2, BAX, BAD and
p-BAD Proteins
In a 96-well plate, RL95-2 cells were cultured (80,000 cells per well) in growth

media for a period of 24 h, after which they were serum and L-arginine starved for an
109

additional 24 hours in an L-arginine free media (RPMI-1640 SILAC). Cells were then
treated (n = 3 wells per treatment) with either 0 µmol/L, 200 µmol/L, or 800 µmol/L Larginine in a serum-free environment. After 24 hours, cells were fixed with
paraformaldehyde (4% in PBS). BCL2, BAX, BAD, and p-BAD expression was assessed
using the Pierce Colormetric In-Cell ELISA kit (Thermo Scientific) as per the
manufacturer’s instructions. BCL2, BAX, BAD, and p-BAD measurements were
obtained and normalized to cell number using the Janus Green Whole-Cell stain supplied
with the kit. The entire experiment was repeated three independent times. Total protein
was isolated from frozen-thawed RL95-2 cells using complete RIPA buffer (Santa Cruz
Biotech Inc., Santa Cruza, CA). Isolated protein was resolved onto an SDS PAGE gel and
transferred to a PVDF membrane. The WesternBreeze Chromogenic kit (Life
Technologies, Inc., Grand Island, NY) was utilized for immunodection as per the
manufacturer’s instructions. Primary antibody concentration for western-immunoblotting
were the following: BCL2: 0.004 µg/µL; BAX: 0.004 µg/µL; p-BAD: 0.008 µg/µL; and
BAD: 0.001 µg/µL. BCL2 (sc-130307), BAD (sc-8044) and serine-136 phosphorylated
BAD (p-BAD; sc-12969) primary antibodies were obtained from Santa Cruz
Biotechnolgy, Inc. BAX primary antibody (B3428) was obtained from Sigma-Aldrich,
Inc.
5.3.7

Statistical analysis
The Shapiro-Wilk test was utilized to test the data for normal distribution. All

data were normally distributed except for cell-proliferation and JC-1 data. Normally
distributed data were analyzed using one-way or two-way ANOVA, when appropriate,
followed by Fisher’s LSD test for pairwise comparison. Data that tested to be non110

parametric was analyzed by Friedman’s one-way or two-way non-parametric ANOVA,
when appropriate, followed by Tukey’s HSD test for pairwise comparison. The threshold
of significance was fixed at P < 0.05. Data are presented as least square means ± standard
error of the mean (SEM).
5.4
5.4.1

Results
Effect of L-arginine on endometrial RL95-2 cell proliferation
The presence of L-arginine at physiological (200 µmol/L) and supraphysiological

(800 µmol/L) concentrations increased (P < 0.05) endometrial RL95-2 cell proliferation
at days 2 and 4 post-treatment with proliferation being increased by approximately 4-fold
on day 4 (Figure 5.1 a). Additionally, a dose dependent effect of L-arginine on
endometrial RL95-2 cell proliferation was observed on day 2 post-treatment at which
time cell proliferation was greater (P < 0.05) for cells treated with 800 µmol/L L-arginine
compared to those exposed to 200μM.
5.4.2

Inhibitory effect of nor-NOHA on endometrial RL95-2 cell proliferation
To test whether polyamines, L-arginine metabolites, are responsible for L-

arginine’s effect on cell proliferation, cells were exposed to L-arginine and the arginase
inhibitor nor-NOHA. As in experiment one, the addition of L-arginine (200 µmol/L and
800 µmol/L) increased (P < 0.05) endometrial RL95-2 cell proliferation, but this effect
was reduced 2-fold (P < 0.05) with the addition of 800 µmol/L nor-NOHA (Figure 5.1b).
5.4.3

Inhibitory effect of 7-NI on endometrial RL95-2 cell proliferation
Cells were exposed to L-arginine and the NOS inhibitor 7-NI to determine if L-

arginine enhances endometrial RL95-2 cell proliferation through NO biosynthesis. Again,
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L-arginine (200 µmol/L and 800 µmol/L) increased (P < 0.05) endometrial RL95-2 cell
proliferation, and this effect on cell proliferation was reduced (P < 0.05) with the addition
of 100 µmol/L of 7-NI (Figure 5.1c).
5.4.4

Effect of L-arginine on endometrial RL95-2 cell apoptosis
Because of the inverse relationship that exists between cell proliferation and

apoptosis (Ambrosini et al. 1998), we sought to determine if L-arginine’s positive effect
on cell proliferation was associated with a concomitant decrease in apoptosis. The
addition of L-arginine (200 µmol/L and 800 µmol/L) decreased (P < 0.05) the proportion
of cells that stained positive for TUNEL by approximately 13-fold, indicating a reduction
in DNA fragmentation and, thus, apoptosis in the presence of L-arginine (Figure 5.2).
5.4.5

Effect of L-arginine on mitochondrial membrane potential (ΔΨm)
Fluorescence microscopy analysis of JC-1 stained endometrial RL95-2 cells

revealed that the presence of L-arginine (200 µmol/L and 800 µmol/L) increased the
proportion of cells with healthy ΔΨm, as indicated by more cells yielding an orange
emission upon excitation (Figure 5.3 a,b, and c). Furthermore, flow cytometry revealed
that the addition of L-arginine to the culture media increased (P < 0.05) the ratio of cells
with JC-1 aggregates compared to cells with JC-1 monomers by approximately 2.5-fold
(Figure 5.3 d), indicating that L-arginine reduces mitochondrial membrane potential
disruption in endometrial RL95-2 cells.
5.4.6

Effect of L-arginine on BAX and BCL2 gene and protein expression
The presence of L-arginine at physiological (200 µmol/L) and supraphysiological

(800 µmol/L) concentrations dose-dependently reduced (P < 0.05) the amount of BAX
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mRNA expression, with endometrial RL95-2 cells exposed to 800 µmol/L L-arginine
expressing the least (P < 0.05) amount of BAX mRNA (Figure 5.4a). Interestingly, cells
exposed to L-arginine also expressed less (P < 0.05) BCL2 mRNA, and had a lower (P <
0.05) BCL2 to BAX mRNA ratio (Figure 5.4 b and c). Exposure to L-arginine resulted in
a BCL2 to BAX mRNA ratio of approximately one, while cells not exposed to L-arginine
exhibited a ratio of two. L-arginine at physiological (200 µmol/L) and supraphysiological
(800 µmol/L) concentrations had no effect on BAX protein expression (Figure 5.4d);
however, in cells that were not exposed to L-arginine, BCL2 protein levels were elevated
(P < 0.05; Figure 5.4e). Additionally, cells exposed to L-arginine had a lower (P < 0.05)
BCL2 to BAX protein ratio compared to cells not exposed to L-arginine (Figure 5.4f).
5.4.7

Effect of L-arginine on phosphorylation of BAD protein
Because L-arginine did not increase the BCL2 to BAX mRNA and protein ratio,

an alternate mechanism for L-arginine’s promotion of cell survival and prevention of
apoptosis was investigated. To this end, endometrial RL95-2 cells were exposed to 0,
200, or 800 µmol/L of L-arginine to determine total and phosphorylated forms of BAD,
which is a promoter of mitochondrial mediated apoptosis when not phosphorylated (Zha
et al. 1996). L-arginine at 200 and 800 µmol/L did not affect the relative levels of total
BAD protein in RL95-2 cells (Figure 5.5a). However, the addition of L-arginine did
increase (P < 0.05) the relative levels of phosphorylated (Ser-136) BAD protein and, thus,
the ratio of phosphorylated BAD protein to total BAD protein in endometrial RL95-2
cells (Figure 5.5 b and c).

113

5.5

Discussion
L-arginine is a versatile amino acid, serving as a precursor for many molecules

including NO and polyamines (Wu & Morris 1998). The plasma concentration of Larginine has been reported to be around 200 µmol/L in humans during the fed state
(Castillo et al. 1993a, Wu & Morris 1998). Therefore, we sought to determine the effect
of L-arginine on endometrial RL95-2 cells at physiological (200 µmol/L) and
supraphysiological (800 µmol/L) concentrations. The presence of NOS and/or arginase
enzymes in the endometrium of many species indicates the ability of the endometrium to
catabolize L-arginine (Telfer et al. 1997, Wu et al. 1998, Massmann et al. 1999, Kwon et
al. 2003, Yu et al. 2003, Kwon et al. 2004, Zeng et al. 2008). In females, NO is produced
in the endometrium (Cameron & Campbell 1998) and is involved in embryo implantation
and development (Gouge et al. 1998, Purcell et al. 1999, Manser et al. 2004). Polyamines
are also produced by the endometrium (Rodriguez-Sallaberry et al. 2001, Zhao et al.
2008) and have been shown to be important for embryo implantation, as inhibition of
polyamine synthesis reduced pregnancy rates in mice (Zhao et al. 2008).
L-arginine has been reported to be present in the uterine flushes of sheep (Gao et
al. 2009c), cows (Hugentobler et al. 2007), rats (Leese et al. 2007), and humans (Casslen
1987), with concentrations in human uterine flushes ranging from 220 µmol/L to 330
µmol/L depending upon the phase of the menstrual cycle (Casslen 1987). Additional
work has revealed that mRNA of the L-arginine transporters SLC7A1, SLC7A2, and
SLC7A3 are present in ovine uterine luminal epithelial (Gao et al. 2009a). Furthermore,
the positive influence that L-argnine has on cell signaling, proliferation, hypertrophy,
hyperplasia, and migration of ovine trophectoderm cells (Kim et al. 2011a, Kim et al.
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2011b) suggests that L-arginine is transported into the uterine lumen to support growth
and development of the peri-implantation embryo.
In addition to supporting the peri-implantation embryo, L-arginine may also have
a direct effect on the uterine luminal epithelium. Proliferation of the endometrium has
been implicated as a vital process which provides an optimal environment for embryo
adhesion and implantation (Taylor & Fei 2005), and this argument is further supported by
the observation that increasing endometrial thickness is associated with improved
implantation rates in humans (Gonen & Casper 1990, Sher et al. 1991, Zhang et al.
2005). Interestingly, the uterine lumen concentration of L-arginine is greatest during the
proliferative phase of the menstrual cycle (Casslen 1987), suggesting that L-arginine may
have a role in the proliferation of the endometrial epithelium which must regenerate
following menstruation. L-arginine and its metabolites, NO and polyamines, have a dual
role in cell proliferation and apoptosis. In some cell types, L-arginine, NO, and
polyamines stimulate cell proliferation and reduce apoptosis (Seidenfeld et al. 1986,
Ziche et al. 1994, Nitta et al. 2002, Kim et al. 2011b), yet they inhibit cell proliferation
and promote apoptosis in others (Albina et al. 1993, Cornwell et al. 1994, Poulin et al.
1995, Okazaki et al. 1997). Results from the current study indicate that L-argrinine
enhances endometrial RL95-2 cell proliferation at physiological and supraphysiological
concentrations. Moreover, Nor-NOHA, an arginase inhibitor, and 7-NI, an NOS inhibitor,
reduced the positive effect that L-arginine had on endometrial RL95-2 cell proliferation.
Conversion of L-arginine to ornithine, via arginase, is the first enzymatic process
involved in polyamine synthesis (Wu & Morris 1998). Likewise, NOS is responsible for
converting L-arginine to NO (Wu & Morris 1998). Together, the inhibitory effect that
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Nor-NOHA and 7-NI exhibited in the presence of L-arginine indicates that L-arginine
enhances endometrial RL95-2 cell proliferation through polyamine and NO mediated
pathways, which both have a positive influence on cell proliferation (Ziche et al. 1994,
Ray et al. 1999, Vasa et al. 2000, Ray et al. 2001, Zheng et al. 2004, Hu et al. 2005, Kim
et al. 2011b).
Cell proliferation is often inversely related to apoptosis (Ambrosini et al. 1998,
Jang et al. 2002, Meresman et al. 2002, Sheng et al. 2005), and a reduction in apoptosis
is a contributing factor in the enhancement of cell proliferation (Takeda et al. 1998).
Therefore, we hypothesized that the enhancement of cell proliferation in the presence of
L-arginine would be associated with decreased endometrial RL95-2 cell apoptosis.
Apoptosis in the endometrium is a key feature of the human menstrual cycle and aids in
maintaining endometrial homeostasis by eliminating cells from the functionalis layer
during the late secretory phase (Harada et al. 2004). In the functionalis layer of the
endometrium, apoptosis exhibits a cyclic pattern with the least amount being observed
during the proliferative phase followed by an increase during the secretory phase and the
maximum being observed during menstruation (Tao et al. 1997, Vaskivuo et al. 2000).
The exposure of endometrial RL95-2 cells to physiological and supraphysiological
concentrations of L-arginine reduced the proportion of cells that exhibited DNA
fragmentation as assessed by TUNEL assay. Activation of endonucleases (Wyllie 1980)
and the subsequent DNA fragmentation (Wyllie et al. 1984) are considered to be
hallmark characteristics of cells undergoing apoptosis. To this end, the current results
demonstrate that the presence of L-arginine reduces the proportion of endometrial RL952 cells experiencing apoptosis. Apoptosis can occur through either receptor-ligand
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mediated pathways or mitochondrial mediated pathways, with both resulting in DNA
fragmentation (Fulda & Debatin 2006). Receptor-ligand mediated apoptosis requires an
external signal, while mitochondrial mediated apoptosis occurs through the disruption of
the mitochondrial membrane (Fulda & Debatin 2006). As the presence or absence of Larginine would represent an intracellular event rather than receptor mediated extracellular
signaling, we hypothesized that L-arginine’s prevention of apoptosis in endometrial
RL95-2 cells is mediated through the mitochondria. The presence of L-arginine in the
culture media increased the ratio of cells with a healthy mitochondrial membrane
compared to cells with an altered mitochondrial membrane potential. Thus, the current
study indicates that L-arginine reduces the incidence of endometrial RL95-2 cell
apoptosis by preventing the disruption of mitochondrial membrane potential, suggesting a
role for L-arginine in the regulation of endometrial epithelial apoptosis.
Mitochondrial membrane potential is highly influenced by proteins that belong to
the BCL2 family (Lalier et al. 2007). The pro-apoptotic protein BAX and the antiapoptotic protein BCL2 are often studied together as indicators of apoptosis. In healthy
cells, a balance exists in which BCL2 is normally found imbedded in the mitochondrial
membrane (Gross et al. 1999). Under apoptotic conditions, activated BAX will embed in
the mitochondrial membrane with BCL2 and disrupt the mitochondrial membrane
potential (Gross et al. 1999). Accordingly, we examined if L-arginine’s prevention of
apoptosis is through a BCL2 and BAX mediated event. Interestingly, the presence of Larginine did not increase the ratio of BCL2 to BAX in endometrial RL95-2 cells. In fact,
the BCL2 to BAX mRNA and protein ratios were higher in endometrial RL95-2 cells not
exposed to L-arginine which were undergoing apoptosis through a mitochondrial
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mediated pathway. Despite the anti-apoptotic properties of BCL2, upregulation of BCL2
mRNA and protein has been reported in cells undergoing apoptosis (Yu et al. 1997).
Moreover, increased expression of BCL2 protein can lead to disruption of mitochondrial
membrane potential (Shinoura et al. 1999), as caspases can cleave BCL2 into a BAX-like
molecule which can serve as a latent pro-apoptotic stimuli in apoptotic cells (Cheng et al.
1997).
Because exposure to L-arginine did not increase the ratio of BCL2 to BAX, we
hypothesized that L-arginine might decrease endometrial RL95-2 cell apoptosis through
an alternative mechanism. In addition to BCL2 and BAX, BAD is another member of the
BCL2 family of proteins that affects mitochondrial membrane potential. The presence of
L-arginine in the culture media did not affect the levels of total BAD. However, Larginine increased p-BAD (Ser-136) levels in endometrial RL95-2 cells and increased the
ratio of p-BAD to BAD, indicating that L-arginine enhances the phosphorylation of BAD
protein at serine residue 136 in endometrial RL95-2 cells. When BAD is phosphorylated
at either serine residue 112 (Ser-112) or 136 (Ser-136), it is bound by 14-3-3 and
sequestered in the cytosol (Zha et al. 1996). In contrast, non-phosphorylated BAD
interacts with BCL2 and BCL-XL embedded in the mitochondrial membrane and inhibits
their anti-apoptotic properties (Yang et al. 1995, Kelekar et al. 1997) and causes release
of cytochrome C (Kuwana et al. 2005). In this regard, L-arginine reduces mitochondrial
membrane disruption and, thus, apoptosis through phosphorylation of BAD in
endometrial RL95-2 cells. BAD protein is phosphorylated at serine residue 136 through
the kinase activity of PI3K-dependent Akt-1 (Datta et al. 1997). L-arginine increases
phosphorylation, and therefore the activity, of Akt-1 in ovine trophectoderm cells (Kim et
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al. 2011a). Moreover, NO can stimulate phosphorylation of Akt-1 (Kawasaki et al. 2003,
Fukumura et al. 2006, Bazer et al. 2012), and Akt-1 phosphorylation is also enhanced in
cells with elevated expression of ornithine decarboxylase (Hayes et al. 2005), the enzyme
responsible for converting ornithine to first polyamine putrescine. Thus, it is likely that
the presence of L-arginine in the culture media increased p-BAD levels in endometrial
RL95-2 cells by influencing Akt-1 phosphorylation through the action of polyamines
and/or NO.
5.6

Conclusion
In summary, L-arginine added to the culture media at physiological (200 µmol/L)

and supraphysiological concentrations (800 µmol/L) enhanced endometrial RL95-2 cell
proliferation through mechanisms mediated by NO and polyamine biosynthesis and by
reducing endometrial RL95-2 cell apoptosis through the phosphorylation of BAD protein.
Cell proliferation is an important process in human endometrium, as the endometrial
epithelium must regenerate following the losses experienced during menstruation in
preparation for the attachment and implantation of a potential embryo. Accordingly, the
findings of the present study demonstrate a role for L-arginine in the regulation of
endometrial growth and apoptosis. Moreover, a supraphysiological concentration of Larginine had no negative effects on the parameters measured, revealing a possible
beneficial effect of dietary L-arginine supplementation on endometrial growth.
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Table 5.1

Primer sequences and characteristics.
Gene
BAX

GenBank Acc. #
NM_004324.3

BCL2

NM_000633.2

18s rRNA

X03205.1

S, Sense; AS, Anti-sense

Primer sequences (5’-3’)
S: TCTGACGGCAACTTCAACTG
AS: TTGAGGAGTCTCACCCAACC
S: CGTCAACCGGGAGATGTCGCC
AS: CTGGGGCCGTACAGTTCCACA
S: AAACGGCTACCACATCCAAG
AS: CCTCCAATGGATCCTCGTTA

Annealing T (oC)
54.5

Amplicon size (bp)
155

62.0

132

56.0

188
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Figure 5.1

A) Effect of L-arginine on human endometrial RL95-2 cell proliferation. B)
Effect of L-arginine and the arginase inhibitor Nor-NOHA on human
endometrial RL95-2 cell proliferation. C) Effect of L-arginine and the NOS
inhibitor 7-NI on human endometrial RL95-2 cell proliferation.

Each bar represents the mean ± S.E.M.; means without a common letter are significantly
different (P < 0.05).
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Figure 5.2

Effect of L-arginine on human endometrial RL95-2 cell apoptosis as
assessed by TUNEL assay and fluorescent microscopy.

Representative micrographs of cells exposed to (A) 0 µM, (B) 200 µM, or (C) 800 µM Larginine. Cells staining green are TUNEL positive cells experiencing DNA
fragmentation. D) Percentage of cells staining positive for TUNEL after exposure to
either 0 µM, 200 µM, 800 µM L-arginine. Each bar represents the mean ± S.E.M.; means
without a common letter are significantly different (P < 0.05).
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Figure 5.3

Effect of L-arginine on human endometrial RL95-2 cell mitochondrial
membrane potential (ΔΨm) as assessed by JC-1 staining.

Representative micrographs of cells exposed to (A) 0 µM, (B) 200 µM, or (C) 800 µM Larginine. Cells staining green (JC-1 monomers) are cells with a disrupted ΔΨm, while
cells staining orange (JC-1 aggregates) have a healthy ΔΨm. D) Ratio of cells with JC-1
aggregates to cells with JC-1 monomers as assessed by flow cytometry. Each bar
represents the mean ± S.E.M.; means without a common letter are significantly different
(P < 0.05).
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Figure 5.4

Effect of L-arginine on (A) BAX mRNA, (B) BCL2 mRNA, (C) ratio of
BCL2 to BAX mRNA, (D) BAX protein, (E) BCL2 protein, and (F) the
ratio of BCL2 to BAX protein in human endometrial RL95-2 cells.

Each bar represents the mean ± S.E.M.; means without a common letter are significantly
different (P < 0.05).
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Figure 5.5

Effect of L-arginine on (A) total BAD protein, (B) phosphorylated BAD
(p-BAD) protein, and (C) the ratio of p-BAD protein to total BAD protein
in human endometrial RL95-2 cells.

Each bar represents the mean ± S.E.M.; means without a common letter are significantly
different (P < 0.05).
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CHAPTER VI
A PRELIMINARY EXAMINATION OF L-ARGININE BIOSYNTHESIS IN
PRIMARY PORCINE UTERINE EPITHELIAL CELLS

6.1

Abstract
L-arginine is a versatile amino acid that recently has been noted for its role in

mammalian reproduction. In particle evidence exists demonstrating this amino acid’s
function in endometrial tissues as well as being a component of uterine histotroph that is
secreted into the uterine lumen to support the peri-implantation embryo. As a component
of the uterine histotroph, speculation would arise regarding the ability of the endometrial
eptithelium to synthesize L-arginine. To address this question, primary porcine uterine
epithelial (PUE) cells were examined for their ability to convert the precursor L-citrulline
to L-arginine. L-citrulline was able to support PUE cell proliferation in absence of Larginine, indicating possible conversion to L-arginine. Additionally, argininosuccinate
synthase-1 (ASS-1) and argininosuccinate lyase (ASL), which are necessary for Larginine synthesis, were expressed in epethilal cells isolated from the porcine uterine. In
PUE cells deprived of L-arginine, ASS-1 expression was increased, indicating that ASS-1
is regulated by the presence of L-arginine in PUE cells. Interestingly, ASL expression
was not upregulated during L-arginine deprivation; rather, ASL expression was increased
in PUE cells exposed to L-citrulline which indicate a role for the intermediate Largininosuccinate in regulating the expression of this enzyme. Overall, this data would
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support the hypothesis that PUE cells may be able to convert L-citrulline to L-arginine in
PUE cells.
6.2

Introduction
Endogenous synthesis of L-arginine is primarily thought to be a concerted effort

accomplished by the small intestine and kidneys (Figure 2.5). Briefly, the small intestine
converts either L-glutamine or L-proline to L-Δ1-Pyrroline-5-carboxylate (P5C). Next,
P5C undergoes transamination with glutamic acid to produce ornithine which combines
with carbamoyl-phosphate to form L-citrulline via the action of ornithine
carbamoyltransferase (Wu & Morris 1998). Despite the ability to produce L-citrulline,
the primary precursor for L-arginine, the small intestine is not the primary site of Larginine synthesis in many adult mammalian species (Blachier et al. 1993). Once
synthesized, L-citrulline enters the general circulation, and approximately 85 % of
intestinal citrulline is extracted by the kidneys (Brosnan & Brosnan 2004). Renal
conversion of L-citrulline to L-arginine is achieved through the action of two enzymes:
argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL; Wu & Morris
1998). The majority of ASS and ASL expression has been reported to be in the proximal
convoluted tubules of the renal cortex (Dhanakoti et al. 1992), with conversion of Lcitrulline to L-arginine being localized here as well (Morel et al. 1996). In the proximal
convoluted tubule, ASS catalyzes the condensation of L-citrulline and L-aspartate to
yield L-argininosuccinate which is then split by ASL releasing fumarate and L-arginine
(Haines et al. 2011). Once formed, L-arginine exits the kidneys through the renal vein
and enters the general circulation (Brosnan & Brosnan 2004). In addition to the cells of
the proximal convoluted tubule in the renal cortex, synthesis of L-arginine from L127

citrulline has been reported in other cell types, such as endothelial cells (Wu & Meininger
1993) and macrophages (Wu & Brosnan 1992).
L-arginine has been reported to be present in the uterine flushes of ewes (Gao et
al. 2009c), cows (Hugentobler et al. 2007), rats (Leese et al. 2007), women (Casslen
1987), and sows (Iritani et al. 1974). In addition, L-arginine stimulates proliferation,
mTOR signaling, and protein synthesis in ovine (Kim et al. 2011b) and porcine (Kong et
al. 2011) trophectoderm cells, indicating that L-arginine may be a component of the
uterine histotroph which nourishes the peri-implantation embryo. To this end, the
objective of this study was to examine the ability of primary porcine uterine epithelial
(PUE) cells to synthesize L-arginine from L-citrulline.
6.3
6.3.1

Materials and Methods
Isolation of primary PUE cells
The isolation of PUE cells was performed according to a protocol adapted from

Bowen and colleagues (1996). All phosphate buffered saline (PBS) utilized in this
protocol was free of calcium and magnesium. Fresh uteri were obtained from two sows at
a local abattoir and transported in a plastic bag containing 500 mL of PBS supplemented
with 4 % penicillin-streptomycin (PS). Once in the laboratory, a 25 to 30 cm section was
obtained from the uterine horns of each uterus and flushed repeatedly with 40 mL of PBS
(1% PS) using an 18-guage needle to remove any blood and debris. Once flushed, both
ends of the uterine sections were ligated, and using an 18-guage needle, the lumen was
filled with 40 mL PBS containing 4.8 mg/mL dispase II (Zen-Bio Inc., Research Triangle
Park, NC) and 0.0025 mg/mL of pancreatin (Sigma-Aldrich, St. Louis, MO). The uterine
sections were then placed in a plastic bag containing 300 mL of PBS (1% PS) and placed
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in an orbital shaker for 1 hour at 37oC. Sections were gently massaged following
incubation. The contents were emptied into a sterile dish, and the lumen was repeatedly
flushed with PBS (1% PS), with the contents being collected. Flushes were examined
under an inverted microscope, pooled, and subjected to gentle centrifugation. Cells were
then seeded in culture flasks and grown in DMEM/F12 media supplemented with 10%
fetal bovine serum, 10 mg/mL insulin, 10 µg/mL epidermal growth factor, and 1%
penicillin-streptomycin. Cells were grown until confluence at which time they were
harvested with trypsin-EDTA (0.5 g/L trypsin; 0.2 g/L EDTA) and stored in liquid
nitrogen for later use.
For experiments, passage one PUE cells from each sow were pooled and grown in
culture flasks for four days in the DMEM/F12 growth media supplemented with Rat
FibrOut™ 7 for reproductive tissues (Chi Scientific, Inc., Maynard, MA) to minimize
fibroblast contamination. Additionally, prior to passage for experiments, cells were
subjected to differential trypsinization to further minimize fibroblast contamination as
described by Bridger and colleagues (2007). Briefly, cells were first subjected to a weak
trypsin-EDTA solution (0.05 g/L trypsin; 0.02 g/L EDTA) for approximately 2 min.
while on a 37oC warming plate. This procedure has been shown to cause selective
detachment of fibroblast cells prior to detachment of epithelial cells. Before detachment
of epithelial cells, this initial wash was discarded, and the remaining attached epithelial
cells were washed in Dulbecco’s PBS, detached with trypsin-EDTA (0.5 g/L trypsin; 0.2
g/L EDTA), and utilized for experiments.
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6.3.2

Immunoflourescence detection of E-cadherin in primary PUE cells
To determine if the isolated cells were epithelial cells, PUE cells were examined

for expression of E-cadherin using immunofluorescence. Briefly, PUE cells were grown
in chamber slides followed by fixation with 4% paraformaldehyde in PBS. Cells were
then permeabilized with Triton X-100 (0.1% in TBS) for 15 minutes and incubated in
blocking buffer (Thermo Scientific, Inc., Wilminton, DE) for 1 hour. The primary
antibody diluent was a 1:1 mixture of blocking buffer and a wash buffer comprised of
0.1% Tween-20 in TBS. Cells were incubated with E-cadherin primary antibody
(Tansduction Laboratories, Lexington, KY; C20820) overnight at 4oC. Following
overnight incubation, slides were washed and labeled with DyLight 680 (Thermo
Scientific, Inc., Wilminton, DE) and counter-stained with DAPI (Santa Cruz Biotech.
Inc., Santa Cruz, CA).
6.3.3

Cell proliferation assay
Porcine uterine epithelial cells were transferred to 96 well plates (10,000 cells per

well) in growth media for a period of 24 h after which they were serum and L-arginine
starved for an additional 24 hours in an L-arginine free media (RPMI-1640 SILAC,
Sigma-Aldrich, St. Louis, MO). Cells were then treated (n = 3 wells per treatment) with
either media alone, media supplemented with 200 µmol/L L-arginine (Sigma-Aldrich, St.
Louis, MO), or media supplemented with 1000 µmol/L L-citrulline (Sigma-Aldrich, St.
Louis, MO). The media was replenished on day 2 post-treatment, and cell proliferation
was assessed on day 4 post-treatment according to procedures previously described by
Kueng and colleagues (1989). Briefly, cells were washed in Dulbecco’s PBS (DPBS) and
fixed in 3% glutaraldehyde for 15 min. Fixed cells were washed three times by
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submersion in de-ionized water and air dried, after which they were stained with crystal
violet (0.1% in 20% methanol) for 20 min, followed by three washes with de-ionized
water. Crystal violet was eluted using 10% glacial acetic acid, and the optical density was
measured at 590 nm. All experiments were repeated independently three times.
6.3.4

Western-immunoblot detection of ASS-1 and ASL proteins
Two fresh porcine uteri were obtained from a local abattoir and PUE cells were

obtained by gentling scraping the uterine lumen with a sterile microscope slide. Cells
were collected and stored at -80oC for later analysis. As a positive control, porcine renal
cortex tissue samples were obtained from a boar being utilized in an unrelated
experiment. Total protein was isolated from frozen-thawed PUE cells and renal cortex
samples using complete RIPA buffer (Santa Cruz Biotech Inc., Santa Cruz, CA). Isolated
protein was resolved onto an SDS PAGE gel and transferred to a PVDF membrane. The
WesternBreeze Chromogenic kit (Life Technologies, Inc., Grand Island, NY) was
utilized for immunodetection as per the manufacturer’s instructions. Primary antibodies
for ASS-1 and ASL were utilized at a concentration of 0.004 µg/µL for
immunodetection. Primary antibodies were obtained from Santa Cruz Biotechnology, Inc.
(ASS-1; sc-99178, ASL; sc-374353).
6.3.5

In-Cell ELISA detection of ASS-1 and ASL protein expression
Porcine uterine epithelial cells were transferred to 96 well plates (10,000 cells per

well) in growth media for a period of 24 h after which they were serum and L-arginine
starved for an additional 24 hours in an L-arginine free media (RPMI-1640 SILAC,
Sigma-Aldrich, St. Louis, MO). Cells were then treated (n = 3 wells per treatment) with
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either media alone, media supplemented with 200 µmol/L L-arginine (Sigma-Aldrich, St.
Louis, MO), or media supplemented with 1000 µmol/L L-citrulline (Sigma-Aldrich, St.
Louis, MO). After 24 hours, cells were fixed with paraformaldehyde (4% in PBS). ASS-1
and ASL expression was assessed using the Pierce Colormetric In-Cell ELISA kit
(Thermo Scientific Inc., Wilminton, DE) as per the manufacturer’s instructions. ASS-1
and ASL measurements were obtained and normalized to cell number using the Janus
Green Whole-Cell stain supplied with the kit. Primary antibodies were obtained from
Santa Cruz Biotechnology, Inc. (ASS-1; sc-99178, ASL; sc-374353). All experiments
were repeated independently three times.
6.3.6

Statistical analysis
Data were analyzed using one-way ANOVA, followed by Fisher’s LSD test for

pairwise comparison. The threshold of significance was fixed at P < 0.05. Data are
presented as least square means ± standard error of the mean (SEM).
6.4
6.4.1

Results
Phenotypic characteristics of isolated primary PUE cells
Isolated PUE cells were examined under an inverted microscope and displayed a

“cobblestone-like” appearance (Figure 6.1) that is characteristic of uterine epithelial cells
in culture (Wang et al. 2000). E-cadherin is a cell adhesion molecule expressed by
epithelial cells including porcine uterine epithelial cells (Ryan et al. 2001). In the present
study, PUE cells also exhibited E-cadherin expression (Figure 6.1), indicating that the
isolated cells are of epithelial origin.
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6.4.2

Effect of L-arginine and L-citrulline on primary PUE cell proliferation
Porcine uterine epithelial cells were exposed to 1000 µM of L-citrulline to

determine if L-citrulline provides a positive influence on cell proliferation that is similar
to what has been observed when human endometrial cells are exposed to L-arginine. Cell
proliferation was increased (P < 0.05) by approximately 150% in PUE cells exposed to Larginine (Figure 6.2). While less in magnitude, L-citrulline also exerted a positive
influence by increasing (P < 0.05) PUE cell proliferation by approximately 20 % (Figure
6.2).
6.4.3

Western-immunoblotting of ASS-1 and ASL in fresh PUE cells
Western –immunoblotting of PUE cells for the expression of ASS-1 and ASL

revealed an approximately 47 kDa and 51 kDa protein band (Figure 6.3), respectively,
corresponding to the reported molecular weight of ASS-1 and ASL. In addition, similar
protein bands were detected in protein isolated from porcine renal cortex, which is the
primary tissue in which ASS-1 and ASL are expressed.
6.4.4

Effect of L-arginine and L-citrulline on ASS-1 and ASL protein expression
in primary PUE cells
In order to elucidate conditions under which ASS-1 and ASL proteins are

expressed, PUE cells were exposed to either media alone, media supplemented with Larginine, or media supplemented with L-citrulline. Argininosuccinate synthase-1 protein
expression was increased (P < 0.05) in PUE cells that were cultured in media devoid of
L-arginine and L-citrulline, while there was no difference in terms of ASS-1 protein
expression observed between PUE cells exposed to L-arginine and L-citrulline (Figure
6.4). Interestingly, ASL protein expression was not different between PUE cells exposed
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to media alone and media supplemented with L-arginine; however, ASL protein
expression was increased (P < 0.05) in PUE cells cultured with media supplemented with
L-citrulline (Figure 6.4).
6.5

Discussion
The endogenous synthesis of L-arginine occurs primarily through a concerted

effort between the small intestine and kidneys, whereby the small intestine synthesizes Lcitrulline which enters the general circulation and is converted to L-arginine in the renal
cortex via the actions of ASS-1 and ASL (Wu & Morris 1998). In the renal cortex, ASS
catalyzes the condensation of L-citrulline and L-aspartate to yield L-argininosuccinate
which is then split by ASL releasing fumarate and L-arginine (Haines et al. 2011), which
then enters the general circulation (Brosnan & Brosnan 2004). While the intestinal-renal
axis serves as the major source of circulating L-arginine, other cell types have been
reported to synthesize L-arginine as well (Wu & Brosnan 1992, Wu & Meininger 1993).
During the estrous cycle, uterine epithelial cells transition into a secretory
phenotype and form uterine glands which secrete histotroph, which is a collection of as
peptides, hormones, and nutrients that nourish the peri-implantation embryo. Histotroph
is vital to supporting and promoting the survival of the early peri-implantation embryo
and is especially important in species, such as sheep, cattle, pigs, and horses, which
exhibit an extended pre-attachment period (Gray et al. 2001). The y+ amino acid transport
system, which is responsible for the transport of L-arginine, is encoded by the genes
SLC7A1, SLC7A2, and SLC7A3, and during the ovine estrous cycle, SLC7A2 and
SLC7A1 mRNA are expressed, with SLC7A1 mRNA being temporally expressed and
elevated at day 16 of the estrous cycle (Gao et al. 2009a). In addition, L-arginine is
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present in the uterine flushes of ewes (Gao et al. 2009c), cows (Hugentobler et al. 2007),
rats (Leese et al. 2007), women (Casslen 1987), and sows (Iritani et al. 1974).
Interestingly, in both the cow (Hugentobler et al. 2007) and ewe (Gao et al. 2009c), Larginine is elevated in uterine flushes at a time when a potential embryo would be
recognized by the maternal environment and attach to the endometrial lining.
Furthermore, L-arginine has a positive effect on cell signaling, proliferation, hypertrophy,
hyperplasia, and migration of ovine and porcine trophectoderm cells (Kim et al. 2011a,
Kim et al. 2011b, Kong et al. 2011). Together, these findings would suggest that Larginine is a component of the uterine histotroph that is transported into the uterine lumen
to stimulate maternal-embryo signaling and support growth and development of the periimplantation embryo. As such, speculation arises regarding the ability of uterine
epithelial cells to synthesize L-arginine, which was examined in this preliminary study
utilizing primary PUE cells.
In response to L-arginine depletion, PUE cells demonstrated reduced cell
proliferation compared to PUE cells cultured with L-arginine, which is similar to what
has been observed in epithelial cells from the human endometrium. In addition to Larginine, L-citrulline also increased PUE cell proliferation; however, it was less in
magnitude compared the effect of L-arginine. In Jurkat cells, similar findings have been
reported in which cell proliferation was preserved in the presence of L-citrulline under
conditions of L-arginine depletion, which was attributed to conversion of L-citrulline to
L-arginine (Bansal et al. 2004). The current finding would suggest that PUE cells are able
to utilize L-citrulline in place of L-arginine to support proliferation, possibly through the
conversion of L-citrulline to L-arginine.
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As previously mentioned, the conversion of L-citrulline to L-arginine requires the
expression of ASS-1 and ASL proteins. Thus, the expression of these two enzymes in
PUE cells was assessed. Western-immunoblotting revealed an approximately 47 kDa
protein and an approximately 51 kDa protein, corresponding to ASS-1 and ASL,
respectively. The data suggest that PUE cells express the cellular machinery necessary to
convert L-citrulline to L-arginine. In response to changing nutritional conditions,
mammalian cells display the remarkable ability to adapt and respond by altering the
expression of cellular machinery needed to survive (Bansal et al. 2004). This adaptive
response has been observed in vivo in the rat kidney which responds to starvation by
increasing ASS-1 and ASL mRNA expression (Morris et al. 1989), which is likely an
attempt to maintain plasma L-arginine levels under nutritional deprivation (Wu & Morris
1998). In the current study, we observed an increase in ASS-1 protein expression in PUE
cells were cultured in the absence of L-arginine and L-citrulline, indicating that the
expression of ASS-1 is influenced by the ability of PUE to detect nutritional
perturbations. Interestingly, ASS-1 protein expression was not different between PUE
cells cultured with L-arginine and L-citrulline which may suggest that PUE cells have the
ability to utitilize L-citrulline for L-arginine synthesis. The influence of L-arginine on
ASS-1 expression has also been observed in the Jukart cells (Bansal et al. 2004) and
melanoma cells (Tsai et al. 2009), with increased ASS-1 expression being induced by Larginine deprivation. Moreover, the ASS-1 promoter recognizes HIF-1α which
suppresses ASS-1 transcription and is down-regulated during L-arginine depletion (Tsai
et al. 2009). Accumulation of HIF-1α is increased by NO (Sandau et al. 2000), which is a
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direct metabolite of L-arginine. Thus, evidence exists which suggests that L-arginine
regulates ASS-1 expression through NO which has the ability to stabilize HIF-1α.
Inasmuch as ASS-1 protein expression was found to be regulated by the presence
of L-arginine in PUE cells, we sought to determine the conditions under which ASL
protein expression was regulated. Surprisingly, L-arginine deprivation was not the
primary factor that influenced ASL expression. Porcine uterine epithelial cells cultured in
the absence of L-arginine exhibited ASL protein expression similar to cells cultured with
L-arginine. However, PUE cells cultured in the absence of L-arginine but supplied with
L-citrulline had increased expression of ASL. This finding may indicate that ASL
expression in PUE cells is not under the control of L-arginine availability, but rather,
ASL appears to regulated by the presence of its substrate L-argininosuccinate, as Lcitrulline is converted to L-arginiosuccinate by ASS-1.
6.6

Conclusions
The results of the current study represent a preliminary attempt to examine the

ability of PUE cells to synthesize L-arginine from L-citrulline. L-citrulline was able to
support PUE cell proliferation albeit less in magnitude compared to the effect that Larginine exhibited. As previously mentioned, the conversion of L-citrulline to L-arginine
necessitates the expression of ASS-1 and ASL, both of which were found to be expressed
in fresh PUE cells. Additionally, the expression of ASS-1 appears to be regulated by the
presence of L-arginine, while the data suggests that ASL expression is regulated by the
presence of its substrate L-argininosuccinate. Together, these findings would support the
original hypothesis that PUE cells can synthesize L-arginine from L-citrulline; however,
this hypothesis cannot be fully supported without measuring L-arginine biosynthesis
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directly using methods such as high pressure liquid chromatography. Nevertheless, if
biosynthesis of L-arginine is occurring in PUE cells, new avenues of investigation would
be opened regarding the role of this physiological process in relation to mammalian
reproduction.

Figure 6.1

Phenotypic characteristics of isolated primary porcine uterine epithelial
(PUE) cells.

Isolated PUE cells displayed a “cobblestone” appearance that is characteristic of uterine
epithelial cells in culture. Additionally, immunofluorescence revealed the expression of
the epithelial cell adhesion molecule E-cadherin
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Figure 6.2

Effect of L-arginine (200 µmol/L) and L-citrulline (1000 µmol/L) on
procine uterine epithelilal cell proliferation.

Each bar represents the mean ± S.E.M.; means without a common letter are significantly
different (P < 0.05)

Figure 6.3

Western-Immunoblotting detection of argininosuccinate synthatse-1 (ASS1) and argininosuccinate lyase (ASL) in porcine uterine epithelial (PUE)
cells and porcine renal cortex tissue samples.

Western-Immunoblotting of protein isolated from PUE cells revealed the presence of a 47
kDa and a 51 kDa protein corresponding to ASS-1 and ASL, respectively. Additionally,
similar proteins were detected in porcine renal cortex tissue which is known to express
both ASS-1 and ASL. Lanes 1: Ladder; 2: PUE from sow 1; 3: PUE from sow 2; 4:
Ladder; 5 PUE from sow 1; 6: PUE from sow 2; 7: Ladder; 8: Renal cortex; 9: Renal
cortex; 10: Ladder; 11: Renal cortex; 12: Renal cortex.
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Figure 6.4

Effect of L-arginine (200 µmol/L) and L-citrulline (1000 µmol/L) on
expression of (A) argininosuccinate synthase-1 (ASS-1) and (B)
argininosuccinate lyase (ASL) protein expression in porcine uterine
epithelilal cells.

Each bar represents the mean ± S.E.M.; means without a common letter are significantly
different (P < 0.05).
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CHAPTER VII
GENERAL CONCLUSIONS

The current series of studies sought to contribute more scientific knowledge
regarding the role that L-arginine has in mammalian reproductive tissues. One of the
outcomes was the development of bioluminescent murine pregnancy model that allows
for the non-invasive and serial monitoring of VEGFR2 transcription activity within the
fetoplacental unit. Data obtained from this study indicated that a quantitative assessment
of VEGFR2 can be made during the latter third of gestation and that this data parallels
traditional molecular techniques and what has been reported previously in the literature.
In addition to monitoring VEGFR2, this model has the potential to afford researchers the
ability to study aberrations in fetoplacental angiogenesis and allow them to pinpoint a
particular day of gestation for further analysis using various other end-point techniques.
Another outcome of this set of experiments was the finding that dietary
supplementation of L-arginine during mouse gestation has a positive influence on
reproductive performance. Dietary L-arginine supplementation increased the
transcriptional activity of VEGFR2 in the fetoplacental unit, which may benefit fetal
survival given the importance of angiogenesis during fetal development. Moreover, the
supplementation of L-arginine in the diet increased the litter size and increased the
number of implantation sites in the uterus. This would suggest that L-arginine has an
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influence on the process of embryo implantation, possibly at the level of the
endometrium.
The third set of experiments investigated the effect that L-arginine has on cell
proliferation and apoptosis in human endometrial epithelial cells. The presence of Larginine at physiological and supraphysiologcal concentrations enhanced endometrial cell
proliferation through mechanisms mediated by NO and polyamine biosynthesis and by
reducing apoptosis. Specifically, L-arginine reduced mitochondrial mediated apoptosis
which can be attributed to an enhancement of BAD protein phosphorylation. These
findings demonstrate a role for L-arginine in endometrial growth and may have
implications for embryo implantation, as endometrial growth and thickness are associated
with improved pregnancy rates.
Finally, a preliminary assessment of the ability of PUE cells to convert Lcitrulline to L-arginine was undertaken. L-citrulline was able to support PUE cell
proliferation albeit less in magnitude compared to the effect that L-arginine exhibited.
Additionally, the enzymes necessary to convert L-citrulline to L-arginine, ASS-1 and
ASL, were expressed in fresh PUE cells. The expression of ASS-1 appears to be
regulated by the presence of L-arginine, while the data suggests that ASL expression is
regulated by the presence of its substrate L-argininosuccinate. Together, these findings
would support the original hypothesis that PUE cells can synthesize L-arginine from Lcitrulline; however, this hypothesis cannot be fully support without measuring L-arginine
biosynthesis directly using methods such as high pressure liquid chromatography.
The current findings along with the plethora of relevant literature further provide
evidence that L-arginine is a critical amino acid for reproductive processes in mammalian
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species. Despite the early classification of L-arginine as being a non-essential amino acid,
the current findings and other reported studies would suggest that this may not be the
case for some reproductive processes, particularly since the initial classification of Larginine was based solely on body growth experiments. To this end, the essentiality of Larginine for bodily functions other than growth, such as reproduction, may need to be
reevaluated in the future.
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